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Abstract  
Δ9-Tetrahydrocannabinol (THC) is the main psychoactive compound in the plant 
Cannabis sativa and the most widely used illegal drug in the world. Its 
consumption impairs driving skills such as keeping a vehicle on track and has 
been shown to increase the risk of accidents. Urine tests are available for the 
detection of THC in a roadside setting, but necessitate facilities and are prone to 
sample manipulation. In addition, the correlation between impairment and 
positive tests is poor as a THC-metabolite instead of the active THC is analysed. 
Oral fluid sampling has emerged as a simple and quick alternative that permits 
detection of THC itself and therefore evidence for driving under the acute 
influence of THC. Existing oral fluid tests that are based on antibodies fail to 
reach the sensitivity and specificity needed for roadside testing. 
We aimed to select a THC-binding aptamer for the development of new oral fluid 
tests for THC. Aptamers are single-stranded nucleic acids that specifically 
recognise their target molecule with high affinity. Numerous trials with both DNA 
and 2’F-modified RNA did not succeed in enriching such sequences for THC. 
Most likely, this is due to the high hydrophobicity of THC and its thereby 
constrained ability to interact with nucleic acids. Nucleobase-modified aptamers 
have been shown to dramatically increase the selection success for protein 
targets. We thus used a recently developed technique, called click-SELEX, that 
facilitates modification of DNA with an azide of choice. Emulating the interaction 
of THC with the human cannabinoid receptor 1, benzyl- and 
trifluoromethylbenzyl-residues were utilised as nucleobase-modifications. This 
enabled the immediate selection of sequences that bind THC immobilised on 
epoxy-sepharose. While none of the sequences could be shown to recognise 
THC in solution, this thesis established the synthesis of fluorescently-labelled 
THC-derivatives that can be utilised in fluorescence polarisation assays to 
ascertain affinity constants of future clickmers. In addition, THC-solubility in 
aqueous buffers with low amounts of organic solvent was thoroughly 
investigated. Altogether, the findings of this thesis lay the foundation for the 
selection of THC-binding clickmers that can be implemented in roadside tests in 
the future. 
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Zusammenfassung  
Δ9-Tetrahydrocannabinol (THC) ist für den Großteil der psychoaktiven Wirkung 
der Pflanze Cannabis sativa verantwortlich und die meistgenutzte Droge der 
Welt. Der Konsum beeinträchtigt die Fahrfähigkeit: Fahrzeuge können nicht in 
der Spur gehalten werden und die Wahrscheinlichkeit von Unfällen steigt. 
Urintests werden von der Polizei verwendet, können aber verhältnismäßig leicht 
manipuliert werden und setzen das Vorhandensein von entsprechenden Anlagen 
voraus. Zusätzlich ist die Korrelation zwischen Einschränkung der Fahrfähigkeit 
und positiven Ergebnissen schlecht, da ein THC-Metabolit an Stelle des aktiven 
THCs analysiert wird. Speicheltests sind als eine schnelle und einfache 
Alternative bekannt geworden, die zudem die Detektion von THC selbst und 
entsprechend einen viel besseren Nachweis des Fahrens unter akutem 
Drogeneinfluss gestatten. Die bisher erhältlichen Tests sind Antikörper-basiert, 
erreichen jedoch nicht die benötigte Sensitivität und Spezifität.  
Wir wollten ein THC-bindendes Aptamer für die Entwicklung neuer Speicheltests 
für THC selektieren. Aptamere sind einzelsträngige Nukleinsäuren, die spezifisch 
und hochaffin ihr Zielmolekül erkennen. Zahlreiche Versuche mit sowohl DNA als 
auch 2’F-modifizierter RNA konnten keine THC-Aptamere anreichern. Vermutlich 
ist dies auf die hohe Hydrophobizität THCs und seine dadurch eingeschränkten 
Möglichkeiten zur Interaktion mit Nukleinsäuren zurückzuführen. Nukleobasen-
modifizierte Aptamere konnten die Erfolgsrate von Selektionen für Protein-
bindende Aptamere drastisch erhöhen. Entsprechend verwendeten wir eine vor 
kurzem entwickelte Technik, die sich Click-SELEX nennt, und die Modifikation 
der DNA mit einem frei wählbaren Azid ermöglicht. Um die Interaktion von THC 
mit dem humanen Cannabinoid Rezeptor 1 nachzuahmen, wurden Benzyl- und 
Trifluoromethylbenzyl-Reste als Nukleobasen-Modifikationen verwendet. Dies 
ermöglichte die sofortige Selektion von Sequenzen, die auf Epoxy-Sepharose 
immobilisiertes THC erkennen. Obgleich keine der Sequenzen THC in Lösung 
bindet, etablierte diese Arbeit die Synthese fluoreszenzmarkierter THC-Derivate, 
welche für die Bestimmung der Affinität zukünftiger Clickmere mit Hilfe von 
Fluoreszenz Polarisation genutzt werden können. Zusätzlich wurde die 
Löslichkeit von THC in wässrigen Puffersystemen mit geringen Mengen 
organischer Lösungsmittel sorgfältig untersucht. Alles in allem legen die in dieser 
Dissertation dargelegten Ergebnisse das Fundament für die Selektion THC-
bindender Clickmere, die in zukünftige Speicheltests implementiert werden 
können. 
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1 Introduction 
1.1 Δ9-Tetrahydrocannabinol 
Δ9-Tetrahydrocannabinol (THC, Figure 1A) is the main psychoactive constituent 
of the plant Cannabis sativa. Due to its psychoactive effect, it has been used for 
thousands of years for medical and recreational reasons. Nowadays, it is an 
approved medicine for a number of indications in several countries (section 
1.1.3). In addition, THC is still the most widely used illicit drug in the world. A 
survey conducted in Germany in 2015 revealed that 6.1% of all adults specified 
that they used Cannabis in the last year. For teenagers (12-17 years) and young 
adults (18-25 years), the incidence was even higher with 7.3% and 15.3%, 
respectively.1 Consumed are either the leaves (marijuana), the resin (hashish), 
whose THC-concentration is higher, or even more concentrated extracts (hashish 
oil).2,3  
Recent years have seen a decrease in the criminalisation of THC. Uruguay and 
some US states have legalised the drug, while penalties for possession of small 
quantities and use have been abolished in e.g., Germany (§ 31a BtMG).4 In 
contrast, long prison sentences for minimal or death sentences for larger 
amounts are common in e.g., the Philippines, Singapore, and the United Arab 
Emirates (UAE).5-7  
 
1.1.1 Important cannabinoids of Cannabis sativa 
THC is only one of a steadily increasing number of known components of 
Cannabis sativa. As of now, 554 compounds have been identified, 113 of which 
are cannabinoids.8,9  
While the THC-content is most important for the majority of medicinal and all 
recreational uses of Cannabis sativa, quantification of it usually also 
encompasses the content of Δ9-tetrahydrocannabinolic acid (THCA, Figure 1B). 
THCA is the biogenetic precursor of THC and can be converted to THC by 
decarboxylation, which is rapidly achieved by heat exposure (during smoking or 
baking) or slowly during storage.10 In its unprocessed form, up to 85% of the 
plant’s THC-content are present as THCA with large variations depending on the 
origin and type (resin/leaves) of sample.11 
Apart from THC and THCA, cannabidiol (CBD, Figure 1C) is one of the most 
abundant cannabinoids in Cannabis sativa. It amounts to up to 40% of the plant’s 
cannabinoids and is not psychoactive, but known to antagonize the effects of 
THC. Studies regarding the use of CBD in a number of psychiatric disorders like 
anxiety, depression, and psychosis have been published.12 In addition, it is 
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combined with THC in the oromucosal spray Sativex®, which is approved in a 
number of countries, including the European Union (EU), but not in the United 
States (US) (section 1.1.3).13,14 
 
Figure 1: Structures of cannabinoids and endocannabinoids 
Chemical structures of the cannabinoids (A) Δ9-tetrahydrocannabinol (THC), (B) Δ9-
tetrahydrocannabinolic acid (THCA), and (C) cannabidiol (CBD) and of the endocannabinoids (D) 
anandamide (AEA) and (E) 2-arachidonoyl glycerol (2-AG).  
 
1.1.2 Human cannabinoid receptors and THC-binding 
THC is recognised by two different human cannabinoid receptors: Cannabinoid 
receptor 1 (CB1)15 and 2 (CB2)16. Both are G-protein coupled receptors 
(GPCRs). CB1 is mainly expressed in the central and peripheral nervous system 
(CNS, PNS) and is the primary target of both THC and the endocannabinoids 
anandamide (AEA, Figure 1D) and 2-arachidonoyl glycerol (2-AG, Figure 1E).17 
The receptor controls motor function, cognition, memory, and analgesia through 
inhibition of neurotransmitter release.18,19 CB2 can be found in peripheral organs 
with immune functions.19 It plays a role in immunosuppression, neuroprotection, 
and neuropathic and inflammatory pain.20-23  
To increase the understanding of the interaction between CB1 and its ligands, 
pharmacological evaluations, mutation studies, and molecular dynamics (MD) 
simulations were performed.24-26 In 2016 and 2017, two independent groups 
published crystal structures of CB1 with different ligands (Table 1, Figure 
2).17,27,28 Nonetheless, none of them were able to co-crystallise CB1 with THC.  
Table 1: Crystal structures of CB1 
Publication Year PDB-ID Co-crystallised ligand Resolution [Ǻ] 
Hua et al.27 2016 5TGZ AM6538 (stabilising 
antagonist) 
2.8 
Shao et al.28 2016 5U09 taranabant (inverse agonist) 2.6 
Hua et al.17 2017 5XR8 
5XRA 
AM841 (agonist) 
AM11542 (agonist) 
2.95 
2.8 
19 
 
  
 
 
Figure 2: Structures of CB1-ligands used for co-crystallisation 
Chemical structures of the CB1-ligands that were used for the co-crystallisation of CB1 with (A) 
AM6538
27
, (B) taranaband
28
, (C) AM841, and (D) AM11542.
17
  
Therefore, the actual interaction between CB1 and THC remains unknown. All 
predictions based on the crystal structures and MD simulations agree that 
phenylalanine-residues of CB1 are undergoing π-stacking with the aromatic ring 
of THC. They disagree on which specific residues and how many of them are 
responsible (Table 2).17,25,27,28 As THC is a partial agonist of CB1 and major 
changes of the ligand binding pocket were observed between the antagonist- and 
agonist-bound crystal structures, the docking studies based on the agonist-bound 
crystal structures17 can probably be presumed closest to reality as long as no 
CB1-THC co-crystal is available (Figure 3).  
 
Table 2: CB1-residues presumed to interact with THC 
Publication Method CB1-residues interacting with THC 
Shim et al.25 MD simulation F174, F177 
Hua et al.27 crystal structure F268 
Shao et al.28 crystal structure F174 
L193, C355, W356, S383 
Hua et al.17 crystal structure F177, F189, F200, F268, F379 
L193, U196, Y275, L359, M363, S383 
Identical residues are coloured alike. 
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Figure 3: Docking study of the interaction of CB1 with THC modified after Hua et al. 
The cannabinoid receptor is depicted as a cartoon in grey, with helices representing the 
transmembrane regions. Residues interacting with THC are displayed in orange. THC is depicted 
in blue. Most parts of CB1 that do not interact with THC were omitted. Modified after Hua et 
al. 2017.
17
 
 
1.1.3 THC as a medicinal drug  
Long before THC or any other cannabinoid had been identified as psychoactive 
constituent of cannabis, the whole plant was used for medical purposes.  
Reports of cannabis use in China date back to 2700 BC.29 In India, old sacred 
texts count cannabis as one of the five sacred plants due to its psychoactive 
effect.29 In addition, it was used for a multitude of medical reasons that include 
analgesic, anaesthetic, anti-inflammatory, antibiotic, and appetite stimulant 
effects since about 1000 BC.29-31  
In the timeframe until the 18th century, cannabis use spread from India to the 
Middle East and Africa. While the plant is mentioned in a number of plant books 
on the European continent during the Middle Ages, including Hildegard von 
Bingen’s Physica (1150), far fewer applications are known in comparison with 
other parts of the world.30,32  
Cannabis entered western medicine in the 19th century, when an Irish physician 
brought the knowledge from his service in India and successfully experimented 
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with the plant’s use for rheumatism, convulsions, and muscular spasms that 
occurred due to tetanus and rabies in 1839.33 At the start of the 20th century, it 
was used mainly as a sedative, hypnotic, and analgesic and to improve appetite 
and digestion.34  
The first decades of the 20th century saw a decrease in cannabis use. As no 
knowledge of the constituents responsible for single effects were identified, 
results were hard to reproduce with the plant material.34 This problem was 
eventually solved and standard extracts and tinctures became available in the 
1930’s.35 In 1937, the (later on disabused) claim of the American police that 
cannabis was the cause of crime, violence, insanity, and death led to an extreme 
tax increase on cannabis products, effectively stopping its use in pharmaceutical 
formulae.34  
The identification of the chemical structure of THC in 1964 and of the 
endocannabinoid system in the early 1990’s enabled the investigation of the 
effects of single cannabinoids.36,37 Nowadays, three different cannabis 
preparations are available: Dronabinol (THC), Nabilone (THC-analogue38,39), and 
Nabiximols (THC:CBD 1:1). The approved indications vary between countries. In 
Germany, Dronabinol (Marinol®) is approved for any pain indication, Nabilone 
(Canemes®) for chemotherapy-induced emesis, and Nabiximols (Sativex®) for 
spasticity in multiple sclerosis (MS). In addition, 14 different kinds of cannabis 
flowers are available for the pain management of patients with severe diseases. 
In all cases, it is a drug of last resort when other, more traditional medications 
have failed.40  
Ongoing studies and an as of now low number of clinical trials further implicate 
THC as possible treatments for different types of cancer41, agitation in 
Alzheimer’s disease42, and CBD for epilepsy.43 A lot more knowledge has to be 
gained to confirm the consistency of the observed effects and treatment safety to 
gain an approval for the respective indication. 
 
1.1.4 Psychoactive effects of THC 
The use of THC as a drug is based on the fact that some plant parts contain a 
multitude of cannabinoids in varying concentrations.10,11,44 Moreover, the plant 
has been bred to contain higher levels of THC in comparison to the amounts 
found in the 1990’s.3 In addition to this, most reports about psychoactive effects 
origin from people whose drug use history, emotional state, as well as the setting 
of the use have an impact on the experienced effects and might therefore be less 
accurate and more subjective than desired.45  
Altogether, this renders the objective description of cannabis effects difficult. To 
give future investigators a list of possible effects, Charles T. Tart distributed a 
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thorough questionnaire to experienced cannabis users. Common effects were 
reported in nearly every imaginable category (visual, auditory, touch, taste, and 
smell effects, space-time perception, perception of the body, physical movement, 
interpersonal relations, sexual effects, thought processes, memory functioning, 
emotions, self-control, sense of identity, and effects on sleep).45  
The most abundantly reported influence is an increase in intensity and scope of 
all senses.45 Space-time perception46,47, understanding, memory48, emotion, and 
sense of identity are changed.45,49 Motor coordination and judgment are 
impaired.48,50 
 
1.1.4.1 Pharmacokinetics and THC-metabolites  
The administration of THC influences its absorption. Bioavailability after smoking 
varies between 12-37%, depending on the subject and smoking dynamics 
(number, duration, spacing, and volume of inhalation).51,52 Oral bioavailability is 
reported to be slightly lower with 3-20%.51,53 Plasma concentrations of THC peak 
quickly during or shortly after smoking. This is followed by a fast decrease until 
30 min after smoking onset and a steady decline over the next hours.54,55 In 
contrast, oral THC is absorbed slowly and, after an hour, concentrations decline 
even slower (Figure 4).51 Subjective THC effects (feeling “high”) have been 
reported both parallel to the concentration peak after smoking as well as delayed 
by about 15 min alongside already decreasing plasma levels. Oral administration 
leads to an even later effect onset (peaking 2 h after ingestion), but longer effect 
duration, which lasts through lower plasma THC concentrations compared to 
those eliciting effects after smoking.51,54  
In plasma, about 97% THC is lipoprotein-conjugated.56,57 From there, it is taken 
up by highly perfused tissues like lung, heart, brain, and liver.58 The amount of 
THC detectable in the brain, where it can bind to CB1 and result in psychoactive 
effects, is reported to be less than 1%. This is most likely due to its retention by 
the blood-brain barrier. Instead, it accumulates in fat tissue.59-61 A post-mortem 
study of twelve cannabis users showed consistently higher concentrations of 
THC in the brain than in the blood. In three cases, THC could not even be 
detected in blood any longer, while it was still present in the brain samples. It 
therefore seems that even though bioavailability in the brain is low, THC that 
arrives there is retained for a longer time. These stores might be the reason for 
long-lasting THC-effects that have been observed, but more research is needed 
for a thorough analysis.62 
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Figure 4: Schematic illustration of the plasma THC-concentration after different routes of 
administration 
THC-concentrations peak during or shortly after smoking (black curve). They rapidly decline until 
30 min after smoking and then slowly decline over the subsequent hours. After oral ingestion, 
plasma THC-concentrations increase to a low peak after about 1 h and then decline even more 
slowly (blue curve).
51
 
THC is metabolised in the liver to the two main metabolites 11-hydroxy-
tetrahydrocannabinol (11-OH-THC) (Figure 5A) and 11-nor-9-carboxy-
tetrahydrocannabinol (THC-COOH) (Figure 5B). Both are formed by oxidation, 
with inactive THC-COOH resulting from oxidation of the psychoactive 11-OH-
THC.63-66 THC-COOH and its phase-II-metabolite, THC-COOH glucuronide are 
the major end products of the human metabolism.67,68 After the initial distribution, 
the rate with which THC is metabolised is determined by the rate with which the 
drug re-enters the blood from its storage tissue.69 In addition, THC can be 
metabolised to hydroxylated forms in brain microsomes, but little is known about 
these metabolites and their psychoactivity.70  
  
Figure 5: Chemical structures of THC-metabolites 
Structures of the main THC-metabolites (A) 11-hydroxy-tetrahydrocannabinol (11-OH-THC) and 
(B) 11-nor-9-carboxy-tetrahydrocannabinol (THC-COOH). 
THC is excreted within days to weeks, depending on the route of administration 
and abuse history of the subject. THC-COO-glucuronide is the major urinary 
metabolite, while 11-OH-THC is the main metabolite found in the faeces.53,67,71 
Minor amounts of THC-COOH are also excreted in urine (section 1.1.5.2.1).58  
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1.1.5 THC and driving 
The high prevalence of THC-use indicates that it might be commonly consumed 
by drivers. A large scale study about driving under the influence of drugs, alcohol, 
and medicines (DRUID) was performed between 2006 and 2011 in 18 European 
states. About 50,000 drivers were randomly selected and tested for drug and 
alcohol levels.72 According to the results, the average prevalence of driving under 
the influence of THC is 1.32%, which amounts to one third of the prevalence of 
alcohol.73  
Considering the psychoactive effects of THC, which include changes in motor 
coordination, judgement, and sensual as well as space-time-perception (section 
1.1.4), it stands to reason that THC affects driving capability. Two different types 
of studies have tried to quantify the impairment: Experimental ones that test the 
subject’s responses in tests simulating driving situations and epidemiological 
studies. For the latter, samples from real drivers are taken and analysed to 
assess the risk of traffic accidents based on the alcohol or drug concentration in 
the samples. 
The most consistent finding in experimental studies is that the ability to keep a 
vehicle on track is reduced under the influence of THC.74-78 This is also reported 
after the use of Dronabinol® (medical THC) by heavy and occasional cannabis 
users. The impairment after THC-consumption is less pronounced in heavy 
users, but stronger than the one resulting from a blood alcohol concentration 
(BAC) of 0.5 g/l, the legal limit for driving in Germany (§ 24a StVG).79 Two studies 
report no significant impairment to keep a vehicle on track, even though other 
signs of impairment were detected in one of them.80,81 These inconsistencies 
might result from differences in THC-amounts, subject drug use history, and the 
delay between drug use and start of the tests.82 In addition, a number of studies 
report that subjects that were aware of their impairment compensated by driving 
slowly, overtaking less, and keeping longer distances.75,81,83,84 Nevertheless, not 
every impaired psychomotor skill could be compensated76,85 and not all subjects 
tried to: Studies testing judgement were able to show an increase in impulsive 
behaviour78,86 and choice of the risky option if subjects were asked to choose 
between a safe and risky option.87 
Most epidemiological studies report a 2- to 3-fold increase in accident risk under 
the influence of cannabis72,88 and the same for the culpability of the drugged 
driver.89,90 Higher blood levels (> 5 µg/ml) have also been associated with a 5- to 
7-fold increase in risk.89,90 This is relatively low compared to the risk reported for 
alcohol, which varies between a 4- and 15-fold increase, depending on the 
study.89,91,92 
Depending on the study, between 30 and 45% of all drivers under the influence of 
THC had also consumed alcohol.93,94 For this combination, most studies report a 
synergistic effect.77,80,85,95 The drivers are less attentive, even though neither drug 
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alone has such an impact96, and the ability to keep a vehicle on track is further 
impaired.97 Compensation as mentioned above is no longer possible.84 The risk 
factor for the responsibility in car crashes rises accordingly (odds ratio (OR) 11-
16).72,98,99  
 
1.1.5.1 Legislation for driving under the influence of THC 
To prevent people from driving under the influence of THC, limits for the drug 
concentration have been set. In Europe, three different policies are prevalent: per 
se limits, impairment (obvious from personal behaviour or driving style), and a 
combination of those two, the two-tier approach, which is also used in 
Germany.73,82  
Legal limits for THC range from 0.5 (Italy, per se) to 3 ng/ml (Portugal, per se) in 
whole blood and 0.3 (Slovenia, per se) to 2 ng/ml (Luxembourg, impairment) in 
plasma. The limit in Germany is set to 1 ng/ml in plasma.  
Only a few countries have also set limits for THC-COOH. Those range from 0.5 
(Italy, per se) to 50 ng/ml (Poland, per se) in whole blood. Slovenia is the only 
country in Europe to have set plasma limits (5 ng/ml, per se).82  
 
1.1.5.2 Roadside testing for THC 
While the plasma concentration is necessary for any legal sentence82, sampling 
of blood is restricted to healthcare practitioners and, in theory, requires a judicial 
order in Germany. As alcohol and drugs are metabolised and the concentration at 
a later time point might not be sufficient for sentencing, the judicial order is not 
mandatory for traffic offenses (§ 81a StPO). Nevertheless, it requires both a 
healthcare practitioner and a probable cause (§ 81a StPO), which might not 
always be the case for routine roadside tests. Therefore, alternative testing 
matrices have been established. The two most common methods are tests using 
urine or oral fluid. After a positive response in one of those initial tests, blood 
sampling and quantification of THC using more sophisticated analytical methods 
like gas chromatography – mass spectrometry (GC-MS) is mandatory.100,101  
 
1.1.5.2.1 Urine testing for THC-COOH 
Urine tests are based on the detection of THC-COOH.101 Although the majority of 
THC-COOH is present in urine as glucuronide, most tests do not differentiate 
between the two and thus also detect THC-COOH glucuronide. Before laboratory 
confirmation e.g., by GC-MS, the glucuronide has to be hydrolysed.58 
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Although sensitivity and specificity of available urine based testing devices for 
THC-COOH are excellent102, the matrix encompasses some inherent problems 
for roadside testing. First of all, sample taking is invasive and has to be observed 
closely to hinder attempts at sample manipulation.103,104 As the process is quite 
intimate, a police officer of the same sex is needed and might not always be 
available in a roadside setting. The same goes for facilities, which have to be 
sought out, costing time of both subject and officers.105  
Most importantly, the detected substance is not the pharmacologically active one, 
but a metabolite. The first detection of THC-COOH in urine occurs 4 (gas 
chromatography – tandem mass spectrometry, GC-MS-MS) or 6 h (enzyme 
immunoassay, EIA) after smoking.101 This is later than the strongest impairment: 
A subjective intoxication as well as significant negative effects on driving 
performance are present up to 6-10 h after use, with the majority of the subjective 
effect in the first two hours.74,78,106,107 Twenty-four hours after smoking, no effects 
could be measured.83 The detection of THC-COOH in urine then, depending on 
the method, lasts until an average of 33 or 26 h with maximum detection times of 
58 or 42 h (Figure 6).101 Chronic daily cannabis users under monitored 
abstinence were positive for THC-COOH for 13 days (median).108  
 
Figure 6: Timeline of positive test results in urine and oral fluid samples 
Timeline of positive test results in urine (THC-COOH) and oral fluid (THC) samples. Given is the 
time point of the first positive test result after smoking of cannabis, as well as the average 
duration of positive results (line) and the time of the last positive test result for results obtained by 
GC-MS-MS and EIA. Indicated by a dotted line is the approximate duration for which driving skills 
are impaired (10 h).
101
  
Taken together, those studies show that the timewise correlation between 
positive urine testing and impaired driving skills is far from optimal. Impaired 
users will be tested negatively for the majority of the time that impairment lasts 
and users that are no longer impaired will be tested positively. Confirmation of the 
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results determining plasma THC will exonerate the latter, but impaired drivers 
cannot be detected adequately.  
 
1.1.5.2.2 Oral fluid testing for THC 
THC enters oral fluid by deposition into the oral mucosa during smoking or oral 
administration. The concentration decreases slowly as THC is released from the 
mucosa and moved to the gastro-intestinal tract with the oral fluid. If at all, only 
minor amounts enter oral fluid by passive diffusion from the blood.109,110 THC can 
be detected in oral fluid immediately after smoking and, depending on the 
method, for a mean of 13 or 15 h. The maximum detection time is 34 or 31 h 
(Figure 6). Samples of chronic daily users under monitored abstinence were 
positive for up to 48 h.101,108 Therefore, the timewise correlation between positive 
results and impairment is much improved over urine sampling, if still longer than 
the actual impairment of a maximum of 10 h (section 1.1.5.2.1).  
Problems associated with oral fluid testing consist of the actual sampling, as THC 
consumption is known to lead to a dry mouth and collection of the necessitated 
volume of oral fluid might be difficult.111,112 The high hydrophobicity of THC 
complicates the recovery of the drug from oral fluid collection devices. Some 
devices like the Cozart® and Quantisal® collectors have found a way to 
circumvent this and ensure high recovery levels.113,114 Food, beverages, and 
mouthwashes that are consumed or used can reduce the measured 
concentration in oral fluid, but are not able to lead to a negative result if the 
assay’s sensitivity is sufficient.115,116 Passive cannabis smoking was shown to 
generate measurable THC-concentrations in oral fluid for up to 1 h.101,117,118 In 
one study, samples were positive for up to 3 h after the subjects had spent 3 h in 
a coffee shop.119 Despite these rare exceptions, oral fluid based assays should 
be stable enough for initial roadside testing.  
Immediately after consumption, THC-concentrations in oral fluid are far higher 
than in blood. After this initial contamination has dissipated, studies have been 
able to show correlations between impairment or plasma and oral fluid 
concentrations, even though inter-subject variations are relatively high.117,120,121 
Nonetheless, the calculation of plasma THC based on oral fluid drug-
concentrations remains impossible.122  
Sensitivity and specificity have long been a problem for oral fluid roadside testing 
devices for THC100,123-125. The last years have seen the development of more 
promising tests even though they still do not reach the sensitivity and specificity 
of 90% that have been set as limit for testing devices by the European roadsite 
testing assessment project (ROSITA).126 The Dräger DrugTest5000® showed 
sensitivities of 92 and 93% and specificities of 97 and 71% in two different 
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studies.127,128 With those values, it remains the best oral fluid roadside testing 
device on the market right now. 
 
1.2 Aptamers 
Aptamers are oligonucleotide-based affinity tools. They are selected in vitro from 
libraries comprised of single-stranded RNA- or DNA-oligonucleotides to bind a 
target molecule with high affinity and selectivity.129,130 Aptamers have been 
identified for proteins131, small organic molecules132, ions133, cells134, whole 
viruses135, and even in vivo for tumours.136 They fold into a three-dimensional 
structure, which enables recognition of their target molecule. Therefore, 
interaction conditions like e.g., buffer system, pH, or temperature cannot be 
varied without risking partial or complete loss of affinity.137  
As affinity tools, aptamers combine several advantages: They are thermally 
stable and can be renatured after denaturation. Their chemical synthesis enables 
an easy way to incorporate modifications at specific positions combined with 
relatively low production costs and no batch-to-batch variations.138 In addition, 
they have low immunogenicity.139,140 This explains the increasing attention 
aptamers have been gaining for the development of diagnostics141,142 as well as 
therapeutics.143-146 Nonetheless, commercialised aptamer-based therapeutics 
and diagnostics remain rare.147  
Aptamer-based biosensors, also called aptasensors, are one of the consistently 
growing uses of aptamers in the last couple of years. A wide variety of 
mechanisms148 as well as targets has been explored and many sensors even 
work in real samples and reach limits of detection and quantification sufficient for 
real-life use. Problematic remains the stability and reproducibility necessary for 
commercialisation as the method descriptions in the proof-of-concept papers 
often lack vital details like exact buffer conditions.147 Additionally, companies 
dealing with aptamers are still rare in comparison to those experienced with 
antibodies.147 The investment needed to commercialise aptamer-based sensors 
(or any other kind of therapeutic or diagnostic) is therefore much higher than for 
antibodies, where well-established protocols and knowledge shorten and 
cheapen the process. 
 
1.2.1 SELEX 
Aptamers are (mostly) selected in vitro by a technique called systematic evolution 
of ligands by exponential enrichment (SELEX). The starting library (SL) consists 
of single-stranded DNA or RNA with a randomised region flanked on the 5’- and 
3’-end with constant primer binding sites for amplification during polymerase 
chain reaction (PCR). In the first selection cycle, the SL is incubated with the 
29 
 
  
target molecule of interest. Often, this target molecule is immobilised on some 
kind of solid phase like magnetic beads or sepharose to enable easy separation 
of binding and non-binding sequences.149 Other options include the use of the 
change in migration between bound and non-bound nucleic acids in electronic 
fields in capillary electrophoresis 150 or the immobilisation of the SL, which is 
eluted from the beads upon binding to the target of interest.151 
After incubation with the target molecule, non-binders are removed and binding 
sequences recovered and amplified. Depending on the nature of the nucleic 
acids used for SELEX, the resulting PCR-product is either transcribed into RNA 
(for RNA-SELEX) or the 3’-strand is digested, resulting in single-stranded DNA 
(for DNA-SELEX). The enriched library can then be used for the subsequent 
selection cycle.149  
After in average 8-12 selection cycles, the enriched DNA/RNA is tested for 
interaction with the target molecule. If significantly increased interaction in 
contrast to the DNA of the SL is observed, the DNA from the enriched selection 
cycle is sequenced. Single sequences are further characterized for affinity and 
specificity and those that show both for the target molecule are defined as a new 
aptamer.152  
 
1.2.2 Aptamer identification through next-generation sequencing 
Sequencing of the DNA from enriched selection cycles is necessary for aptamer 
identification and can be performed with two different techniques: Sanger and 
next-generation sequencing. Using traditional Sanger sequencing153, the DNA 
from about 50 clones can be sequenced. As the gained number of sequences is 
low, the final selection cycle has to be highly enriched to enable aptamer 
identification. In contrast, the millions of reads obtained from next-generation 
sequencing (NGS) allow the identification of only slightly enriched aptamer 
candidates. They also create the unique opportunity to gain an insight into the 
selection process as DNA of several selection cycles can be sequenced. The 
enrichment of single aptamer candidates can be followed over the course of the 
SELEX and the impact of changes in selection conditions can be directly 
evaluated.154,155 It is therefore not surprising that NGS is used for aptamer 
identification by an increasing number of research groups.156-158 In addition, 
several analysis tools have been described to enable fast and easy analysis of 
the resulting NGS data.154,159-162  
NGS can be performed using different techniques.163 All data in this thesis was 
obtained using sequencing by synthesis (SBS), which is implemented in Illumina 
sequencers.164 For this technique, average error rates between 0.1 and 2.6% 
have been published with single nucleotide substitutions as the most abundant 
error type.165-168 Independent of the sequencing technique, mutations have also 
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been assigned to result from PCR errors either during sample preparation or 
sequencing.165,169 
In addition, some errors are intrinsic to the SBS approach170: Overlays of 
excitation and emission spectra of the different fluorophores lead to colour or 
laser cross-talk, which can result in base miscalling.171 The same effect can also 
be observed between adjacent clusters.172 Phasing describes two phenomena 
that lead to the resulting strand being out of phase with the actual sequencing 
rate: Pre-phasing leads to the strand preceding all others as two or more 
nucleotides are incorporated in one cycle. This can result from inadequate 
flushing of the flow cell as leftover dNTPs are incorporated after removal of the 
terminator. (Figure 7, right strand) Post-phasing leads to the strand lagging 
behind. Here, the terminator is not completely removed, so no nucleotide can be 
added.173 (Figure 7, left strand) If the terminator cannot be removed, the 
fluorescence of the cluster is dimmed. This also occurs over the course of the 
sequencing due to laser damage to the DNA strands, which reduces the number 
of strands in a cluster.171  
 
Figure 7: Phasing effects 
The left strand depicts a post-phased sequence, the right a pre-phased one. The middle strand 
continues without phasing effects of any kind. The black dots represent the sequencing primers 
and the black star the terminator, which prevents addition of the subsequent nucleotide. After 
incorporation of the correct dNTP (upper middle), the non-incorporated dNTPs are washed away 
(upper right). If some remain due to inadequate washing, these are incorporated into the growing 
strand after removal of the terminator (lower left, right strand), resulting in a pre-phased 
sequence. If the terminator cannot be removed (lower left, left strand), no base will be attached in 
the next sequencing cycle (lower middle, left strand). This results in a post-phased sequence.  
As these errors are well-known, efforts have been undertaken to find methods to 
correct for them. Bustard, the base-calling software implemented in Illumina 
sequencers, corrects for phasing based on a constant phasing rate.174 BayesCall 
and Ibis also consider the surrounding bases.174,175 The more complex All Your 
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Base adjusts for e.g., cycle-wise differences in cross-talk on a run-by-run 
basis.171  
 
1.2.3 Nucleobase-modified aptamers 
Specific characteristics of an identified aptamer can be improved by using a wide 
variety of modifications. While sugar-modifications like 2’-fluoro or 2’-methoxy are 
mostly used to increase RNA-stability176, locked nucleic acids (LNA, containing a 
2’-O,4’-C-methylene bridge) also have an effect on duplex stability.177,178 
Additions to the 3’- and 5’-end can increase nuclease resistance (by capping the 
end using an inverted nucleotide) or decrease renal filtration and thereby improve 
the serum half-life (by addition of a high molecular weight PEG).176  
Although these modifications can already be included during selection140, many 
are added post-selection to improve the stability or pharmacokinetics of the 
aptamer. A prime example is the FDA-approved (Food and Drug Administration) 
Pegaptanib, an aptamer against age-related macular degeneration. Of its 27 
bases, only two remain unmodified.144  
Nucleobase-modifications, in contrast, are chosen to improve the interaction 
between the target molecule and the aptamer. They all build on the premise that 
the interaction possibilities of nucleic acids are much more restricted than those 
of antibodies due to the high chemical diversity of the amino acids in comparison 
with the four canonical nucleobases.179 This is regarded as the reason for the 
failure of about 70% of all aptamer selections for protein targets. Modifications of 
the nucleobase increase the available chemistries and thereby the interaction 
possibilities. They were shown to elevate the success rate of selections to 84% in 
the case of slow off-rate modified aptamers (SOMAmers).180  
The first aptamer containing a nucleobase-modification (5’-(1-pentynyl)-2’-
deoxyuridine) was selected for thrombin by Latham et al. in 1994. The ability to 
interact with thrombin depended on the modification, but the affinity of the 
modified aptamer was no better than those reached with non-modified 
aptamers.181,182 
Several options for the selection of nucleobase-modified aptamers have since 
been established (sections 1.2.3.1 to 1.2.3.3). 
 
1.2.3.1 Aptamers containing an expanded genetic alphabet 
While not strictly nucleobase-modifications, the use of an extended genetic 
alphabet definitely increases the available interaction possibilities. Two different 
groups published approaches for the selection of aptamers using different 
additional nucleobases. 
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Kimoto et al. base their work on the additional base pair dDs-dPx (Ds: 7-(2-
thienyl)imidazo[4,5- b]pyridine, Px: 2-nitro-4-propynylpyrrole). The base pair 
interacts through hydrophobic and packing forces in contrast to the hydrogen 
bonding responsible for the pairing of the natural nucleobases (Figure 8A).183 
dDs is incorporated into the DNA used for selection, whereas dPx is only used for 
PCR-amplification. The resulting library therefore consists of five different 
nucleobases – the four canonical ones plus dDs.  
 
Figure 8: Additional base pairs in aptamers with an extended genetic alphabet 
(A) dDs-dPx base pair, whose interaction is based on hydrophobic and packing forces. 
dDs has been implemented in aptamer selections. (B) dZ-dP base pair, whose 
interaction is based on hydrogen bonding. The base pair has been used for aptamer 
selections. 
While the original selections constricted dDs to predetermined positions to enable 
their identification via sequencing of a corresponding index code184,185, this 
restriction was recently overcome and aptamers for the von Willebrand factor A1-
domain were selected with a completely randomised library.186 The fact that the 
affinity of all aptamers selected with the hydrophobic dDs was significantly higher 
in contrast to those selected with the natural nucleobases and increased further 
with the complete randomisation of the additional base dDs supports the 
hypothesis that an increase in interaction possibilities of the nucleobases also 
improves aptamer selection and characteristics.184,186,187 
The second unnatural base pair used for aptamer selection is dZ-dP (dZ: 6-
amino-5-nitro-3-(1′-β-D-2′-deoxyribofuranosyl)-2(1H)-pyridone, dP: 2-amino-8-(1′-
β-D-2-deoxyribofuranosyl)-imidazo[1,2-a]-1,3,5-triazin-4(8H)one). Like the natural 
base pairs, its interaction is based on hydrogen bonding (Figure 8B).183 Both 
additional bases were inserted into the random region, resulting in a library 
composed of six different nucleobases.  
Aptamers containing these six nucleobases were published for breast cell cancer 
cells, for a protein overexpressed on a cell line, and for a purified protein.188-190 All 
of them contained fewer unnatural bases than the SL179, which might result from 
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an imperfect retention of those bases during PCR.188 Even though the aptamers 
had similar affinities as those consisting of only the natural base pairs188-190, one 
of them showed an uncharacteristic peak in CD-spectroscopy experiments. This 
might reflect an as of now unknown folding behaviour induced by the additional 
base pair, which would also change the interaction possibilities of aptamers 
containing such base pairs.190  
 
1.2.3.2 SOMAmers 
SOMAmers have been invented by SomaLogic® as an alternative to 
conventional aptamers. They consist of nucleobase-modified aptamers that 
contain uracil carrying an amide-linked modification at position five instead of 
thymidine. A wide variety of modifications, mostly based on amino acid side 
chains, has been used for selection successfully (Figure 9A).180,191  
 
Figure 9: Modified nucleotides in SOMAmers 
(A) The modified uridine is used as fourth base for SOMAmer selection. The modification is 
attached via an amide-linker. Shown are two exemplary hydrophobic, aromatic modifications that 
are present in the so-far crystallised SOMAmers. (B) The modified deoxycytidine was used for the 
selection with two different modifications. The same modifications as with the modified uridine 
were used. 
While the technique has some drawbacks – a modification has to be synthesised 
as both phosphoramidite and triphosphate to be useable for selection and a two-
step PCR procedure is needed to gain a fully modified, enriched library192 – it was 
the first to prove that nucleobase-modifications are able to dramatically increase 
selection success for protein targets as mentioned above (section 1.2.3). At the 
same time, affinities are strongly improved in comparison with aptamers 
consisting of the canonical nucleobases.180,191 Of all tested modifications so far, 
aromatic, hydrophobic side chains like those shown in Figure 9A have proven to 
be the most successful.191 
A recent publication showed that this technique enables the selection with two 
different modifications: In addition to uridine, deoxycytidine is also modified with 
an amide linker at position five (Figure 9B). Two different modifications lead to 
even further improved SOMAmer affinities in comparison with those carrying only 
one modification.193 
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SOMAmers are the first of the published nucleobase-modified aptamers that 
were crystallised and therefore give an insight into the impact these types of 
modifications have on aptamer – or SOMAmer – folding and the molecular 
interaction with the target molecule. Four different SOMAmer structures have 
been solved: benzyl-deoxyuridine (Bn-dU, Figure 9A) ones for platelet-derived 
growth factor B (PDGF-BB, PDB-ID: 4HQX and 4HQU)194, interleukin-6 (IL-6, 
PDB-ID: 4NI7 and 4NI9)195, and nerve growth factor (NGF, PDB-ID: 4ZBN)196, as 
well as a naphthyl-modified (naphthyl-deoxyuridine, Nap-dU, Figure 9A) 
SOMAmer for interleukin-1 (IL-1, PDB-ID: 5UC6).197 In all of them, the 
hydrophobic modifications cluster together and stabilise compact conformations. 
Often, these contain non-helical zipper structures, in which the modification π-
stacks with a second uridine and acts as a pseudo base pair (Figure 10).197 The 
interaction with the target molecules is based on less polar contacts than in non-
modified aptamers as the hydrophobic modifications take over the majority of this 
interaction.194,195,197 An exception to this is the NGF-SOMAmer, of which only few 
modified nucleotides directly interact with the target protein. Most build 
hydrophobic clusters that stabilise an S-shaped structure made up of three 
aligned strands.179,196  
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Figure 10: Zipper structure in the IL-1-SOMAmer 
(A) Excerpt from the IL1-SOMAmer structure showing the non-helical zipper structure 
that can be also be found in other SOMAmers. The naphthyl-modification π-stacks with 
the adjacent uridine. This way, two modified uridines act as base pairs and unwind the 
helical structure. The structure (PDB-ID: 5UC6) was modified with the freeware program 
RCSB PDB Protein Workshop 4.2.0.198 (B) Schematic representation of the structure 
shown in (A) to illustrate the base pairing. Cytosines are depicted in light blue, guanines 
in red, and naphthyl-modified uridines in black. The backbone is shown in grey. 
 
1.2.3.3 Clickmers 
Copper-catalysed alkyne-azide cycloaddition (CuAAC, click chemistry) has also 
been used to modify nucleobases for aptamer selection. CuAAC is one of the 
most widely utilised techniques to functionalise biomolecules nowadays.199,200 It 
has become popular because the tags are small and do not react with functional 
groups intrinsic to biomolecules and the reaction is quantitative.199 Chelating 
agents can be used to solve the problem that Cu+ in solution damages DNA, 
facilitating the use of click chemistry to functionalise DNA.201  
The group of Thomas Carell showed that alkyne-modified DNA-building blocks 
can be incorporated into DNA, amplified by PCR, and modified by CuAAC with a 
multitude of functionalisations.202-204 This enabled the development of a CuAAC-
based technique for the selection of nucleobase-modified aptamers, called 
clickmers.205  
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For this, the SL is synthesised with 5-ethynyl-2’-deoxyuridine (EdU) instead of 
thymidine and modified with the functionalisation of choice via CuAAC (Figure 
11). The click-modified DNA is incubated with the target molecule as in a normal 
SELEX, followed by wash steps to remove unbound DNA and the recovery of the 
bound DNA. During PCR, unmodified 5-ethynyl-2’-deoxyuridine triphosphate 
(EdUTP) is incorporated, which enables one-step amplification of the 
functionalised DNA. Single-strand displacement can be performed as with 
unmodified DNA because the alkyne does not affect enzymatic compatibilities. 
Afterwards, the enriched ssDNA is refunctionalised by CuAAC and the thereby 
gained DNA can be used for the subsequent selection cycle (Figure 12).152,205  
 
Figure 11: Copper-catalysed alkyne-azide cycloaddition 
Indicated are the modified nucleobases resulting from the use of ethylindole-azide as 
applied in the published click-SELEX205 as well as those resulting from benzyl- and 
trifluoromethylbenzyl-azide, both of which are utilised in this thesis. 
In contrast to the above mentioned technique using an expanded genetic 
alphabet, the modification can be freely chosen as long as the respective azide is 
commercially available or can be synthesised. This is also possible for 
SOMAmers, but the latter requires synthesis of the modified triphosphate for 
PCR-amplification and the modified phosphoramidite for synthesis of the library. 
Click-SELEX relies on commercially available building blocks. Modifications can 
be chosen to suit the target without laborious syntheses and change of the 
modification can modulate clickmer affinity. In addition, the removal of the 
modification during amplification facilitates the use of larger modifications that 
might otherwise lead to enzymatic compatibility issues.152 
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Figure 12: Schematic illustration of a click-SELEX cycle 
The SL containing EdU instead of thymidine is modified with the azide of choice and incubated 
with the immobilised target molecule. After removal of non-binding sequences by washing, the 
binding sequences are recovered and amplified by PCR using EdUTP. The functionalisation is 
thereby removed. The alkyne-modified DNA can be enzymatically digested to the single strand 
and the enriched library refunctionalised by CuAAC before starting the next selection cycle. 
As of now, the technique has been shown to work for a model target, GFP, with 
an ethylindole-azide as clicked-in modification.205  
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2 Aim of the study 
THC is the most widely used illegal drug worldwide. Amongst a multitude of 
effects, its use negatively affects driving skills. This necessitates the ability to 
detect THC on the roadside. As urine tests fail to detect THC in impaired drivers 
and oral fluid tests do not reach the needed sensitivity and specificity, a different 
approach was called for.  
The objective of this study was the identification and characterisation of THC-
binding aptamers that could then be used for the development of oral fluid-based 
roadside tests. In contrast to antibodies, aptamers are thermostable and can be 
stored at room temperature. In addition, their chemical synthesis enables 
relatively cheap and consistent production. Therefore, such a test would probably 
be cheaper and more stable than an antibody-based one and could be stored in a 
police car until needed without necessitating any kind of cooling equipment.  
For the selection of THC-binding aptamers, strategies for the immobilisation of 
THC on a solid support had to be developed. As THC itself only contains a single 
functional group that can be used for immobilisation, the carboxylated, biological 
precursor, THCA, was also taken into consideration.  
To evaluate binding of potential aptamers in solution, knowledge about THC-
solubility was imperative. Due to its high hydrophobicity and the resulting limited 
solubility in aqueous solutions in combination with the low solubility of DNA or 
2’F-RNA in organic solvents, conditions that keep DNA, 2’F-RNA, and THC in 
solution had to be identified. The most likely candidates were combinations of 
buffers and low percentages of organic solvents. 
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3 Results 
Selections for THC-binding aptamers were performed both with non-nucleobase-
modified nucleic acids (section 3.1) as well as with the technique called click-
SELEX (section 1.2.3.3), where click-chemistry is used to introduce modifications 
into the nucleic acid library used for selection. The respective results of the 
selection as well as experiments undertaken to characterise the resulting THC-
binding sequences can be found in section 3.2. The final section, 3.3, illustrates 
the results of a toggle-SELEX, for which THCA-modified magnetic beads and 
THC-sepharose were used alternatingly as solid support during the selection 
process. 
 
3.1 THC-selections with non-nucleobase-modified DNA and 2’F-
RNA 
The initial selections for THC-binding aptamers were performed with non-
nucleobase modified DNA and 2’F-RNA, both of which are nuclease-resistant 
and might be usable in saliva. Prior to the actual selection, THC was immobilised. 
Two different solid supports were used: amine-functionalised magnetic beads 
and epoxy-activated sepharose. The immobilisation technique as well as the 
selections performed using the respective solid support and their results are 
described in section 3.1.1 for the amine-functionalised magnetic beads and in 
3.1.2 for epoxy-activated sepharose. 
 
3.1.1 Selections on THCA-functionalised amine-dynabeads 
In order to retain the hydroxyl group of THC and its possibility of forming 
hydrogen bonds with a potential aptamer, selections for a THC-binding aptamer 
were performed using the biological precursor THCA. The additional carboxyl 
group could be used for the immobilisation on amine-functionalised magnetic 
beads (Figure 1A and B).  
Due to the low solubility of THCA in aqueous solutions, the immobilisation was 
performed in DMSO, which is well tolerated by the magnetic beads.206 THCA was 
activated with N,N'-dicyclohexylcarbodiimide (DCC) and the activated carboxylic 
acid reacted with the amine-groups on the magnetic beads, building an amide 
bond between magnetic bead and THCA (Figure 13).  
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Figure 13: Coupling of THCA to magnetic amine-dynabeads 
THCA (upper left) is activated using DCC (upper arrow). Upon addition of amine-functionalised 
magnetic beads (lower arrow), the activated THCA is coupled to the beads via an amide-bond 
and dicyclohexylurea is cleaved off.  
In order to verify the successful coupling of THCA to the magnetic amine-beads, 
a THC-binding antibody was used. Figure 14 shows the signal from both the 
THCA-coupled beads as well as the non-modified amine-functionalised beads. A 
clear increase in antibody-signal was detected for the THCA-beads. THCA had 
therefore been successfully coupled to the magnetic beads and these were used 
for the selection of THC-binding aptamers. 
 
Figure 14: Detection of THCA on magnetic amine-beads 
Detection of THCA using a THC-antibody. (A) Signal for THCA on magnetic amine-beads that 
have been coupled to THCA. (B) Background signal on non-modified magnetic amine-beads. 
Overall five different selections were performed using THCA-beads as solid 
support: Two selections used 2’F-RNA-, two DNA-based libraries, and one 
selection was performed using 2’F-RNA in a library that is prestructured to form a 
G-quadruplex. Table 3 gives an overview over the respective length of the 
random regions, selection buffers, elution methods, and the number of selection 
cycles.  
The DNA or 2’F-RNA of several selection cycles of each selection (Table 3) was 
tested for its interaction with THCA-beads as well as non-modified magnetic 
amine-beads. The DNA or 2’F-RNA of the last respective selection cycle did not 
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show improved interaction with the THCA-beads in comparison with the non-
modified beads or the DNA/2’F-RNA from earlier selection cycles (Figure 15). 
For SELEX 1 (Figure 15A), the interaction with non-modified beads was not 
tested as it was already apparent from the tests on THCA-beads that no 
enrichment of THC-binding sequences had occurred.  
Table 3: Selections performed on THCA-modified amine beads with non-nucleobase-
modified DNA/RNA 
SELEX Library Buffer Elution 
Selection 
cycles 
1 
  
PBS, pH 7.4 
500 mM NaCl,  
3 mM MgCl2, 
0.1 mg/ml salmon sperm DNA 
heat: 3 min 80°C 
15 
N40 
2 
2'F-RNA affinity: 5 mM THC, 
7% Cremophor   
3* 
G-quadruplex 
2'F-RNA 
50 mM Hepes, pH 8.0 
50 mM KCl, 3 mM MgCl2 
heparin 
(Beads into PCR) 10 4 
N43 
DNA 
5 
N75 
DNA 
* performed by Patrick Günther 
In general, all selections on THCA-coupled magnetic beads were unsuccessful 
even though THCA was detectable on the beads (Figure 14). Therefore, a 
different immobilisation was chosen for the subsequent selections. 
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Figure 15: Interaction analysis of THC-selections performed on THCA-modified amine 
beads with non-nucleobase-modified DNA/RNA 
32
P-labelled DNA/2’F-RNA was incubated with THCA-beads (black bars) or unmodified beads 
(grey bars). After two washing steps, the amount of radioactivity on the beads was quantified. 
Depicted is the interaction analysis of (A) SELEX 1, (B) SELEX 2, (C) SELEX 3, (D) SELEX 4, 
and (E) SELEX 5. No interaction analysis of SELEX 1 (A) on unmodified beads was performed. 
The experiments for the data presented in (C) were performed by Patrick Günther.  
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3.1.2 Selections on THC-sepharose 
3.1.2.1 Immobilisation of THC on epoxy-activated sepharose 
To optimise the immobilisation of THC on epoxy-activated sepharose, the 
reaction was first established in solution. The linker that is found on epoxy-
activated sepharose is commercially available: 1,4-butanedioldiglycidyl ether 
(BDE). As with THCA and the magnetic beads, the reaction was carried out in 
DMSO to ensure THC-solubilisation.  
In preliminary tests, 10% triethylamine (TEA) was found to be effective in 
transferring phenol into the aqueous phase, an indication of its deprotonation. As 
the acid dissociation constant (pKA) of phenol (9.99)
207,208 is similar to the one of 
THC (10.6)56 identical conditions should be able to deprotonate THC, which 
should in turn enable its reaction with BDE.  
The reaction scheme is depicted in Figure 16 and includes the exact masses of 
both educts and the product. 
 
Figure 16: Coupling of THC to BDE in solution 
THC (on the left) reacts with BDE (on the arrow) in solution to THC-linker (THC-L, on the right). 
The reaction takes place in 90% DMSO with 10% TEA as a base at 50°C.  
Figure 17 shows the liquid chromatography – mass spectrometry (LC-MS) 
analysis of the coupling after 1, 3, 6, and 7 days. Peak 1 as indicated in the UV 
chromatograms in Figure 17A represented unreacted THC as apparent by the 
corresponding mass that was analysed in Figure 17B. Peak 2 represented the 
coupling product, THC-L. The corresponding mass and its sodium adduct (+22 = 
539.4) was analysed in Figure 17C.  
The two peaks between peak 1 and 2 contained masses 513.42 and 515.51, 
respectively, in addition to the corresponding sodium adducts (data not shown). 
These masses were only slightly reduced (-4 or -2, respectively) in comparison 
with the mass of the coupling product, THC-L, and might represent elimination 
products.  
An additional sample with ten times more of the coupling product from day 7 
(day7_conc, Figure 17A) was also analysed to see if the sample concentration 
had an influence on the distribution of the peaks and to identify low abundance 
peaks that might not be visible in the lower concentrated samples. No distinctive 
differences between the samples from day 7 and day7_conc can be observed. 
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The tail of the product peak (peak 2) is less pronounced in the concentrated 
sample, indicating that the tail might result from the low sample concentration and 
not represent a real contamination. 
 
Figure 17: LC-MS analysis of the coupling of THC to BDE after 1, 3, 6, and 7 days 
(A) UV-chromatograms of the LC-MS analysis of the coupling of THC to BDE after 1, 3, 6, and 7 
days. The last line shows the analysis of a ten times more concentrated, but otherwise identical 
sample from day 7 (day 7_conc). (B) Positive and negative mass spectrum of peak 1 on day 1. 
The found mass matches THC. (C) Positive and negative mass spectrum of peak 2 on day 7. The 
found masses correspond to THC-L and THC-L with Na
+
 (+22 = 539.4). 
 
Peak 1 and peak 2 were analysed regarding the area under the curve for 
quantification of the coupling yields. It was apparent that the percentage of 
coupling product (peak 2) increased with increasing reaction time (Figure 17A 
and Figure 18). The increase in coupling product was only minor between day 6 
and 7, indicating that the reaction was completed and longer reaction times would 
not lead to higher coupling yields. The yield reached 94.3% THC-L after 7 days. 
In the more concentrated sample, day7_conc, the calculated yield was even 
higher with 99.4%. As both of these samples were taken after 7 days of coupling, 
the real yield was probably in between those two values and high enough to 
enable successful coupling of THC to epoxy-activated sepharose. 
 
45 
 
  
 
Figure 18: Time course of the coupling of THC to BDE 
Yield of coupling product, THC-L, according to the LC-MS-analysis. 100% equals the sum of peak 
1 and 2 and is indicated with a dashed line. Black dots represent the normal analysis setup, while 
the grey rectangle stands for the more concentrated sample (day 7_conc).  
The coupling reaction of THC to epoxy-activated sepharose is depicted in Figure 
19. The linker on the sepharose is identical to BDE, the linker used for the in 
solution experiments. One of the epoxy rings has opened and reacted with the 
sepharose. 
 
Figure 19: Coupling of THC to epoxy-activated sepharose 
THC (on the left) reacts with epoxy-activated sepharose (on the arrow) to THC-sepharose (on the 
right). The reaction takes place in 90% DMSO with 10% TEA as a base at 50°C for 7 days.  
As for the THCA-coupled magnetic beads, the successful coupling was verified 
using a THC-antibody. THC was clearly detected on the surface of the THC-
sepharose, while only a minor background signal was detected on the unmodified 
epoxy-activated sepharose (Figure 20). In comparison to the signal obtained on 
the THCA-beads (Figure 14), the signal on the THC-sepharose was much more 
intense, while the background on the non-modified sepharose was only slightly 
more pronounced. This indicates a denser coupling of THC on the sepharose 
than THCA on the amine-beads. 
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Figure 20: Detection of THC on epoxy-activated sepharose 
Detection of THC using a THC-antibody. (A) Signal for THC on epoxy-activated sepharose that 
has been coupled to THC. (B) Background signal on non-modified epoxy-activated sepharose. 
 
3.1.2.2 Selections performed on THC-sepharose 
After successfully coupling THC to epoxy-activated sepharose, two different 
selections were performed: One with a traditional, unstructured DNA-library and 
one with a DNA-library that is prestructured to form a G-quadruplex. This library 
had been used before as a 2’F-RNA-library in SELEX 3 (Table 3). Table 4 gives 
an overview of the selection libraries, buffer, elution technique, and number of 
selection cycles.  
Table 4: Selections performed on THC-sepharose with non-nucleobase-modified DNA 
SELEX Library Buffer Elution 
Selection 
cycles 
6 
N43 
DNA 
  
heat: 10 min 65°C,  
4.25 M urea,  
12.5 mM EDTA 
10 
PBS, pH 7.0 
7 
G-quadruplex 
DNA 
20 mM K
+
, 3 mM MgCl2 
  
 
The DNA of several selection cycles of each selection was tested for its 
interaction with THC-sepharose as well as unmodified sepharose. For both 
selections, a clear increase in interaction with the unmodified sepharose, but not 
with the THC-sepharose was observed for DNA from higher selection cycles 
(Figure 21). Therefore, the selections most likely only enriched sepharose-
binding sequences that are incapable of recognising THC-sepharose. 
At this point, an overall number of seven selections with DNA, 2’F-RNA, libraries 
of varying random region lengths, different buffers, elution techniques, and 
immobilisation techniques had failed. Therefore, a completely new and innovative 
approach was needed for the selection of THC-binding aptamers. 
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Figure 21: Interaction analysis of THC-selections performed on THC-sepharose with non-
nucleobase-modified DNA 
32
P-labelled DNA from different selection cycles and the SL was incubated with THC-sepharose 
(black bars) or unmodified sepharose (grey bars). After two washing steps, the amount of 
radioactivity on the sepharose was quantified. Depicted is the interaction analysis of (A) SELEX 6 
and (B) SELEX 7.  
 
3.2 Click-SELEX on THC-sepharose 
None of the THC-selections with non-nucleobase-modified nucleic acids had 
resulted in an enrichment of THC-binding sequences (section 3.1). This might be 
due to the high hydrophobicity of THC and its low amount of functional groups 
that allow little interaction with the canonical nucleic acids. 
Click-SELEX enables the modular introduction of nucleobase-modifications into 
the DNA-library that is used for selection (section 1.2.3.3). It therefore presents a 
possibility to introduce side chains into the nucleic acid library that might enable 
its interaction with THC. Based on the knowledge that the interaction of THC with 
the cannabinoid receptor is mainly conferred through π-π-stacking with 
phenylalanine residues (section 1.1.2, Figure 3, Table 2), we chose benzyl- and 
trifluoromethylbenzyl- (CF3-) azides for the modification of the library and 
performed two selections in parallel, one with each modification. 
The following sections detail the selections with those two modifications (section 
3.2.1) as well as the characterisation and sequencing of the DNA from the 
enriched libraries. The initial characterisation of the THC-sepharose-binding 
sequences that resulted from those selections follows (section 3.2.2 and 3.2.3). 
The NGS approach used for sequencing is verified (section 3.2.4) before section 
3.2.5 deals with the determination of THC-solubility. This was necessary for the 
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analysis of the interaction of the THC-sepharose binding sequences with THC in 
solution. 
As none of the sequences showed interaction with THC in solution, a re-selection 
using affinity elution was performed. Details on the selection itself, the 
subsequent sequencing, and on the identified sequences can be found in section 
3.2.6. 
Finally, fluorescence polarisation assays were performed for the interaction 
analysis between THC in solution and the THC-sepharose-binding sequences. 
The synthesis and purification of two different THC-FITC-compounds and the 
corresponding fluorescence polarisation assays are detailed in sections 3.2.7 and 
3.2.8. 
 
3.2.1 Click-SELEX 
Two click-selections utilising either benzyl- or CF3-azide were performed to 
identify THC-binding clickmers. An overview of the changing selection conditions 
can be found in Table 5. The amount of THC-sepharose was kept constant and 
binding sequences were eluted using heat elution. 
Table 5: Selection conditions for the click-SELEX 
SELEX 
cycle 
wash 
volume 
PCR-
cycles 
1 2 mL 
B: 14 
C: 18 
2 3 mL 
B: 18 
C: 18 
3 4 mL 
B: 15 
C: 17 
4 5 mL 
B: 16 
C: 14 
5 6 mL 
B: 21 
C: 16 
6 7 mL 
B: 22 
C: 19 
7 8 mL 
B: 18 
C: 20 
8 9 mL 
B: 19 
C: 19 
9 10 mL 
B: 18 
C: 18 
10 11 mL 
B: 15 
C: 15 
B: Selection using benzyl-modified DNA. C: Selection using CF3-modified DNA. 
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For both selections, the selection buffer was composed as follows: 1x D-PBS (pH 
5.4, with 4.93 mM MgCl2, and 9 mM CaCl2) with 1 mg/ml BSA, 0.1 mg/ml salmon 
sperm DNA, and 0.1% Tween-20. The incubation was performed at 20°C for 
15 min to imitate a temperature and time frame that are realistic for a roadside 
testing device.  
As a slight decrease in the number of PCR-cycles was detected only in cycle 10 
and none of the prior selections with non-nucleobase-modified nucleic acids had 
succeeded, the wash volume was only slightly and slowly increased over the 
selection cycles. For the same reason, the amount of THC-sepharose and 
therefore the amount of target was kept constant throughout the selection 
process. 
 
3.2.2 Characterisation and sequencing of the benzyl-modified click-
SELEX 
After ten selection cycles, the interaction between THC-sepharose and the 
benzyl-modified DNA from different selection cycles was evaluated. DNA from 
selection cycle 8 and 10 showed a clearly increased binding to THC-sepharose, 
both in comparison to the interaction with unmodified sepharose as well as to the 
interaction of the DNA of selection cycle 1 and 4 (Figure 22A). This indicates that 
the selection was successful in enriching THC-sepharose-binding sequences. 
 
Figure 22: Interaction analysis of THC-selection performed on THC-sepharose with benzyl-
modified DNA 
32
P-labelled DNA with (full bars) or without benzyl-modification (alkyne-modified, striped bars) was 
incubated with THC-sepharose (black bars) or unmodified sepharose (grey bars). After two 
washing steps, the amount of radioactivity on the sepharose was quantified. (A) Interaction 
analysis of DNA from selection cycles 1, 4, 8, and 10. (B) Interaction analysis of benzyl-modified 
and non-modified (EdU-containing) DNA from selection cycles 1 and 10.  
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To test if the benzyl-modification is necessary for the interaction with THC-
sepharose, DNA from the first and last selection cycles (1 and 10) was tested 
both as modified (clicked with benzyl-azide) and unmodified (unclicked, 
containing EdU) DNA on THC- and unmodified sepharose. Contrary to modified 
DNA, the unmodified DNA from selection cycle 1 and 10 interacted with neither 
THC- nor unmodified sepharose (Figure 22B). Therefore, the benzyl-modification 
is required for the interaction of the DNA of selection cycle 10 with THC-
sepharose. 
The DNA from selection cycle 10 was sequenced by Sanger sequencing to 
identify potential THC-binding sequences. Table 6 shows the identified 
sequences that were tested, the number of modified nucleotides (EdUs), and 
their frequency both in the initial Sanger sequencing as well as in a later-on 
performed NGS analysis (Table A 1). Figure A 1A depicts the frequency of the 
identified sequences in all selection cycles analysed by NGS. The amount of 
modifications ranged from 5 EdUs in B13 to 9 in B12. The most abundant 
sequence in both Sanger and NGS was B27, the least abundant B10. The order 
of the sequences in between varied depending on the sequencing method used.  
Table 6: Sequences from the THC-selection with benzyl-modified DNA 
Seq. consensus sequence of the random region EdUs Sanger 
[%] 
NGS 
[%] 
B10 AXACXGGACCGCXACACCCCGCACCACCXCGCCAAXXGGXGA 7 5.4 0.5 
B11 GAXGCCGGACGXXGGAACGGGCGXGXCAXCAXAGGXACAGG 8 10.8 5.1 
B12 CAGCGGXCCXAGCGCGGXACXACGCAXCCCCXAXCXCCCCCX 9 13.5 4.1 
B13 GXGGGGCACAXCAGCGACCGXAXCCCCCAGACAGACXCAGGC 5 8.1 1.7 
B14 AACCCXGACXGGGAGXGAXGCCXACCGXAACACCXCCCGCAC 7 24.3 1.6 
B27 CXACAAXCGXGCGAXCCCCXAXCXCCAGACCXACGGGAACAC 8 35.1 10.6 
Seq. = sequence. X = EdU. Sanger = frequency in Sanger sequencing of selection cycle 10. NGS 
= frequency in NGS of selection cycle 10. 
All sequences described in Table 6 were tested for their interaction with THC- 
and unmodified sepharose. All sequences but the least abundant sequence, B10, 
interacted with THC-sepharose to varying degrees (Figure 23). The strongest 
interaction was apparent for B14 and B27, which were also the most abundant 
sequences in the final selection cycle according to NGS. B11 and B12 had the 
weakest interaction with THC-sepharose, but the interaction was still far more 
pronounced than that of B10, the DNA from selection cycle 1, or the interaction of 
any sequence with unmodified sepharose.  
The selection with benzyl-modified DNA thus led to the identification of five THC-
sepharose-binding sequences. Sequence B10 did not show binding to THC-
modified sepharose and was used as a non-binding control sequence for all 
subsequent assays. 
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Figure 23: Interaction analysis of the sequences from the selection with benzyl-modified 
DNA 
32
P-labelled DNA of the single sequences or from the indicated selection cycle was incubated with 
THC-sepharose (black or dark blue bars) or unmodified sepharose (grey or light blue bars). After 
two washing steps, the amount of radioactivity on the sepharose was quantified. All DNA was 
benzyl-modified.  
To analyse the specificity of the benzyl-modified THC-sepharose-binding 
sequences, their interaction with THCA-functionalised tosylated magnetic beads 
was tested. In comparison to the THC-sepharose, the hydroxyl-group of THC is 
unconjugated on the magnetic beads. Like with the THCA on magnetic amine 
beads used for the initial selections described in this thesis (section 3.1.1), THCA 
is immobilised via an amide bond with its carboxyl-group (Figure 24). The 
success of the coupling was verified by Malte Rosenthal, who also performed the 
coupling reaction.a 
 
Figure 24: Chemical structure of THC-sepharose and THCA-beads. 
(A) Structure of THC-sepharose that has been coupled according to Figure 19. (B) Structure of 
THCA-beads, for which THCA (Figure 1B) was coupled to tosylated magnetic beads. The 
coupling and detection of THCA on the beads according to section 6.2.2.4 was performed by 
Malte Rosenthal.  
                                            
a
 Malte Rosenthal, PhD thesis in preparation, Bonn, 2018/2019 
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The interaction analysis depicted in Figure 25 shows that only sequence B11 
interacted with the THCA-beads. While the control sequence B10 did not bind to 
the THCA-beads, the DNA from selection cycle 1 recognised THCA with a similar 
ratio modified:unmodified beads as the DNA from cycle 10. B12 and B27 showed 
better binding to the THCA- than to the methylamine-blocked tosylated beads, 
but barely better than the control B10. The percentage of binding of the remaining 
sequences was reduced in comparison to those on THC-sepharose (Figure 23). 
None of the sequences interacted with the methylamine-blocked tosylated beads.  
 
Figure 25: Interaction analysis of the benzyl-modified sequences with THCA-beads 
32
P-labelled DNA was incubated with magnetic THCA-beads (black or dark blue bars) or 
methylamine-blocked tosylated beads (grey or light blue bars). After two washing steps, the 
amount of radioactivity on the beads was quantified. Tested were B10, B11, B12, B13, B14, and 
B27, as well as DNA from selection cycle 1 and 10. All DNA was benzyl-modified. 
 
3.2.3 Characterisation and sequencing of the CF3-modified click-
SELEX 
The DNA from selection cycle 1, 4, 8, and 10 of the selection with CF3-modified 
DNA was incubated with THC- and unmodified sepharose. DNA from both 
selection cycle 8 and 10 showed an increase in binding to THC-sepharose and a 
decrease in binding to unmodified sepharose, indicating an enrichment of THC-
binding sequences in the later selection cycles (Figure 26A).  
The DNA from selection cycles 1 and 10 was also tested without modification 
(unclicked, containing EdU). This should elucidate the necessity of the 
modification for the increase in interaction with THC-sepharose, which had been 
observed for CF3-modified DNA from selection cycle 10. Without modification, the 
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interaction of the DNA from selection cycle 10 with both types of sepharose was 
even lower than the interaction of the modified DNA with the unmodified 
sepharose. No difference between unmodified DNA from selection cycle 1 and 10 
was detectable (Figure 26B). Therefore, the CF3-modification is necessary for 
the interaction with THC-sepharose. 
 
Figure 26: Interaction analysis of THC-selection performed on THC-sepharose with CF3-
modified DNA 
32
P-labelled DNA with (full bars) or without CF3-modification (alkyne-modified, striped bars) was 
incubated with THC-sepharose (black bars) or unmodified sepharose (grey bars). After two 
washing steps, the amount of radioactivity on the sepharose was quantified. (A) Interaction 
analysis of DNA from selection cycles 1, 4, 8, and 10. (B) Interaction analysis of CF3-modified and 
non-modified (EdU-containing) DNA from selection cycles 1 and 10.  
In order to identify the THC-binding sequences, the DNA from selection cycle 10 
was sequenced by both Sanger and NGS. Three different sequences were 
identified as enriched: C15, C30, and C47 (Table 7 and Table A 2). Figure A 1B 
depicts the frequency of the identified sequences in all selection cycles analysed 
by NGS. They contained between 4 and 9 modifications. Even though the 
frequency of the identified sequences was far lower in NGS than detected by 
Sanger sequencing, the order was identical with both methods: C15 was the least 
abundant sequence, followed by C30 and C47.  
All three sequences (Table 7) were radioactively labelled and tested for their 
interaction with THC- and unmodified sepharose. All of them interacted with THC-
sepharose to a similar degree as DNA from selection cycle 10 (Figure 27).  
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Table 7: Sequences from the THC-selection with CF3-modified DNA 
Seq. consensus sequence of the random region EdUs Sanger 
[%] 
NGS 
[%] 
C15 XGGCGCGXCCAGAGGCXXAXAGGGGGGGAGCCXACGXXGAAX 9 6.3 0.1 
C30 CCAGCCGCGCGGAAGACAAXACACGXXGGGCCACXAAGGAAG 4 9.4 0.6 
C47 CGAXAAXACACGXXCGGCCCCXAAAGCCGGXCGGCCCXXGCA 8 43.8 11.4 
Seq. = sequence. X = EdU. Sanger = frequency in Sanger sequencing of selection cycle 10. NGS 
= frequency in NGS of selection cycle 10. 
The selection with CF3-modified DNA enabled the identification of three THC-
sepharose-binding sequences. No non-binding sequence was identified. 
Therefore, DNA from selection cycle 1 was used as a negative control in the 
subsequent assays.  
 
Figure 27: Interaction analysis of the sequences from the selection with CF3-modified DNA 
32
P-labelled DNA was incubated with THC-sepharose (black or dark green bars) or unmodified 
sepharose (grey or light green bars). After two washing steps, the amount of radioactivity on the 
sepharose was quantified. Tested were C15, C30, and C47 as well as DNA from selection cycles 
1 and 10. All DNA was CF3-modified. 
 
3.2.4 Verification of the NGS approach 
The use of NGS for aptamer identification is a relatively new technique (section 
1.2.2) and its results can differ vastly from those obtained by Sanger sequencing 
as is obvious from the results presented in Table 6. To verify our analysis, we 
evaluated different sample preparation techniques and determined average 
mutation rates by analysing a single sequence with millions of reads. The results 
are presented in the subsequent sections. The influence of the sample 
preparation on mutation rates is described in section 3.2.4.1. Repetitive 
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sequences are analysed in section 3.2.4.2 and the influence of the exclusion of 
shortened sequences is portrayed in section 3.2.4.3. Error rates after the 
omission of shortened sequences are calculated (section 3.2.4.4) and the effect 
of the exclusion of shortened sequences on SELEX samples is displayed in 
section 3.2.4.5. 
 
3.2.4.1 Influence of the sample preparation on mutation rates 
PCRs during sample preparation (‘index-PCR’) and sequencing have been 
indicated as a reason for increased mutation rates that result in sequencing 
errors.165,169,209 The NGS samples for the analysis of the click-selections 
presented above (section 3.2.2 and 3.2.3) were prepared using Pwo polymerase. 
To assess the impact of the index-PCR (section 6.2.6.6), the sequence of C12, 
the clickmer identified for GFP205, was prepared for NGS-analysis using Pwo 
(T_Pwo) and Taq polymerase (T_Taq) as well as without index-PCR (T_w/o). All 
samples were amplified from a template containing thymidine instead of EdU. A 
forth sample was prepared from an EdU-containing template with Pwo 
polymerase (EdU_Pwo) (Table 8). The NGS-analysis showed that EdU_Pwo led 
to the highest frequency of mutated sequences and the highest error rate 
(average mutation per base). From the samples with thymidine-containing 
templates, T_Pwo obtained the lowest frequency of mutated sequences, but the 
highest error rate, while T_Taq had the highest frequency of mutated sequences 
and T_w/o the lowest error rate (Table 8).  
Table 8: Frequency of mutations in differently prepared C12-samples 
Sample 
name 
EdU/T in 
template 
Polymerase 
for index-
PCR 
Mutated 
seq. [%] 
Error rate [%] 
(mean ± SD) 
Analysed 
seq. 
T_Pwo T Pwo 12.23 3.04 ± 1.87 1,119,179 
T_Taq T Taq 12.47 2.85 ± 1.75 3,416,163 
T_w/o T none1 12.43 2.55 ± 1.83 1,872,807 
EdU_Pwo EdU2 Pwo 32.02 6.15 ± 4.01 4,593,685 
Seq. = sequences. SD = standard deviation. 
1
 DNA was solid-phase synthesised including the indices 
2
 due to solid-phase synthesis of template, 20% of EdUs are oxidized to KdU
210,211
 
We next analysed each position of the sequence. All samples showed an 
increase in mutation frequency over the length of the sequence, resulting in a 
roughly ten times higher mutation rate at the end than at the start of the analysed 
sequence (Figure 28). Overall, EdU_Pwo had increased mutation frequencies in 
comparison with the samples prepared from thymidine-containing templates. 
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Figure 28: Mutation frequency in differently prepared C12-samples 
Mutation frequency at each position of the analysed sequence. Colours indicate the original 
nucleotide at the respective position. The colour legend in (A) is valid for all four graphs. The 
analysed samples were prepared using (A) a thymidine-containing template and Pwo polymerase, 
(B) a thymidine-containing template and Taq polymerase, (C) a thymidine-containing template 
without index-PCR, and (D) an EdU-containing template and Pwo polymerase. 
To further compare the differently prepared samples, the average mutation 
frequency of the single nucleotides and of the nucleotides, into which the original 
nucleotide mutated, were analysed. EdU_Pwo had a significantly increased 
mutation frequency of the mutated nucleotides (Figure 29A). As expected, the 
preparation without index-PCR (T_w/o) showed the lowest mutation rate. 
However, the slight differences between the three samples with the thymidine-
containing template were not significant. The same trends could be seen for the 
mutation into a specific nucleotide, but the increase for EdU_Pwo was not 
significant for this analysis (Figure 29B). It was discovered that the mutation 
frequencies into a specific nucleotide reflected the nucleotide distribution of the 
original sample (Figure 29C). To identify the reason for this correlation, we 
studied samples with repetitive sequences. 
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Figure 29: Average mutation frequencies of differently prepared C12-samples and 
nucleotide distribution of C12 
(A) Average mutation frequencies of the original nucleotides. EdU_Pwo has a statistically 
increased mutation frequency in comparison to the three other data sets: EdU_Pwo vs. T_Pwo, 
T_Taq, and T_w/o p = 0.0286. Mann-Whitney tests, two-tailed. Preliminary Kruskal-Wallis-test 
p = 0.0132. n = 9, 8, 19, and 6 for A, C, G, and T, respectively. (B) Average frequencies, with 
which the original nucleotide mutated into the denoted one. The differences are non-significant: 
Kruskal-Wallis-test. n = 33, 34, 23, and 36 for A, C, G, and T, respectively. (C) Nucleotide 
distribution in non-mutated C12.  
 
3.2.4.2 Analysis of repetitive sequences 
We evaluated repetitive sequences with one or four identical nucleotides in a row: 
FT2_GATC and FT2_G4A4T4C4. While the frequency of mutated sequences 
was slightly higher for FT2_G4A4T4C4 than for FT2_GATC, the latter had a 
higher error rate (Table 9). In comparison to the C12-samples, both repetitive 
samples showed lower frequencies of mutated sequences and lower error rates 
(Table 8). 
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Table 9: Frequency of mutations in repetitive sequences 
Sample name Mutated 
sequences [%] 
Error rate [%] 
(mean ± SD) 
Number of analysed 
sequences 
FT2_GATC 8.44 1.63 ± 0.82 10,059,713 
FT2_GATC_II 6.62 1.48 ± 0.78 2,332,475 
FT2_G4A4T4C4 10.87 0.83 ± 0.83 8,235,942 
FT2_G4A4T4C4_II 10.15 0.83 ± 0.83 7,288,615 
FT2_G2A2T2C2 11.33 1.54 ± 0.96 2,301,791 
FT2_G3A3T3C3 11.66 1.46 ± 1.08 6,265,796 
FT2_TGCA 10.94 2.18 ± 1.16 7,441,266 
D3_TGCA 7.27 1.09 ± 0.56 429,868 
FT2_T4G4C4A4 10.79 0.92 ± 0.90 1,956,098 
D3_T4G4C4A4 10.90 0.87 ± 0.97 5,930,886 
 
Regarding their mutation frequencies at each position, the trend was identical to 
what had been observed before: The frequency increased from the start to the 
end of the sequence by a factor of about ten (Figure 30A and B). The increase 
was steady for FT2_GATC. In FT2_G4A4T4C4, only the last nucleotide of each 
block made up of four identical nucleotides had a high and rising mutation 
frequency. The first three nucleotides showed a low mutation frequency. This can 
explain the discrepancy observed in Table 9. As only every fourth nucleotide had 
a high mutation frequency, the average error rate was lower than for FT2_GATC. 
The high mutation frequency of the fourth nucleotide nonetheless led to a 
relatively high frequency of mutated sequences. 
For both repetitive sequences, clear preferences for the conversion from one 
nucleotide into another specific nucleotide were observed (Figure 30C and D). 
These preferences are depicted in Figure 31. The conversions occurred primarily 
from one nucleotide into the subsequent one.  
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Figure 30: Mutation frequencies of repetitive sequences 
The colour legend in (A) denotes the colour of the original nucleotide for all four subpanels. 
Mutation frequency of FT2_G4A4T4C4 (A) and FT2_GATC (B) at each position of the analysed 
sequence as well as average mutation frequency, with which the mutation occurred into the 
denoted nucleotide for FT2_G4A4T4C4 (C) and FT2_GATC (D). The conversions for (C) are non-
significant (Kruskal-Wallis test, n=8). Those for (D) are significant with a p ≤ 0.0174 (t-tests, two-
tailed, preliminary one-way ANOVA: p=<0.0001, 0.0002, <0.0001, and 0.0007 for mutated into T, 
A, C, and G, respectively, n=8).  
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Figure 31: Main conversions of repetitive GATC-samples 
The most frequent mutations of one nucleotide into another of the FT2_GATC and 
FT2_G4A4T4C4-samples. The dotted arrow is only valid for the FT2_G4T4A4C4-sample.  
To evaluate this hypothesis, additional repetitive sequences were analysed by 
NGS. Sequences containing different primer binding sites and different nucleotide 
orders (D3_TGCA, D3_T4G4C4A4, FT2_TGCA, FT2_T4G4C4A4) as well as 
some with two or three identical nucleotides in a row (FT2_G2A2T2C2, 
FT2_G3A3T3C3) were chosen to identify potential biases (Table 9). All analysed 
sequences, including the C12-samples, showed a bias towards mutation to the 
subsequent nucleotide (Table 10): A completely random mutation would result in 
mutations to the subsequent nucleotide around 33.3% due to the three available 
options. All samples tested in this study showed mutation frequencies to the 
subsequent nucleotide ≥ 60%.  
Table 10: Frequency of mutation to the subsequent nucleotide 
Sample name Mutation to subsequent nt [%] 
(mean ± SD) 
EdU_Pwo 76.0 ± 14.80 
T_Pwo 73.2 ± 17.14 
T_Taq 74.1 ± 18.34 
T_w/o 76.5 ± 15.14 
FT2_GATC 64.3 ± 3.85 
FT2_GATC_II 65.0 ± 4.49 
FT2_TGCA 60.2 ± 7.98 
D3_TGCA 71.7 ± 11.45 
FT2_G2A2T2C2 77.2 ± 8.65 
FT2_G3A3T3C3 80.1 ± 8.07 
FT2_G4A4T4C4 83.8 ± 9.63 
FT2_G4A4T4C4_II 83.8 ± 9.63 
FT2_T4G4C4A4 86.0 ± 6.57 
D3_T4G4C4A4 86.6 ± 6.81 
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Independent of the nucleotide order and the primer binding site, the mutation 
frequency to the subsequent nucleotide increased significantly with the number of 
identical nucleotides in a row from about 65% for a single nucleotide to about 
85% for four identical nucleotides in a row (Figure 32).  
 
Figure 32: Mutation frequency to the subsequent nucleotide 
Depicted is the average frequency, with which a nucleotide mutated to the subsequent nucleotide 
for all analysed, repetitive sequences. The difference between one consecutive identical 
nucleotide and four is significant with p=0.0294 (Mann-Whitney test, two-tailed, n=31 and 7 for 1 
and 4 nucleotides in a row, respectively). 
 
3.2.4.3 Omission of shortened sequences 
Phasing effects (section 1.2.2) are a possible explanation for the increase in 
mutation frequency over the length of the analysed sequence as well as for the 
high mutation rates to the subsequent nucleotide. Analysis of the most abundant 
sequences of each sample showed that pre-phased sequences are shortened 
(Table A 3 to Table A 16). Although shortening might also occur through 
deletions, we decided to omit all shortened sequences and reanalyse the 
samples under these conditions. 
Omission of shortened sequences led to a decrease of the number of analysed 
sequences by about 5% and an increase of the frequency of non-mutated 
sequences by the same margin. At the same time, the error rate dropped by 
about 79%. Due to the presence of EdU in EdU_Pwo and the resulting high error 
rates and mutation frequencies in comparison with all other analysed sequences, 
EdU_Pwo was excluded for the calculation of all averages (Table 11). 
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Table 11: Change upon omission of shortened sequences 
Sample name Δ analysed 
seq. [%]  
Δ non-
mutated 
seq. [%] 
Δ error 
rate [%] 
Mutation to 
subsequent nt: 
deviation from 33.3% 
w/                 w/o 
shortened sequences 
EdU_Pwo -15.76 18.70 -86.83 42.7 3.7 
T_Pwo -7.75 8.41 -95.07 39.9 11.4 
T_Taq -7.17 7.71 -93.33 40.8 12.9 
T_w/o -7.40 7.99 -92.94 43.2 2.1 
FT2_GATC -2.94 3.04 -87.73 31.0 0.5 
FT2_GATC_II -2.80 2.88 -72.97 31.7 0.1 
FT2_G4A4T4C4 -3.16 3.26 -66.27 26.9 1.3 
FT2_G4A4T4C4_II -3.25 3.37 -69.88 38.4 6.3 
FT2_G2A2T2C2 -3.90 4.06 -81.17 43.9 -0.1 
FT2_G3A3T3C3 -4.56 4.78 -43.48 46.8 6.5 
FT2_TGCA -4.00 4.17 -88.99 50.5 2.0 
D3_TGCA -1.97 2.01 -83.49 50.5 -2.1 
FT2_T4G4C4A4 -3.86 4.01 -72.83 52.7 13.5 
D3_T4G4C4A4 -3.52 3.65 -70.11 53.3 6.5 
average -5.15 5.57 -78.93 42.31 4.61 
Seq. = sequences. 
EdU_Pwo was excluded for calculation of the averages. 
Both the average mutation frequencies of each nucleotide of the C12-samples as 
well as the average frequency, with which a nucleotide mutates into the denoted 
one, were severely reduced for all samples. The mutation frequencies of 
EdU_Pwo were still significantly higher than those of the other samples (Figure 
33A and B). Most importantly, the mutation frequencies into the denoted 
nucleotide no longer reflected the nucleotide composition of C12 (Figure 33B 
and Figure 29C). One representative of the mutation frequency at each position 
is depicted in Figure 33C and displays that the mutation frequency no longer 
increased over the length of the analysed sequences. This was the case for all 
analysed samples after omission of the shortened sequences (data not shown). 
For FT2_GATC and FT2_G4A4T4C4, specific mutation hotspots became 
apparent (Figure 33C). The mutation frequency to the subsequent nucleotide 
dropped to values around the expected 33.3%. In addition, it no longer depended 
on the number of identical nucleotides in a row (Figure 33D and Table 11). 
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Figure 33: Mutation frequencies after omission of shortened sequences 
Average mutation frequencies of the original nucleotides (A) and frequencies, with which the 
original nucleotide mutated into the denoted one (B) for the four different C12-samples. The 
legend in (A) is valid for both (A) and (B). The larger graphs are scaled according to Figure 29A 
and B to simplify comparisons before and after omission of shortened sequences. The smaller 
zoom-ins are scaled to allow a detailed view of the results. For (A), EdU_Pwo vs. T_Taq and 
T_w/o and T_Pwo vs. T_Taq are significant with a p = 0.0067 each. (Mann-Whitney tests, two-
tailed, preliminary Kruskal-Wallis test: p = 0.0067, n = 9, 8, 19, and 6 for A, C, G, and T, 
respectively.) For (B), EdU_Pwo vs. T_Pwo, T_Taq, and T_w/o is significant with a p = 0.0286. 
(Mann-Whitney tests, two-tailed, preliminary Kruskal-Wallis test: p = 0.026, n = 33, 34, 23, and 36 
for A, C, G, and T, respectively.) (C) Mutation frequency for each position of the analysed 
sequences of FT2_GATC and FT2_G4A4T4C4. The graph is scaled according to Figure 30A and 
B to simplify comparisons before and after omission of shortened sequences. (D) Mutation 
frequency of one nucleotide into the subsequent nucleotide for all repetitive sequences after 
omission of shortened sequences. The expected average mutation frequency of 33.3% is 
indicated with a dotted line. The difference between the samples containing one and four identical 
nucleotides in a row is no longer significant. (Mann-Whitney test, two-tailed, n = 31 and 7 for 1 
and 4 nucleotides in a row, respectively.) 
All of this indicated that the omission of shortened sequences managed to 
exclude the majority of the pre-phased sequences without loss of the majority of 
sequences as only about 5% of all analysed sequences were omitted (Table 11).  
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3.2.4.4 Error analysis after omission of shortened sequences 
Having thus excluded pre-phased sequences, we analysed the ‘real’ error rates 
in samples sequenced by NGS. EdU_Pwo was excluded due to its high mutation 
rates. After exclusion, the average percentage of mutated sequences of the 
remaining sequences was 6.4 ± 1.24% and the average error rate 0.24 ± 0.06% 
per base. The C12-samples (apart from EdU_Pwo) had slightly lower 
percentages of mutated sequences and error rates compared to the majority of 
repetitive sequences. 
Table 12: Frequency of mutations if shortened sequences are omitted 
Sample name Mutated 
seq. [%] 
Error rate [%] 
(mean ± SD) 
Mutation to 
subsequent nt [%] 
(mean ± SD) 
Analysed 
seq. 
EdU_Pwo 19.31 0.81 ± 0.57 37.0 ± 16.87 3,869,868 
T_Pwo 4.85 0.15 ± 0.06 44.7 ± 18.29 1,032,398 
T_Taq 5.72 0.19 ± 0.08 46.2 ± 21.52 3,171,344 
T_w/o 5.43 0.18 ± 0.07 35.4 ± 15.04 1,734,189 
FT2_GATC 5.66 0.20 ± 0.09 33.8 ± 15.38 9,763,653 
FT2_GATC_II 3.93 0.14 ± 0.05 33.4 ± 22.45 2,267,079 
FT2_G4A4T4C4 7.96 0.28 ± 0.28 34.6 ± 9.37 7,975,576 
FT2_G4A4T4C4_II 7.12 0.25 ± 0.23 39.6 ± 19.39 7,051,464 
FT2_G2A2T2C2 7.73 0.29 ± 0.16 33.2 ± 24.18 2,211,912 
FT2_G3A3T3C3 7.44 0.26 ± 0.14 39.8 ± 23.50 5,979,814 
FT2_TGCA 7.23 0.24 ± 0.16 35.3 ± 24.73 7,143,566 
D3_TGCA 5.41 0.18 ± 0.11 31.2 ± 25.28 421,388 
FT2_T4G4C4A4 7.21 0.25 ± 0.17 46.8 ± 23.74 1,880,590 
D3_T4G4C4A4 7.65 0.26 ± 0.22 39.8 ± 21.08 5,722,279 
Seq. = sequences. 
The conversion from each nucleotide to a specific, different nucleotide was 
analysed for each of the samples (Table 13). Again, EdU_Pwo was excluded 
from the calculation of the averages due to its high mutation rates. As expected, 
EdU_Pwo showed very high mutation rates of thymidine (in average 0.65%), 
which was replaced by EdU in the sequencing template. In the other samples, C 
followed by G mutated most often (in average 0.093 and 0.083%, respectively) 
and A and T showed the lowest mutation rates (in average 0.067 and 0.06%). 
This was turned around when analysing the nucleotides into which mutations 
occurred most abundantly: T and A were most frequently mutated into (both in 
average 0.107%) and G and C least (in average 0.05 and 0.04%, respectively). 
Regarding specific conversions, the conversion from C to A was most likely to 
occur with an average of 0.13% and the conversions from A to C, C to G, G to C, 
and T to C least likely with an average of 0.04%. FT2_G2A2T2C2 and 
FT2_G3A3T3C3 had especially high mutation rates from C to A and G to T 
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(0.27% for both for FT2_G2A2T2C2 and 0.26 and 0.24%, respectively, for 
FT2_G3A3T3C3). 
Table 13: Conversion between nucleotides after omission of shortened sequences 
Original A C G T 
Mutated to [%] C G T A G T A C T A C G 
EdU_Pwo 0.36 0.20 0.07 0.29 0.19 0.10 0.13 0.16 0.35 0.61 0.79 0.54 
T_Pwo 0.03 0.11 0.03 0.05 0.04 0.05 0.08 0.02 0.04 0.03 0.06 0.08 
T_Taq 0.05 0.14 0.02 0.11 0.04 0.05 0.08 0.03 0.06 0.03 0.10 0.10 
T_w/o 0.02 0.05 0.07 0.11 0.04 0.06 0.06 0.03 0.07 0.07 0.06 0.06 
FT2_GATC 0.06 0.04 0.13 0.08 0.04 0.10 0.08 0.04 0.08 0.09 0.04 0.05 
FT2_GATC_II 0.02 0.02 0.10 0.07 0.02 0.07 0.05 0.02 0.09 0.06 0.02 0.02 
FT2_G4A4T4C4 0.09 0.18 0.18 0.10 0.07 0.10 0.07 0.05 0.10 0.07 0.05 0.04 
FT2_G4A4T4C4_II 0.16 0.05 0.09 0.06 0.04 0.03 0.13 0.05 0.01 0.16 0.06 0.16 
FT2_G2A2T2C2 0.01 0.03 0.09 0.27 0.03 0.14 0.11 0.05 0.27 0.13 0.03 0.01 
FT2_G3A3T3C3 0.01 0.03 0.09 0.26 0.05 0.13 0.10 0.04 0.24 0.10 0.03 0.01 
FT2_TGCA 0.01 0.03 0.20 0.16 0.04 0.14 0.09 0.05 0.10 0.11 0.03 0.01 
D3_TGCA 0.01 0.03 0.15 0.09 0.04 0.14 0.10 0.02 0.08 0.04 0.02 0.01 
FT2_T4G4C4A4 0.02 0.02 0.08 0.18 0.03 0.20 0.17 0.04 0.14 0.07 0.03 0.03 
D3_T4G4C4A4 0.02 0.03 0.07 0.16 0.04 0.19 0.11 0.02 0.16 0.20 0.02 0.02 
average 0.04 0.06 0.10 0.13 0.04 0.11 0.10 0.04 0.11 0.09 0.04 0.05 
The colouring indicating high (red) or low (green) values was performed separately for A) 
EdU_Pwo, B) the other samples, and C) the average. EdU_Pwo was excluded for calculation of 
the averages. 
 
3.2.4.5 Effect of exclusion of shortened sequences on analysis of 
SELEX samples 
To investigate the effect of the exclusion of the shortened sequences on the 
analysis of complex SELEX samples, we analysed several selection cycles of the 
selection that yielded C12.152,205 Displayed in Figure 34 are patterns, which are 
clustered using relative information entropy and regarded as sequence families. 
The NGS-frequency values given in Table 6 and Table 7 as well as those 
displayed in section 3.2.6 were obtained from such patterns that contain the 
specified sequence family. While slight differences in frequencies resulted from 
the omission of shortened sequences, the overall trends remained unchanged 
(Figure 34).  
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Figure 34: Frequency of different SELEX patterns before and after exclusion of shortened 
sequences 
Frequency of six different SELEX patterns over the course of the GFP-SELEX. Selection cycles 
before cycle six were omitted as the frequencies were too low to be visible. (A) Frequencies 
before omission of the shortened sequences. (B) Frequencies after omission of the shortened 
sequences.
152
 
 
3.2.5 Solubility determination of THC 
Having thus validated that NGS can be used for the identification of potential 
clickmer candidates, we went on to determine the affinity of the identified 
sequences to THC in solution. As a multitude of assays at low THC-
concentrations was not successful (data not shown), higher THC-concentrations 
had to be evaluated. More knowledge on THC-solubility in the used buffer was 
required. For this analysis, the area under the curve of the THC-peak as 
determined by high performance liquid chromatography (HPLC) was measured. 
Solubility was analysed by linear regression and determination of the coefficient 
of determination (R2). An R2-value of 1 represents perfect linearity and therefore 
solubility. A similar method has been published by Hazekamp et al.212  
THC has a high hydrophobicity with an octanol/water partition coefficient (logP) of 
5.65.208,213 Accordingly, solubility in aqueous solutions is low with 2.45 µM THC in 
0.15 M NaCl.56 The selection buffer contains slightly less NaCl (137 mM), in 
which THC-solubility is expected to be about 2.5 µM.  
THC-solubility in organic solvents is much better: THC is known to be soluble in 
methanol (MeOH) and up to 100 mg/ml in ethanol (EtOH).214,b As non-PEGylated 
(polyethylene glycol) nucleic acids are not soluble in pure organic solvents215, low 
percentages of organic solvents were added to D-PBS and examined for their 
ability to enhance THC-solubility.c,216 First of all, different concentrations of 
                                            
b
 Personal communication with PD Dr. Andras Bilkei-Gorzo, Institute of Molecular Psychiatry, 
University of Bonn 
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DMSO, 100% of which can solubilise 60 mg/ml (190.7 mM) THC, were 
studied.c,216  
The detergent Tween-20 was added to some samples to evaluate its effect on 
THC-solubility as it is part of the selection buffer used for the click-selections. 
Tween-20 is a non-ionic detergent with a critical micelle concentration (CMC) of 
0.06 mM (0.0067% (v/v)).217 
For the samples containing 100% DMSO, the area under the curve of the THC-
peak increased linearly (Figure 35A). This indicated, as expected, that all THC 
was in solution and that this sample can serve as a control. In contrast, the signal 
for THC in 10% DMSO was not linear and was reduced in comparison to the 
control. The addition of 0.1% Tween led to similar values as measured for 100% 
DMSO, indicating that THC-solubility was recovered (Figure 35A).  
As 0.1% Tween apparently enabled the use of low concentrations of organic 
solvents to solubilise THC, the best solvent had to be discovered. Acetonitrile 
(ACN), ethanol, and DMSO were tested. Both 5% EtOH and ACN led to good 
linearities (> 0.98), which were far higher than those reached with the same 
amount of DMSO (0.69) (Figure 35B). ACN was chosen for further tests. 100% 
DMSO and ACN both showed good linearities, but the signal intensities varied 
between the two solvents (Figure 35B). 
                                            
c
 Information regarding solubility in organic solvents could be found on 
http://www.caymanchem.com (product insert for product 12068, extracted 24.04.2014): 
[…] Solvents such as ethanol, methanol, DMSO, and dimethyl formamide (DMF) […] 
can be used. The solubility of Δ
9
-THC in these solvents is approximately 35, 30, 60, 
and 50 mg/ml, respectively. 
Δ
9
-THC is sparingly soluble in aqueous buffers. […] Δ
9
-THC has a solubility of 
approximately 250 µg/ml [0.8 mM, annotation of the author] in a 1:3 solution of 
DMF:PBS (pH 7.2) […]. […] 
No references were given and the product insert has since been exchanged for one that does not 
contain any information on THC-solubility.  
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Figure 35: HPLC-measurement of THC-dilutions in DMSO, ACN, and EtOH 
(A) Analysis of a single sample each of 5, 10, and 20 µM THC in 100% DMSO, 10% DMSO, or 
10% DMSO with 0.1% Tween-20. As only a single sample was measured, no R
2
-values were 
determined. (B) Analysis of THC-concentrations between 5 and 10 µM in 5% DMSO, ACN, and 
EtOH, all of which also contained 0.1% Tween. Measurements in 100% DMSO and ACN were 
performed as controls. 
Having established that 5% ACN with 0.1% Tween can solubilise THC in 
concentrations up to 10 µM, higher concentrations were tested to discover the 
upper limit of THC-solubility under these conditions. As shown in Figure 36, the 
linearity of the regression curve for 5% ACN was satisfactory up to a 
concentration of 150 µM THC. A measurement of 250 µM THC suffered from very 
large error bars, indicating relatively unreproducible data points and strongly 
reduced the obtained linearity. Therefore, 150 µM THC in 5% ACN with 0.1% 
Tween were set as the maximum THC-concentration used in the subsequent 
assays. 
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Figure 36: HPLC-measurement of THC-dilutions in 5 and 100% ACN 
HPLC-analysis of THC-concentrations between 5 and 250 µM THC in 5% ACN with 0.1% Tween 
and in 100% ACN as control. The linearity (R
2
) for 5% ACN has been calculated both including 
(incl.) and excluding (excl.) the value measured for 250 µM THC.  
Before these conditions could be used for interaction analysis of the identified 
THC-sepharose-binding sequences, it had to be determined if the addition of 5% 
ACN (0.1% Tween is already part of the selection buffer) has an influence on the 
interaction of the sequences with the THC-sepharose. Figure 37A shows the 
results for most of the benzyl-modified sequences: The interaction of B14 and 
B27 with THC-sepharose was reduced in the presence of 5% ACN, but sufficient 
to categorise both as binding sequences. B13 did not interact with THC-
sepharose in the presence of 5% ACN. Both B11 and B12 bound to THC-
sepharose in the presence of 5% ACN (Figure 37B). The analysis of the CF3-
modified sequences can be found in Figure 37C. All sequences interacted with 
THC-sepharose in the presence of 5% ACN. 
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Figure 37: Interaction analysis of all sequences in the presence of 5% ACN 
Benzyl-modified DNA is depicted in shades of blue, CF3-modified DNA in shades of green. 
32
P-
labelled DNA was incubated with THC-sepharose (dark blues and dark green) or unmodified 
sepharose (light blues or light green). After two washing steps, the amount of radioactivity on the 
sepharose was quantified. The incubation took place in the presence and absence (A only) of 5% 
ACN. (A) Test of benzyl-modified sequences B10, B13, B14, and B27. (B) Test of benzyl-modified 
sequences B10, B11, and B12. (C) Test of CF3-modified sequences. cyc 1 = CF3-modified DNA 
from selection cycle 1.  
These successfully established conditions (≤150 µM THC, 5% ACN, 0.1% 
Tween) were used in a multitude of assays in order to obtain information on the 
affinity of the THC-sepharose-binding sequences and on their ability to recognise 
THC in solution. Tested were, amongst others, microscale thermophoresis, filter 
retention assays using THC immobilised on BSA, lysozyme, or THC-sepharose, 
competition assays using a combination of immobilised THC (THC-sepharose 
and THCA-beads (structure see Figure 24)) and varying concentrations of THC 
in solution, and pulldown assays, for which the sequences were biotinylated and 
immobilised on streptavidin-coated plates. None of the assays was able to 
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reproducibly and clearly show binding of any of the sequences to THC in solution 
(data not shown). 
 
3.2.6 Re-selection of THC-binding sequences utilising affinity elution 
As none of the assays showed binding of any sequence to THC in solution, the 
sequences that had been identified so far were suspected to recognise THC only 
if it was immobilised on sepharose. The original selections had used heat elution 
to unspecifically recover bound DNA (Table 5). In a re-selection approach, bound 
DNA was eluted by addition of decreasing concentrations of THC in 5% ACN to 
enrich sequences that interact with non-immobilised THC. The re-selection was 
performed based on DNA from the old selection cycles 4. The buffer used to 
wash away unbound or unspecifically binding sequences also contained 5% 
ACN. Table 14 details the selection conditions during each selection cycle. 
Table 14: Conditions for the re-selection with affinity elution 
SELEX 
cycle 
incubation 
time 
wash 
volume 
wash time elution 
PCR-
cycles 
5 15 min 6 ml n.d. 
150 µM 
THC 
B: 14 
C: 15 
6 15 min 7 ml n.d. 
15 µM 
THC 
B: 18 
C: 12 
7 15 min 
B: 8 ml B: 15 min 1.5 µM 
THC 
B: 15 
C: 14 ml C: 30 min C: 18 
8 10 min 
B: 14 ml B: 22 min 150 nM 
THC 
B: 14 
C: 14 ml C: 23 min C: 15 
9 
B: 10 min B: 22 ml B: 43 min 15 nM 
THC 
B: 10 
C: 5 min C: 20 ml C: 43 min C: 11 
10 5 min 
B: 40 ml B: 84 min 1.5 nM 
THC 
B: 11 
C: 40 ml C: 81 min C: 12 
B: Selection using benzyl-modified DNA. C: Selection using CF3-modified DNA. n.d. = not 
determined. 
After selection cycle 10, DNA from selection cycles 1, 5, 8, and 10 was tested for 
its interaction with THC-sepharose. DNA from selection cycle 10 of the first 
selections (10*) was used as a positive control. DNA from selection cycles 8 and 
10 from both selections showed a clear increase in binding to THC-sepharose. 
The DNA from cycle 10 interacted with THC-sepharose to an equal (benzyl-
modified selection) or even stronger degree (CF3-modified selection) than the 
DNA from the original selection (10*) (Figure 38).  
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Figure 38: Interaction analysis of THC-selections performed on THC-sepharose using 
affinity elution 
32
P-labelled DNA with benzyl- (A) and CF3- (B) modification was incubated with THC-sepharose 
(black bars) or unmodified sepharose (grey bars). After two washing steps, the amount of 
radioactivity on the sepharose was quantified. Indicated with an asterisk is the final selection cycle 
of the first successful THC-selections with the same modification (compare Figure 22A for (A) 
and Figure 26A for (B)). 
To identify potential THC-binding sequences, the DNA from both selection cycles 
10 was analysed by Sanger sequencing. The identified sequences from the 
benzyl-modified selection are detailed in Table 15. B11, B14, and B27 were 
known from the first selection. Sequence 3 had also been identified in the first 
selection, but as a unique sequence and therefore not tested alongside the 
original sequences (Table A 1). Sequence 27 was newly discovered, but only 
present as a unique sequence (Table A 17). 
Table 15: Sequences from the affinity THC-selection with benzyl-modified DNA.  
Seq. consensus sequence of the random region EdUs Sanger 
[%] 
B11* GAXGCCGGACGXXGGAACGGGCGXGXCAXCAXAGGXACAGG 8 29.3 
B14* AACCCXGACXGGGAGXGAXGCCXACCGXAACACCXCCCGCAC 7 12.2 
B27* CXACAAXCGXGCGAXCCCCXAXCXCCAGACCXACGGGAACAC 8 48.8 
3* ACACXGGAXAGAXGCGGGGGGCAACGCCXXCAGGCAXCAGX 7 7.3 
27 ACGXCCXCAXCACCXCCCAXGXCXCCGGAGXCCACGGACAGG 8 unique 
Seq. = sequence. X = EdU. Sanger = frequency in Sanger sequencing of selection cycle 10. * = 
beforehand identified in the first THC-selection with benzyl-modified DNA 
Table 16 compares the frequencies of all known benzyl-modified sequences in 
the two Sanger sequencings and the NGS (Table A 1 and Table A 17). The non-
binding B10 as well as the binding B12 and B13 could not be detected in the 
Sanger sequencing of the re-selection. B27 was still the most abundant 
sequence. B11 was much more abundant than in the Sanger sequencing of the 
first selection, but was already the second most abundant sequence according to 
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the NGS of the first selection. Both new sequences, 3 and 27, could be found in 
the NGS data of the first selection cycle 10, but with frequencies close to the 
0.5% of the non-binding B10. 
Table 16: Frequencies of all benzyl-modified sequences identified from the first (1
st
) and 
second (affinity, 2
nd
) THC-selection 
Seq. 1st Sanger [%] 1st NGS [%] 2nd Sanger [%] 
B10 5.4 0.5 n.f. 
B11 10.8 5.1 29.3 
B12 13.5 4.1 n.f. 
B13 8.1 1.7 n.f. 
B14 24.3 1.6 12.2 
B27 35.1 10.6 48.8 
3 unique 0.8 7.3 
27 n.f. 0.2 unique 
Seq. = sequence. Sanger = frequency in Sanger sequencing of the respective selection cycle 10. 
NGS = frequency in NGS of the respective selection cycle 10. n.f. = sequence not found. 
The tested sequences that were identified from the final selection cycle of the 
new CF3-SELEX are depicted in Table 17. C15 was not found, but both C30 and 
C47 were present in the new selection (Table A 18). A multitude of new 
sequences was identified: 49, 53, 63, 67, 74, and 77. C47 was the most 
abundant sequence, but closely followed by the new sequence 53. All other new 
sequences were at least as abundant as C30.  
Table 17: Sequences from the affinity THC-selection with CF3-modified DNA 
Seq. consensus sequence of the random region EdUs Sanger 
[%] 
C30* CCAGCCGCGCGGAAGACAAXACACGXXGGGCCACXAAGGAAG 4 4.9 
C47* CGAXAAXACACGXXCGGCCCCXAAAGCCGGXCGGCCCXXGCA 8 19.5 
49 XGCGCGAGGGAXGAXXAAGAGAAGCXCAACCGCGCGGAGGCC 5 9.8 
53 XXCGGACGGAGAGAGCAGGGGGXGAGXAAAGAGXAGGXCCAG 6 14.6 
63 GCXCACGCCACACAAGGCAGAXCCXGAGCXCCGGGGGXCCAC 5 7.3 
67 AACXGCAGAAAGGGGAAGGCGAGGAAXAGXCCCCGGXXGGCA 5 4.9 
74 GCACGGAACAACCGCGAACGXACXAGCAXCCCGCGGCGAACA 3 9.8 
77 GGXAAXGGXGGAGGGXAAGGAGGACCCCGAAXXGXCCCCGXG 8 7.3 
Seq. = sequence. X = EdU. Sanger = frequency in Sanger sequencing of selection cycle 10. * = 
beforehand identified in the first THC-selection with CF3-modified DNA 
When comparing all three sequencing approaches for the selections with CF3-
modified DNA, C47 was always the most abundant sequence. Some of the new 
sequences were identified in the final selection cycle of the first selection by 
NGS, but their frequencies were extremely low. Sequences 63 and 74 could not 
be identified at all in the original selection cycle (Table 18). 
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Table 18: Frequencies of all CF3-modified sequences identified from the first (1
st
) and 
second (affinity, 2
nd
) THC-selection 
Seq. 1st Sanger [%] 1st NGS [%] 2nd Sanger [%] 
C15 6.3 0.1 n.f. 
C30 9.4 0.6 4.9 
C47 43.8 11.4 19.5 
49 n.f. 0.005 9.8 
53 n.f. 0.01 14.6 
63 n.f. n.f. 7.3 
67 n.f. 0.03 4.9 
74 n.f. n.f. 9.8 
77 n.f. 0.002 7.3 
Seq. = sequence. Sanger = frequency in Sanger sequencing of the respective selection cycle 10. 
NGS = frequency in NGS of the respective selection cycle 10. n.f. = sequence not found. 
All newly identified sequences were tested for binding to THC-sepharose in a 
radioactive assay alongside B10 as a negative control. All sequences interacted 
with THC-sepharose to varying degrees. Sequence 67 was the weakest binder 
(Figure 39).  
 
Figure 39: Interaction analysis of the new sequences from the affinity THC-selection 
Benzyl-modified DNA is depicted in shades of blue, CF3-modified DNA in shades of green. 
32
P-
labelled DNA was incubated with THC-sepharose (dark blue or green) or unmodified sepharose 
(light blue or green). After two washing steps, the amount of radioactivity on the sepharose was 
quantified. B10 from the first selection was used as a negative control.  
Competition as well as pulldown assays were performed with the newly identified 
sequences, but, as for the old sequences, no binding to THC in solution was 
detected (data not shown). 
 
3.2.7 Fluorescence polarisation assays with THC-FITC 
Fluorescence polarisation assays represent a method to evaluate in solution 
interaction between two molecules. They are often used with fluorescently-
labelled aptamers for the detection of their interaction with much larger 
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proteins.218 The smaller interaction partner needs to be fluorescent or 
fluorescently labelled. 
Fluorescence polarisation measures the rotation of the fluorescently labelled 
molecule. Figure 40 depicts the reason the linear polarised light, which is used to 
excite the fluorophore, is either emitted as polarised light or not: Small molecules 
rotate before the light is emitted. Thus, the resulting light is not polarised any 
longer. Larger molecules or complexes do not rotate before the light is emitted, 
leading to a high polarisation of the emitted light.219 
 
Figure 40: Fluorescence polarisation assay 
Linear polarised light is used to excite a fluorophore (green). The small fluorophore rotates quickly 
and the light is emitted into different directions, resulting in a low polarisation (upper panel). 
Larger molecules or complexes rotate slowly. The light is emitted before any rotation has taken 
place and is therefore still polarised, leading to a high polarisation value (lower panel).  
 
3.2.7.1 Synthesis and characterisation of THC-FITC 
As THC is the smaller interaction partner and no fluorescently labelled THC-
derivative was commercially available, THC-FITC was synthesised (Figure 41).  
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Figure 41: Coupling of THC to FITC 
THC is coupled to FITC (molar ratio THC:FITC 5:1) in dimethylformamide (DMF) with 20% TEA 
for 2 days at 65°C, yielding THC-FITC. 
The successful coupling was confirmed using LC-MS analysis (Figure 42A). 
Peak 1 was caused by THC, as identified in the mass spectrum (Figure 42B). 
Peak 2 represented the coupling product, THC-FITC (Figure 42C). The two 
peaks were integrated to analyse the coupling yield: About 75% of THC was 
successfully coupled to FITC (Figure 42A). Due to its high water solubility, the 
uncoupled FITC was most likely represented by the peak at min 1-2, which was 
not injected into the mass spectrometer. 
To remove unreacted THC and FITC, the crude product was purified using 
HPLC. LC-MS-analysis of the purified product showed that the THC-peak is no 
longer detectable and the FITC-peak has been severely reduced, indicating that 
the purification was successful (Figure 42A). The remaining peak was THC-
FITC, as ensured by the corresponding mass analysis (Figure 42D). 
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Figure 42: LC-MS analysis of coupling of THC to FITC before and after clean-up 
(A) UV-chromatograms of the LC-MS analysis of the coupling of THC to FITC before (upper 
panel) and after (lower panel) clean-up. Peaks 1 and 2 were analysed regarding the area under 
the curve for quantification of THC (peak 1) and THC-FITC (peak 2). (B) Positive (upper panel) 
and negative (lower panel) mass spectrum of peak 1, pre clean-up. The found mass matches 
THC. (C) Positive (upper panel) and negative (lower panel) mass spectrum of peak 2, pre clean-
up. The found mass matches THC-FITC. (D) Positive (upper panel) and negative (lower panel) 
mass spectrum of peak 2, post clean-up. The found mass matches THC-FITC.  
The newly synthesised THC-FITC was then characterised regarding its spectral 
properties. It showed two absorption maxima at 456 and 492 nm in water with 5% 
ACN (Figure 43). The latter was the known absorption maximum of FITC and 
was used for the concentration determination of THC-FITC. After excitation at 
492 nm, THC-FITC emits at about 520 nm. The emission was strongly reduced at 
pH 5.4 (D-PBS) in comparison to water (Figure 43B). Nonetheless, the 
fluorescence should be sufficient to measure fluorescence polarisation. 
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Figure 43: Absorption and emission spectra of THC-FITC 
(A) Absorption spectrum of THC-FITC (grey) (d = 0.05 cm) in water with 5% ACN (blank, black). 
(B) Emission spectrum of THC-FITC (excitation at 492 nm, depicted in shades of red). 
Fluorescence was measured in D-PBS, pH 5.4 (light red) and ddH2O (dark red). The blanks are 
depicted in grey and black, respectively. All samples contained 5% ACN to solubilise THC-FITC.  
 
3.2.7.2 Establishing the fluorescence polarisation assay 
To determine the optimal concentration for the interaction assays and to uncover 
possible differences between the two fluorophores, different concentrations of 
THC-FITC and FITC were tested for their fluorescence polarisation. The samples 
without Tween in Figure 44A showed that the polarisation of THC-FITC was 
strongly increased in comparison to FITC alone. Such an increase in polarisation 
was expected upon ligand-recognition. Therefore, THC-FITC could not be used 
for fluorescence polarisation assays under these conditions as no interaction with 
the THC-sepharose-binding sequences would be detectable. Thorough 
investigations of the reason for the increase in polarisation were conducted to 
establish conditions, with which THC-FITC could be used in fluorescence 
polarisation assays. Afterwards, binding of the THC-sepharose-binding 
sequences under the new conditions had to be verified. 
First of all, the influence of Tween was investigated. All assays up to this point 
contained 0.1% Tween, which was both part of the selection buffer (of all 
selections with click-modified DNA) as well as known to be necessary to keep 
THC in solution (Figure 35A). Its critical micelle concentration (CMC) of 0.0067% 
is far below the 0.1% used.217  
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Figure 44: Florescence polarisation of FITC and THC-FITC in the presence and absence of 
Tween-20 
The fluorescence polarisation of varying concentrations of FITC (black and grey) and THC-FITC 
(shades of red) was measured in the presence (dark red, black) and absence (light red, grey) of 
0.1% Tween-20. (A) Measurement in D-PBS, pH 5.4. (B) Measurement in PBS, pH 7.4. Values 
for 0.8 and 1.7 nM THC-FITC at pH 7.4 in the absence of Tween were omitted as the intensities 
were not above background intensity. 
The CMC determines the concentration at which a detergents starts to form 
micelles. At concentrations lower than the CMC, the detergent can be found 
either in solution or at the surface (Figure 45A). With increasing detergent 
concentration, increasing amounts are adsorbed at the surface and thereby 
decrease surface tension (Figure 45B). Once the surface is saturated, the 
detergent starts to form micelles (Figure 45C).220 
 
Figure 45: Visualisation of the detergent distribution at concentrations higher and lower 
than its CMC 
The detergent is depicted with an orange hydrophobic tail and a light blue hydrophilic head group. 
(A) At concentrations far below the CMC, the detergent can be found both in solution and at the 
surface. (B) With concentrations approaching the CMC, more and more detergent is adsorbed at 
the surface. The surface tension decreases because of this. (C) Once the surface is saturated 
with detergent, micelles start to form. The CMC has been reached. 
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As the Tween-concentration used is above its CMC, it is possible that THC and 
THC-FITC are contained within Tween-micelles. Repeating the determination of 
the concentration-dependent polarisation in the absence of Tween led to a 
decrease of the polarisation-values for both FITC and THC-FITC. The effect 
became more pronounced at higher concentrations of THC-FITC (Figure 44A). 
The effect was even more noticeable for THC-FITC at pH 7.4 (Figure 44B). FITC 
showed no dependence on the presence or absence of Tween at neutral pH.  
To evaluate the hypothesis that THC and THC-FITC are enclosed by Tween-
micelles, we tested their solubility in the presence of different concentrations of 
Tween: 0.1%, which had been used extensively and is far above the CMC, 
0.01%, which is above the CMC, and 0.05%, which is just below the CMC. The 
results of the HPLC-measurement are depicted in Figure 46.  
For THC-FITC (Figure 46A) and THC (Figure 46B) both, 100% as well as 5% 
ACN with 0.1% Tween led to good linearities. 5% ACN without any Tween also 
resulted in a good linearity for THC-FITC, but the gradient was completely 
different than the one of the regression curves of the two other conditions. Both 
lower Tween-concentrations led to a complete loss of linearity for THC-FITC, 
which mainly resulted from the decrease in signal obtained for the highest 
concentration of 20 µM.  
For THC (Figure 46B), 5% ACN alone led to a decrease in linearity and a 
changed gradient. Both Tween-concentrations above the CMC, 0.1 and 0.01%, 
led to a good linearity and a gradient similar to the sample containing 100% ACN. 
The concentration below the CMC, 0.005% Tween, led to a loss of linearity and a 
gradient similar to the sample containing 5% ACN, but no Tween. 
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Figure 46: HPLC-measurement of THC-FITC- and THC-dilutions in ACN with different 
concentrations of Tween 
HPLC-analysis of THC-FITC- (A) and THC- (B) concentrations between 5 and 20 µM in 100 
(black) and 5% ACN (grey) as controls as well as in 5% ACN with 0.1 (dark blue), 0.01 (medium 
blue), and 0.005% Tween-20 (light blue). 
The addition of Tween was not necessary to keep THC-FITC well solubilised. 
This would prevent any potential problems with Tween-micelles. Therefore, the 
maximal solubility of THC-FITC in 5% ACN was determined. The linearity of the 
resulting regression curve was sufficient for concentrations up to 25 µM (Figure 
47). As the concentrations of THC-FITC used for fluorescence polarisation 
assays were in the nanomolar range, no solubility problems should arise. 
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Figure 47: HPLC-measurement of THC-FITC-concentrations in ACN 
HPLC-measurement of THC-FITC-concentrations between 2 and 25 µM in 100 (black) and 5% 
ACN (grey).  
To determine the optimal buffer for fluorescence polarisation assays to analyse 
the interaction of the THC-sepharose-binding sequences with THC-FITC, 
different components of the selection buffer were tested for their influence on the 
polarisation. At the concentration used, 0.1% Tween had little effect. In contrast, 
the presence of BSA increased the polarisation by a factor of 2 to 2.5. It therefore 
had to be removed from the fluorescence polarisation buffer (Figure 48). 
 
Figure 48: Fluorescence polarisation of THC-FITC in different buffers 
Fluorescence polarisation of THC-FITC (26.5 nM) in the presence of different components of the 
selection buffer: BSA, salmon sperm DNA (sal. DNA), ACN, and Tween.  
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3.2.7.3 Evaluation of the THC-sepharose-binding sequences under 
conditions differing from the original selection buffer 
Before any fluorescence polarisation assays could be performed, the interaction 
of the THC-sepharose-binding sequences with THC-sepharose under the 
changed conditions (no Tween, no BSA) had to be confirmed. 
For this, all THC-sepharose binding sequences were incubated with both THC- 
and unmodified sepharose in the presence and absence of 0.1% Tween. The 
absence of Tween increased the interaction of all sequences with the THC-
sepharose to varying degrees (strongest for C15 and C47). B10 remained non-
binding under both conditions (Figure 49A). 
Figure 49B shows the results of the same assay in the presence and absence of 
BSA. No Tween was added to any of the samples. As with Tween, C15 and C47 
showed the highest differences between samples: BSA increased their 
interaction with THC-sepharose. Nonetheless, the interaction was sufficient also 
in the absence of BSA. The interaction of other sequences was only reduced 
slightly in the absence of BSA. B10 was not influenced at all.  
In conclusion, all sequences still interact with THC-sepharose in the absence of 
both Tween and BSA and are therefore fit to be tested for binding to THC in 
solution in fluorescence polarisation assays. 
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Figure 49: Interaction analysis of all sequences in the presence and absence of Tween and 
BSA 
Benzyl-modified DNA is depicted in shades of blue, CF3-modified DNA in shades of green. 
32
P-
labelled DNA was incubated with THC-sepharose or unmodified sepharose. The values on 
unmodified sepharose were subtracted from those on THC-sepharose and the difference 
depicted. (A) The samples were incubated in D-PBS, pH 5.4, with 0.1 mg/ml salmon sperm DNA, 
0.1 mg/ml BSA, and 5% ACN in the presence (light blue and green) or absence (dark blue and 
green) of 0.1% Tween-20. (B) The samples were incubated in D-PBS, pH 5.4, with 0.1 mg/ml 
salmon sperm DNA, and 5% ACN in the presence (light blue and green) or absence (dark blue 
and green) of 0.1 mg/ml BSA.  
As a last test, binding of all identified sequences at neutral pH was investigated. 
Since the fluorescence polarisation of THC-FITC is lower at pH 7.4 (Figure 44), 
the assay sensitivity is increased at this pH and so is the possibility of detecting in 
solution binding of THC.  
Most sequences lost their ability to interact with THC-sepharose at pH 7.4. 
(Figure 50) The non-binding control, B10, showed slightly higher binding values 
than at pH 5.4. The benzyl-modified sequences B12 and 27 showed equal (B12) 
or slightly decreased (27) interaction. Of the CF3-modified sequences, C15, C47, 
49, 53, and 77 retained their ability to interact with THC-sepharose, although the 
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interaction of 49, 53, and 77 is reduced. Overall, two of six benzyl- and five of 
nine CF3-modified sequences bind to THC-sepharose at neutral pH. The 
identified sequences will be tested for interaction with THC-FITC at pH 7.4 in the 
fluorescence polarisation assay. 
 
Figure 50: Interaction analysis of all sequences at pH 7.4 
Benzyl-modified DNA is depicted in shades of blue, CF3-modified DNA in shades of green. 
32
P-
labelled DNA was incubated with THC-sepharose or unmodified sepharose. The values on 
unmodified sepharose were subtracted from those on THC-sepharose and the difference 
depicted. The samples were incubated in D-PBS with 0.1 mg/ml salmon sperm DNA and 5% ACN 
at pH 7.4 (dark blue and green) and, as control, 5.4 (light blue and green).  
 
3.2.7.4 Fluorescence polarisation measurements using THC-FITC 
Prior to testing the sequences for their recognition of THC in solution, the ability 
of the fluorescence polarisation assay to measure concentration-dependent 
interactions had to be verified. Since no DNA – modified or not – is known to 
interact with THC, we chose the THC-antibody that was also used to detect THC 
on the THCA-beads and THC-sepharose. A galectin 3 (Gal3)-antibody, which 
should not interact with THC-FITC, as well as FITC were used as negative 
controls. The experiment was performed in PBS, pH 7.4. As before (Figure 44), 
the polarisation values were higher for THC-FITC than for FITC alone (Figure 
51). Any combination with either FITC or the Gal3-antibody resulted in antibody-
independent, low fluorescence polarisation values. Only the combination of THC-
FITC and the THC-antibody led to an increase in fluorescence polarisation that 
depended on the antibody-concentration. The determined affinity constants were 
27.8 ± 28.9 and 62.7 ± 60.5 nM for THC-FITC-concentrations of 26.5 and 53 nM, 
respectively.  
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Figure 51: Fluorescence polarisation of FITC and THC-FITC with varying concentrations of 
antibodies 
The fluorescence polarisation of FITC (black, shades of grey) and THC-FITC (shades of red) in 
the presence of varying concentrations of THC- (dots) and Gal3-antibody (squares) was 
measured. A Kd was determined for THC-FITC with the THC-antibody: 27.8 ± 28.9 and 62.7 ± 
60.5 nM for 26.5 and 53 nM THC-FITC, respectively.  
For the assays at pH 5.4, BSA was used as a positive control, as it is not known if 
the THC-antibody stably interacts with THC at this pH. BSA had been shown to 
interact unspecifically with THC-FITC and to increase its polarisation in the 
preliminary buffer test (Figure 48).  
The results of the fluorescence polarisation assay with the different benzyl-
modified sequences are shown in Figure 52A. While BSA led to the expected 
increase in polarisation, none of the sequences had any effect. 
 
Figure 52: Fluorescence polarisation of THC-FITC in the presence of different sequences at 
pH 5.4 
The fluorescence polarisation of THC-FITC (53 nM) was measured in the presence of 500 nM of 
the different sequences, 1 mg/ml BSA, or without any sequence (w/o). BSA was used as a 
positive control. No sequence (w/o) was used as negative control and the dotted line represents 
the corresponding polarisation. Benzyl-modified DNA is depicted in blue, CF3-modified DNA in 
green. (A) Sequences from the selection with benzyl-modified DNA. (B) Sequences from the 
selection with CF3-modified DNA. B10 was measured alongside as an additional, negative control. 
C cyc 1 indicates DNA from the first selection cycle of the selection with CF3-modified DNA.  
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The same is true for the assay concerning the CF3-modified sequences, which is 
depicted in Figure 52B. Some of the sequences led to a slight increase in 
polarisation in comparison to the non-binding B10 and the sample without DNA 
(w/o). Nevertheless, no increase was apparent in comparison to CF3-modified 
DNA from the first selection cycle (C cyc 1).  
The positive control BSA weighs about 66 kDa221, the THC-antibody has a size of 
about 150 kDa.222,223 The sequences consist of around 84 nucleobases and 
weigh 26 to 28 kDa, depending on the individual length, base composition, and 
number and type of modification. While unlikely, it is possible that the weight of 
the sequence alone might not be sufficient to lead to a detectable increase in 
polarisation. To rule this out, the sequences were 5’-biotinylated and streptavidin 
(52 kDa224) was added to the fluorescence polarisation assay. The combined 
weight of at least 78 kDa should lead to an increase in assay sensitivity.  
Figure 53 illustrates that streptavidin had no influence on the polarisation in the 
presence of BSA, but led to a slight increase in polarisation in the absence of 
DNA (w/o), resulting in an increase in background. None of the complexes of 
streptavidin with the biotinylated benzyl- or CF3-modified sequences increased 
the measured polarisation. 
 
Figure 53: Fluorescence polarisation of THC-FITC in the presence of different biotinylated 
sequences and streptavidin 
The fluorescence polarisation of THC-FITC (53 nM) was measured in the presence of 500 nM of 
the different, biotinylated sequences, 1 mg/ml BSA, or without any sequence (w/o). All assays but 
those represented by grey bars contained 750 nM streptavidin. BSA was used as a positive 
control. No sequence (w/o) was used as negative control and the dotted line represents the 
corresponding polarisation. Benzyl-modified DNA is depicted in blue, CF3-modified DNA in green.  
The fluorescence polarisation of THC-FITC is lower at pH 7.4 than at 5.4 (Figure 
44). The resultant increase in assay sensitivity might enable the detection of 
sequences that bind THC in solution. Therefore, the sequences that interacted 
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with THC-sepharose at neutral pH in the radioactive assay (Figure 50) were also 
tested at neutral pH in the fluorescence polarisation assay. As in the assays at 
pH 5.4, no increase in polarisation and therefore no interaction with THC-FITC 
was detectable (Figure A 3). 
So far, none of the setups (increase of molecular weight by addition of 
streptavidin and biotinylation, pH) led to the detection of interaction of THC-FITC 
with any of the sequences. In comparison with THC-sepharose (chemical 
structure see Figure 19), which all the sequences are known to interact with 
(Figure 23, Figure 27, and Figure 39), THC-FITC has the relatively bulky FITC 
directly connected to the oxygen of the former hydroxyl group of THC. This can 
lead to steric hindrances if any of the sequences normally bind from the coupling 
side (Figure 54A). To rule out that the interaction with THC in solution is blocked 
by FITC, a different coupling product was synthesised: THC-L-FITC (TLF, Figure 
54B). Here, THC and FITC are coupled through the same linker that is also on 
THC-sepharose.  
 
Figure 54: Structures of THC-FITC and THC-L-FITC 
Chemical structures of both coupling products of THC and FITC that were used for fluorescence 
polarisation assays in this thesis. (A) THC-FITC. (B) TLF. 
 
3.2.8 Fluorescence polarisation assays with THC-L-FITC 
3.2.8.1 Synthesis and characterisation of THC-L-FITC 
TLF is synthesised from THC-L, whose synthesis is depicted in Figure 16. THC-L 
was reacted with NH3 and FITC to TLF in a two-step synthesis as shown in 
Figure 55. 
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Figure 55: Coupling of THC-L to FITC 
THC-L (on the upper left) reacts with ammoniac (on the upper arrow), opening the epoxide ring. 
The reaction takes place in MeOH for 4 h @ 70°C. After evaporation of the remaining NH3 and 
MeOH, FITC (on the lower arrow) is added to the crude product and reacted in MeOH for 3 h at 
room temperature (RT) to the final product, TLF (lower right). 
The crude product was analysed by LC-MS as depicted in Figure 56A to C. 
While both the positive (Figure 56A) and negative (Figure 56B) mass showed a 
lot of different peaks, the UV chromatogram (Figure 56C) contained only two 
peaks: One that was most likely unreacted FITC (min 0-1, compare Figure 42A) 
and the product peak (min 9-10). 
To remove the leftover FITC as well as whatever kind of impurities were 
represented by the additional mass peaks, the crude product was purified by 
HPLC. Afterwards, most additional mass peaks had vanished (Figure 56D and 
E) and the FITC-peak in the UV chromatogram was dramatically reduced in 
comparison to the product peak (Figure 56F). 
The mass analysis of the product peak (min 9-10) both before and after clean-up 
is depicted in Figure 57 and verified that the peak represents TLF. The increased 
purity of the sample was also indicated by the decrease of contaminating mass 
peaks in this analysis.  
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Figure 56: LC-MS analysis of coupling of THC-L to FITC before and after clean-up 
Positive (A) and negative (B) mass and UV chromatogram (C) of the coupling before clean-up. 
Positive (D) and negative (E) mass and UV chromatogram (F) of the coupling after clean-up. The 
single peak (min 9-10) in the UV chromatograms represents the coupling product.  
Some FITC was left in the sample even after purification (Figure 56F). As no 
unspecific interactions were visible between any of the sequences and THC-FITC 
(Figure 52 to Figure 53) before, this FITC should not lead to false positive 
measurements. The TLF was therefore deemed pure enough to be used for 
fluorescence polarisation assays.  
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Figure 57: MS analysis of coupling of THC-L to FITC before and after clean-up 
(A) Positive (upper panel) and negative (lower panel) mass spectrum of the UV-peak, pre clean-
up (Figure 56C). The found mass matches TLF. Even though masses below 300 m/z are 
indicated on the x-axis, they were neither measured nor analysed during the run. (B) Positive 
(upper panel) and negative (lower panel) mass spectrum of the UV-peak, post clean-up (Figure 
56F). The found mass matches TLF.  
The newly synthesised TLF was characterised regarding its absorption and 
emission spectra, both of which closely resembled those determined for THC-
FITC, including the pH-dependency of the fluorescence intensity (Figure 43, 
Figure A 2). 
 
3.2.8.2 Fluorescence polarisation assays using THC-L-FITC 
To evaluate the fluorescence polarisation properties of TLF, its polarisation was 
measured in comparison with FITC at both pH 5.4 and 7.4 (Figure 58). The 
standard deviation was very high at low concentrations of both fluorophores, but 
improved with increasing concentrations. As before, no pH-dependency of FITC 
could be determined (compare Figure 44). The polarisation of TLF was as low as 
that of FITC at pH 7.4, and only slightly higher at pH 5.4. Overall, the polarisation 
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was reduced in comparison with the one of THC-FITC at both pH-values (Figure 
44).  
 
Figure 58: Fluorescence polarization of FITC and THC-L-FITC at pH 5.4 and 7.4 
The fluorescence polarisation of varying concentrations of FITC (black and grey) and THC-L-FITC 
(shades of red) was measured in D-PBS pH 5.4 with 5% ACN (dark red and black) and in PBS, 
pH 7.4 (light red and grey).  
TLF was then tested in a fluorescence polarisation assay using the THC-antibody 
as a positive and the Gal3-antibody and FITC as negative controls. As expected, 
FITC did not interact with any of the antibodies; Gal3 interacted with neither of 
the fluorophores (Figure 59). The combination of TLF and THC-antibody led to a 
concentration-dependent increase in polarisation with a determined affinity of 
226.5 ± 175.8 nM.  
 
Figure 59: Fluorescence polarisation of FITC and THC-L-FITC with varying concentrations 
of antibodies 
The fluorescence polarisation of 80 nM FITC (black, grey) and THC-L-FITC (shades of red) in the 
presence of varying concentrations of THC- (dots) and Gal3-antibody (squares) was measured. 
The Kd determined for the interaction between THC-L-FITC and the THC-antibody is 226.5 ± 
175.8 nM. 
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Having shown that the assay can be used for affinity determination, all 
sequences were tested at pH 5.4. BSA was again used as a positive control and 
led to the expected increase in polarisation. The slight increases in polarisation 
obtained for B27 and C15 were within the range of the respective error bars. No 
sequence led to a significantly increased polarisation (Figure 60). 
 
Figure 60: Fluorescence polarisation of THC-L-FITC at pH 5.4 in the presence of different 
sequences 
The fluorescence polarisation of THC-L-FITC (80 nM) was measured in the presence of 500 nM 
of the different sequences, 1 mg/ml BSA, or without any sequence (w/o). BSA was used as a 
positive control. No sequence (w/o) was used as negative control and the dotted line represents 
the corresponding polarisation. Benzyl-modified DNA is depicted in blue, CF3-modified DNA in 
green. C pool indicates FT2-SL that has been CF3-modified.  
To increase the sensitivity of the fluorescence polarisation assay, the sequences 
were biotinylated and incubated with streptavidin, thus raising their molecular 
weight (section 3.2.7.4). Figure 61 shows that the addition of streptavidin again 
led to a slight increase in background. None of the sequences elicited a 
significant increase in polarisation.  
Due to the lower background fluorescence polarisation and the resultant increase 
in assay sensitivity (Figure 58), the sequences that interact with THC-sepharose 
at pH 7.4 were also tested at this pH. Neither the unlabelled nor the biotinylated 
sequences in combination with streptavidin induced a detectable increase in 
polarisation (Figure A 4 and Figure A 5).  
Even though the fluorescence polarisation assay worked for the THC-antibody, 
none of the THC-sepharose-binding sequences could be ascertained as binding 
THC in solution. Therefore, we decided to perform a toggle-SELEX. 
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Figure 61: Fluorescence polarisation of THC-L-FITC in the presence of different 
biotinylated sequences and streptavidin 
The fluorescence polarisation of THC-L-FITC (80 nM) was measured in the presence of 500 nM 
of the different, biotinylated sequences, 1 mg/ml BSA, or without any sequence (w/o). All assays 
but those represented by grey bars contained 750 nM streptavidin. BSA was used as a positive 
control. No sequence (w/o) was used as a negative control and the dotted line represents the 
corresponding polarisation. Benzyl-modified DNA is depicted in blue, CF3-modified DNA in green.  
 
3.3 Toggle-SELEX 
The toggle-SELEX alternated between THC-sepharose and THCA-beads (Figure 
24) as solid supports (“toggled”).225 In addition, the selection was performed at 
pH 7.0 in a PBS-buffer with a K+-concentration of 20 mM. Both are closer to the 
‘average’ human oral fluid226 and might therefore facilitate the use of any selected 
aptamer in a roadside testing device. The same buffer was used before for the 
DNA-selections on THC-sepharose, SELEX 6 and 7 (Table 4). No Tween was 
added to circumvent any potential problems (section 3.2.7.2 and 4.7.2).  
The THC-solubility in the selected buffer was determined using HPLC-analysis. 
The addition of 5% ACN resulted in a relatively good linearity up to 200 µM THC 
without necessitating further solvents or detergents (Figure 62). Therefore, this 
concentration was set as the upper limit for affinity elution during the toggle-
selection. The control, 100% ACN, showed a slightly worse than normal linearity 
(0.9168). 
 
95 
 
  
 
Figure 62: HPLC-measurement of THC-concentrations in PBS 
HPLC-analysis of THC-concentrations between 10 and 300 µM in 100 (black) and 5% (grey) 
ACN. Depicted in the table are the R
2
-values of the 5% ACN-sample, depending on the highest 
concentration that has been included in the linearity-calculation.  
It is possible that the disability to identify sequences that recognise THC in 
solution is due to the high local concentration of THC on the sepharose, which 
cannot be reached in solution. To prevent the appearance of this problem in the 
new toggle-SELEX, three different kinds of THC-sepharose were prepared: One 
coupled in the presence of the normal excess of THC, which is from here on 
called 1:1-sepharose. One coupled using only 1/10 the amount of THC that can 
be coupled according to the available chemical functionalities on the surface227: 
1:10-sepharose, and one using only 1/100 the amount: 1:100-sepharose. Figure 
63 details the respective intensities as quantified by the THC-antibody. All three 
THC-sepharoses showed stronger signals than the unmodified sepharose 
(Figure 63A), indicating that the coupling reaction was successful for all three 
preparations. The 1:1-sepharose gave the strongest signal by a factor of about 2 
in comparison with the other two THC-sepharoses (Figure 63B). However, no 
clear difference in signal intensity was detectable between the 1:10- (Figure 63C) 
and 1:100-sepharose (Figure 63D). Since they both contain less THC than the 
1:1-sepharose, all three were used for the selection.  
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Figure 63: Detection of different amounts of THC coupled to epoxy-activated sepharose 
Detection of THC using a THC-antibody. (A) Background signal on non-modified epoxy-activated 
sepharose. (B) 1:1-coupled sepharose: Signal for THC on epoxy-activated sepharose that has 
been coupled to THC in the presence of an excess of THC. (C) 1:10-coupled sepharose: Signal 
for THC that has been coupled using 1/10 THC in comparison with the maximal available 
chemical functionalities on the sepharose. (C) 1:100-coupled sepharose: Signal for THC that has 
been coupled using 1/100 THC in comparison with the maximal available chemical functionalities 
on the sepharose. The quantified signal intensities were 344% of the background-signal for the 
1:1-sepharose, 165% for the 1:10- and 184% for the 1:100-coupled sepharose.  
Table 19 details the selection conditions used during the toggle-SELEX. First, ten 
selection cycles were performed. During these, THC-sepharose and THCA-
beads were used alternatingly as solid support. The amount and coupling grade 
of THC-sepharose and the amount of THCA-beads was reduced over the course 
of the selection, resulting in a reduction in THC(A). The incubation time was 
reduced from 1 h to 5 min, and the washing steps were increased from about 
6.5 min to 3 h. During the first three selection cycles as well as during all cycles 
performed on THC-sepharose, heat elution was performed for 3 min at 80°C. 
From cycle four on, affinity elution with decreasing concentrations of THC 
(starting at 200 µM and stopping at 25 µM THC) were performed on the THCA-
beads. Less PCR-cycles were needed to amplify the DNA if the samples were 
incubated on the THCA-beads than on the THC-sepharose, indicating a higher 
DNA-concentration before amplification. Apart from this observation, no clear 
decrease in PCR-cycles was detectable from selection cycle one to ten when 
evaluating the two different matrices individually.  
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Table 19: Selection conditions for the toggle-SELEX 
SELEX 
cycle 
DNA 
[pmol] 
blocked 
tosyl-beads 
THCA-
beads 
unmodified 
sepharose 
THC-
sepharose 
incubation 
time 
max. THC(A) 
[nmol] 
wash steps elution 
PCR-
cycles 
1 n.d. - - - 25 µl 1:1 1 h 
475 6.5 min 
3 mL 
3 min @ 80°C 
B: 17 
to 1000 C: 17 
2 
B: 28.4 
- 50 µl - - 1 h 
50 30 sec 
2x 5 min (10 min) 
3 min @ 80°C 
B: 13 
C: 19 to 100 C: 13 
3 
B: 25.6 
- - - 25 µl 1:10 30 min 
47,5 15 min 
10 mL 
3 min @ 80°C 
B: 19 
C: 26.3 to 100 C: 19 
4 
B: 5 
- 25 µl - - 15 min 
25 30 sec 
4x 5 min (20 min) 
200 µM THC 
40 nmol 
B: 15 
C: 10.6 to 50 C: 15 
5 
B: 5.7 
- - - 10 µl 1:10 10 min 
19 30 min 
8 mL 
3 min @ 80°C 
B: 20 
C: 27.4 to 40 C: 17 
6 
B: 23.2 
- 10 µl - - 10 min 
10 30 sec 
9x 5 min (45 min) 
100 µM THC 
20 nmol 
B: 16 
C: 51.2 to 20 C: 17 
7 
B: 33 
- - - 25 µl 1:100 5 min 
4,75 1 h 
13 mL 
3 min @ 80°C 
B: 19 
C: 27.3 to 10 C: 18 
8 
B: 24.8 
- 5 µl - - 5 min 
5 30 sec 
9x 10 min (1.5 h) 
50 µM THC 
10 nmol 
B: 14 
C: 24 to 10 C: 14 
9 
B: 15.8 
- - - 10 µl 1:100 5 min 
1,90 2 h  
28 mL 
3 min @ 80°C 
B: 20 
C: 28.8 to 4 C: 17 
10 
B: 22.3 
- 2,5 µl - - 5 min 
2,5 30 sec 
12x 15 min (3 h) 
25 µM THC 
5 nmol 
B: 14 
C: 27.4 to 5 C: 12 
11 
B: 10.55 
- - - 10 µl 1:100 5 min 
1,9 3 h  
21 mL 
3 min @ 80°C 
B: 19 
C: 14.86 to 4 C: 16 
12 
B: 15.96 2x 50 µl 
15 min each 
2.5 µl - - 5 min 
2,5 30 sec 
12x 15 min (3 h) 
25 µM THC 
5 nmol 
B: 10 
C: 10.6 to 5 C: 12 
13 
B: 5.69 
- - 
2x 50 µl 
15 min each 
10 µl 1:100 5 min 
1,9 3 h  
30 mL 
3 min @ 80°C 
B: 22 
C: 5.05 to 4 C: 22 
14 
B: 10.87 
- - 
2x 50 µl 
15 min each 
10 µl 1:100 5 min 
1,9 3 h 
30 mL 
3 min @ 80°C 
B: 19 
C: 3.07 to 4 C: 19 
B/C: Selection with benzyl-/CF3-modified DNA. n.d. = not determined.
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After ten selection cycles, the DNA from the SL, as well as from selection cycles 
4, 8, and 10 was radioactively labelled and tested for interaction with both the 
THC-sepharose (1:1) and the THCA-beads as well as the respective unmodified 
solid supports. The results on the sepharose for the selection with benzyl- and 
CF3-modified DNA are depicted in Figure 64A and B, respectively. B12 and C15 
were radioactively labelled in parallel and used as positive controls. Their 
absolute values cannot be compared to the others as the assays were performed 
in different buffers, but both showed that the two assays worked as expected. For 
the samples from the new toggle-SELEX, neither the benzyl- nor the CF3-
modified samples showed an increase in interaction with THC-sepharose in 
comparison to either their interaction with the unmodified sepharose or with the 
modified DNA from the SL.  
The results on the THCA-beads for the selection with benzyl- and CF3-modified 
DNA are shown in Figure 64C and D, respectively. For both modifications, 
roughly 60% of the DNA from the SL stuck to the THCA-beads. This high 
background binding decreased to about 20% for the DNA of selection cycle four 
of the selection with benzyl-modified DNA and stayed like this for the higher 
selection cycles (Figure 64C). The samples from the selection with CF3-modified 
DNA showed a slight reduction of background binding over the selection process, 
but about 40% of the DNA from the final selection cycle remained on the beads.  
In case ten selection cycles were not sufficient to enrich THC-binding clickmers, 
an additional four selection cycles (11 to 14) were added and are detailed in 
Table 19. For these, the incubation and washes were kept constant. Cycles 11, 
13, and 14 were performed on THC-sepharose; cycle 12 on THCA-beads. A 
negative selection step was added to deplete matrix-binding sequences during 
selection cycles 12 to 14. For this, the DNA from the previous selection cycle was 
incubated with the unmodified solid support before non-bound sequences were 
added to the THC(A)-containing matrix. As for the first ten selection cycles, no 
decrease in the number of PCR-cycles needed for amplification was detectable 
(Table 19). 
To test if the additional selection cycles led to an enrichment of THC-binding 
sequences, DNA from the SL, selection cycle 10, and 14 was radioactively 
labelled and incubated with THC- and unmodified sepharose. Due to the high 
background binding on the THCA- and methylamine-blocked tosylated beads 
apparent in the previous assay (Figure 64C,D), the interaction with this matrix 
was not tested.  
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Figure 64: Interaction analysis after ten selection cycles of toggle-selections for THC-
binding clickmers 
32
P-labelled DNA with benzyl- (A, C) and CF3- (B, D) modification was incubated with sepharose 
(A, B) or magnetic beads (C, D). THC(A)-modified solid supports are depicted in black, dark blue, 
and dark green. Non-target solid supports are depicted in grey, light blue, and light green. After 
two washing steps, the amount of radioactivity on the solid support was quantified. In blue and 
green are sequences from the first successful click-SELEX that are known to be interacting with 
THC-sepharose as positive controls. (A) DNA from the SL as well as selection cycles 4, 8, and 10 
from the selection with benzyl-modification on sepharose. B12 was used as a positive control. (B) 
DNA from the SL as well as selection cycles 4, 8, and 10 from the selection with CF3-modification 
on sepharose. C15 was used as a positive control. (C) DNA from the SL as well as selection 
cycles 4, 8, and 10 from the selection with benzyl-modification on magnetic beads. (D) DNA from 
the SL as well as selection cycles 4, 8, and 10 from the selection with CF3-modification on 
magnetic beads.  
Figure 65 depicts the results for the samples from both selections. B11 and C30 
were tested in parallel as positive controls. Both clearly distinguished between 
THC- and unmodified sepharose. As their selection buffer differed from the one 
used for the new selections, the absolute values of the samples cannot be 
compared. Neither of the samples from selection cycles 14 differentiated between 
THC- and unmodified sepharose.  
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Therefore, both toggle-selections were unsuccessful in enriching THC(A)-binding 
sequences.  
 
Figure 65: Interaction analysis after 14 selection cycles of toggle-selections for THC-
binding clickmers 
32
P-labelled DNA with benzyl- and CF3-modification was incubated with THC- (black, dark blue, 
and dark green) or unmodified sepharose (grey, light blue, and light green). After two washing 
steps, the amount of radioactivity on the sepharose was quantified. In blue (benzyl-modified) and 
green (CF3-modified) are sequences from the first successful click-SELEX that are known to be 
interacting with THC-sepharose as positive controls. DNA from the SL as well as selection cycles 
4, 8, and 10 from the toggle-SELEX with benzyl-modification and CF3-modification was tested. 
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4 Discussion 
Section 4.1 deals with the different immobilisation techniques used for THC. It is 
followed by the discussion of all THC-selections performed with non-nucleobase-
modified nucleic acids, which stresses possible reasons for the failure of those 
selections (section 4.2). The two initial click-selections and the identified 
sequences are discussed in section 4.3. The validation of the use of NGS for 
aptamer or clickmer identification is evaluated in section 4.4. To evaluate the 
binding of the THC-sepharose-binding sequences in solution, efforts were 
undertaken to determine the solubility of THC. These are elucidated on in section 
4.5. Since no binding in solution could be determined, an affinity re-selection was 
performed. The results and the identified sequences are discussed in section 4.6. 
The setup of the fluorescence polarisation assays that were used to determine 
interaction with THC in solution is detailed in section 4.7. Section 4.8 contains the 
discussion of the toggle-SELEX. 
 
4.1 Immobilisation of THC(A) 
Three different immobilisation techniques were used for THC(A) during the 
course of this thesis: THCA on amine-functionalised magnetic beads, THC on 
epoxy-activated sepharose, and THCA on tosylated magnetic beads, which were 
prepared by Malte Rosenthal.d  
For the first selections, THCA was immobilised by coupling to amine-
functionalised magnetic beads. THCA was chosen instead of THC due to the 
additional carboxyl group, which enabled immobilisation without loss of the 
hydroxyl group. Another option that would have offered the same advantage was 
the THC-metabolite, THC-COOH (section 1.1.4.1, Figure 5A). The choice in 
favour of THCA was based on the fact that the developed test would also be 
useable in urine. If the selected aptamer differentiated between THC and THC-
COOH, the test would still be able to indicate recent consumption of THC and 
therefore current impairment of the driving skills. 
THC was coupled to epoxy-activated sepharose for the subsequent selections, 
because none of the selections on THCA-functionalised amine beads had led to 
the identification of THC-binding aptamers. Sepharose has been the predominant 
choice as immobilisation matrix for the selection of small molecule-binding 
aptamers.147 For small molecule targets, its density of chemical functionalities on 
the surface results in a higher target molecule density than possible on magnetic 
beads. For example, the amine-functionalised dynabeads contain 5-10 nmol 
functional groups on the surface, the epoxy-activated sepharose 0.95-
                                            
d
 Malte Rosenthal, PhD thesis in preparation, Bonn, 2018/2019 
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2 µmol.147,228 This becomes apparent when comparing the results in Figure 14 
and Figure 20: Much more THC can be detected on the sepharose than THCA 
on the magnetic beads. However, it cannot be excluded that this results from 
differences in the antibody-affinity for the differentially coupled THC(A). To 
exclude this possibility, trials to couple THC to three different types of epoxy-
modified magnetic beads were performed using the protocol established for the 
coupling of THC-sepharose. None of them was successful (data not shown, see 
also section 4.8).  
Malte Rosenthal coupled THCA to tosylated magnetic beads.e These beads were 
used to ascertain the specificity of the benzyl-modified THC-sepharose-binding 
sequences (Figure 25) and for the toggle-SELEX (section 3.3). In contrast to the 
amine beads, they are hydrophobic.228 This facilitates the selection process as 
the unspecific binding of DNA/RNA to the beads is reduced. 
Even though the toggle-SELEX was as unsuccessful as all selections performed 
on the THCA-modified amine-beads, Malte Rosenthal selected a benzyl-modified 
THC(A)-binding clickmer on the THCA-modified tosylated beads.e The failure of 
all selections on magnetic beads presented in this thesis can therefore not be 
due to the matrix alone and the corresponding low target molecule density on the 
surface. Possible reasons are discussed in the subsequent section. 
 
4.2 THC-selections with non-nucleobase-modified nucleic acids 
Overall, seven different selections for THC-binding aptamers were performed 
using non-nucleobase-modified nucleic acids. None of them enriched THC-
binding sequences.  
As the selected aptamer was supposed to be implemented in an oral fluid-based 
roadside test and oral fluid is known to contain nucleases, RNA was deemed too 
instable.229 2’F-RNA has a higher resistance towards degradation by nucleases 
and was therefore used for all RNA-selections (Table 3).176  
To increase the selection stringency, competitors such as salmon sperm DNA or 
polyanions (heparin) were added during incubation of the library with the target 
molecule in all selections. These reagents unspecifically interact with both the 
target molecule and the matrix. They thereby compete with unspecifically binding 
sequences that are part of the selection library. The unspecific binders thus do 
not bind to the target molecule and are removed from the library during the wash 
steps. Only specifically binding sequences are amplified. 
For SELEX 1 and 2, the same linear, unstructured 2’F-RNA-library was used. The 
selections were performed in parallel with a PBS-based selection buffer. The only 
                                            
e
 Malte Rosenthal, PhD thesis in preparation, Bonn, 2018/2019 
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difference between the two setups was the elution technique: During SELEX 1, 
2’F-RNA was recovered by heat, which should unspecifically denature all folded 
nucleic acids and allow their recovery. For SELEX 2, 5 mM THC was used in 
combination with 7% Cremophor EL, a polyethoxylated castor oil, as 
recommended by PD Dr. Andras Bilkei-Gorzo to keep the THC solubilised (Table 
3).f None of them enriched THC-binding sequences in 15 selection cycles 
(Figure 15). While no clear reason for SELEX 1 is apparent, SELEX 2 most 
probably did not succeed due to the high amount of Cremophor EL during the 
recovery of the DNA. The CMC of Cremophor EL is reported as 0.02%.230 
Accordingly, all THC molecules are probably inside micelles and not able to be 
bound by potential aptamers. Instead, 2’F-RNA that dissociated from the THCA-
beads has been recovered and amplified. Any initially present THC-binding 
sequences have thus most likely been depleted. 
SELEX 3 to 5 used a 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES)-based buffer. Instead of recovering the DNA or 2’F-RNA by heat or 
affinity elution before PCR, the beads were added to the PCR. During the 
denaturation phase of the PCR, the DNA or 2’F-RNA is denatured and can serve 
as template afterwards. The three selections differed regarding the library used 
for selection: SELEX 3 was performed with a prestructured 2’F-RNA-library. The 
random region contains G-stretches that predispose the library to form G-
quadruplex structures. The DNA-libraries used for SELEX 4 and 5 have random 
regions of different lengths to enable formation of different three-dimensional 
structures (Table 3).  
However, all three selections did not enrich THC-binding sequences in ten 
selection cycles without obvious reason (Figure 15). THC is thermostable231 and 
remains unchanged throughout the PCR. Potential THC(A)-recognising 
sequences might have refolded during annealing and elongation and then re-
associated with THC. They would then be unavailable for amplification. G-
quadruplex structures are known to be exceptionally stable with melting 
temperatures reaching 50°C for sequences as short as 15 nucleotides.232 
Accordingly, this explanation for the unsuccessfulness of the selection is most 
likely for SELEX 3.  
Due to the higher density of functional groups on the surface that might allow a 
higher local target molecule concentration (section 4.1), the matrix was 
exchanged for THC-sepharose for SELEX 6 and 7.  
Both selections (SELEX 6 and 7) were performed in a PBS-buffer at pH 7.0 and 
with an increased concentration of KCl to emulate oral fluid.226 A combination of 
heat (10 min at 65°C) and denaturing agents (urea and 
ethylenediaminetetraacetic acid (EDTA)) was used to recover binding sequences. 
                                            
f
 Personal communication with PD Dr. Andras Bilkei-Gorzo, Institute of Molecular Psychiatry, 
University of Bonn 
104 
 
  
The selections differed concerning the utilised DNA-libraries: The library for 
SELEX 6 was unstructured, whereas SELEX 7 made use of the same 
prestructured library as SELEX 3 that is supposed to preferentially form G-
quadruplex structures. Here, the library was used as DNA, not as 2’F-RNA 
(Table 4). None of the two selections enriched THC-binding sequences in ten 
selection cycles without obvious reasons (Figure 21).  
Overall, seven out of seven selections failed. A reason for the failure is only 
obvious for SELEX 2. All others were unsuccessful despite the differences 
concerning libraries, buffer conditions, and elution and immobilisation techniques. 
For proteins, it is known that about 30% of all selections do not lead to aptamer 
identification180, but even with equally low success rates, one of the selections 
should have worked. After all, DNA-aptamers have been successfully selected for 
three hydrophobic hormones, progesterone233, 17ß-estradiol234-236, and 
cortisol.237 All three are less hydrophobic than THC according to their logP-values 
(THC: 5.65213, progesterone: 3.87238, estradiol: 4.01239, cortisol: 1.61240)208. 
Accordingly, they are probably easier targets for the hydrophilic non-nucleobase-
modified nucleic acids. Nevertheless, DNA-aptamers have also been selected for 
polychlorinated biphenyls (PCBs), which are more hydrophobic than THC (logP-
values: PCB 77: 6.72241, PCB 72: 6.4242, PCB 106: 6.9243). They do not 
differentiate well between the different PCBs, but achieve affinities in the 
nanomolar range and were able to bind the target molecules in solution.244,245 
The ability of PCBs to interact with aptamers has been hypothesised to result 
from the aromatic groups.245,246 While THC also contains an aromatic ring, two of 
the three rings are non-aromatic (Figure 1A) and therefore unable to interact with 
the nucleobases via π-π-stacking. The two selections (SELEX 3 and 7) 
performed with the G-quadruplex library were chosen in the hope that these 
interactions might suffice to enable the selection of THC-binding aptamers. As 
they were not successful, π-π-stacking with non-modified nucleobases is – at 
least under the conditions tested – not sufficient for the successful selection of 
aptamers for THC. 
While it is entirely possible that different selection conditions and libraries might 
lead to the successful selection of aptamers for THC, it has to be deemed 
unlikely. Our approach of introducing hydrophobic modifications into the DNA to 
imitate the interaction of THC with the CB1 (section 1.1.2, Figure 3) led to the 
immediate successful selection of THC-sepharose-binding sequences in two 
different selections. We therefore conclude that non-nucleobase-modified DNA 
and 2’F-RNA is highly unlikely to form structures that can stably interact with 
THC.  
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4.3 Click-SELEX on THC-sepharose 
The click-SELEX for GFP published by Tolle et al. was the only successful use of 
the technique at the onset of this part of the thesis.205 To maximise the chances 
of success, the selections were performed as similar to the GFP-SELEX as 
possible, including the use of the same library and selection buffer, regardless of 
its pH of 5.4. A major change was the inclusion of a clicked competitor from the 
first selection cycle on. Due to the additional chemical functionalities of clicked 
DNA, the usual competitors (section 4.2) are not sufficient to remove the majority 
of unspecifically binding DNA. This was observed in the first click-selection, 
where only the late addition of a double-stranded click-modified DNA-competitor 
lead to the enrichment of the two clickmers.152 For the selections presented in 
this thesis, a solid phase-synthesised single-stranded DNA of equal length as the 
random region of the selection library was used (sequence: 5’-N42-A-3’). This 
click-modified DNA competitor contains EdU and is modified with the same azide 
as the selection library. Therefore, it is able to imitate any potential unspecific 
interaction the selection library is capable of and can compete with it. This 
reduces the amount of unspecifically binding DNA that is amplified and thus 
increases selection stringency. 
The number of PCR-cycles necessary for amplification decreased from 18 to 15 
between selection cycles nine and ten for both the selection with benzyl- as well 
as CF3-modified DNA (Table 5). This is often interpreted as an indication that the 
selection has been successful. The interaction analysis of both click-selections as 
depicted in Figure 22A and Figure 26A shows how unreliable this decrease in 
PCR-cycles is as readout of selection success: Both selections were already 
visibly enriched for THC-binding sequences in selection cycle eight, before any 
apparent decrease of PCR-cycles.  
The fact that the benzyl- and CF3-modified-selections were successful on the first 
try after the failure of seven conventional selections proofs the merit of the 
technique for difficult targets. To the best of our knowledge, this is the first 
example of the successful selection with nucleobase-modified libraries for small 
molecule targets. More selections have to be performed to determine the 
increase in selection success as SomaLogic® has done for protein targets (30% 
without, 84% with nucleobase-modifications).180 Nonetheless, nucleobase-
modifications seem to be a worthwhile possibility if conventional selections for 
small molecule aptamers fail.  
In addition to the nucleobase-modification per se, click-SELEX enables the 
modular and strategic choice of the modification. For THC, we chose benzyl and 
CF3 to imitate the interaction between THC and its receptor (section 1.1.2, Figure 
3, Table 2). Gold et al. have shown that, at least for protein targets, not all 
modifications work equally well.180 It stands to reason that this is also true for 
click-SELEX and that the thoughtful choice of azide is necessary for selection 
106 
 
  
success. A first indication for this is given by the fact that the affinity of two 
different GFP-binding clickmers is influenced by the clicked-in modification, some 
of which completely preclude binding to the original target molecule.152,205 The 
interaction of the SL with THC-modified beads has also been shown to vary 
depending on the chosen modification.152  
Both selections performed with benzyl- as well as CF3-modified DNA were visibly 
enriched from cycle 8 on (Figure 22A and Figure 26A). The selections were 
performed in parallel with identical conditions (apart from the number of PCR-
cycles). The ratio of binding between THC- and unmodified sepharose is higher 
for the benzyl-modified selection (Figure 22A and Figure 26A). This is an 
indication that of the two analysed libraries, benzyl seems to be the better choice 
of modification.  
The DNA from both selections does not interact with sepharose if it is not 
modified with THC (Figure 22B and Figure 26B). This is further proof of the 
hypothesis that the nucleobase-modifications are necessary for the selection 
success and not only the different buffer or elution conditions. 
The THC-sepharose-binding sequences that were identified from both selections 
interact with THC-sepharose to different degrees. The strength of the interaction 
is independent of the number of modifications (Table 6 and Table 7, Figure 23 
and Figure 27). As B10 has as many or more modifications than the THC-binding 
sequences B14, B13, and C30, it is obvious that the modifications alone are not 
responsible for the interaction with THC. It has to be a combination of the 
modifications and the three-dimensional structure the DNA folds into. As of now, 
no clickmer structures have been published. Due to the unsuccessfulness of all 
selections with non-nucleobase-modified nucleic acids, it seems likely that – as 
for most known SOMAmer structures (section 1.2.3.2) – the modification directly 
interacts with the target molecule. Confirmation of this hypothesis has to await 
structural studies of clickmers. 
In the selection with CF3-modified DNA, the least abundant sequence, C15, also 
interacts with THC-sepharose to a slightly lower degree in comparison with the 
two more abundant sequences (Figure 27A and Table 6). No such correlation is 
apparent for the benzyl-modified sequences (Figure 23 and Table 7). Knowledge 
of the affinity constants might explain the frequency of the sequences and give an 
insight into the differences between Sanger and NGS. As it was not possible to 
elucidate the kD during the course of this thesis, the question will have to remain 
unanswered for now.  
In the specificity test, B11 is the only benzyl-modified sequence that clearly 
shows interaction with the THCA-beads (Figure 25). Therefore, B11 is less 
specific than the other sequences that only recognise THC-sepharose. 
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No preliminary specificity test was performed for the CF3-modified sequences. 
Because the binding of CF3-modified DNA from selection cycle 1 to the THCA-
beads was as high as for the benzyl-modified DNA from selection cycle 1 (data 
not shown, Figure 25), no negative control for such an assay was available.  
 
4.4 Verification of the NGS approach 
Although NGS has been used for aptamer identification before156-158, 
discrepancies between the data obtained by Sanger and next-generation 
sequencing (Table 6 and Table 7) caused us to investigate the actual error rates 
in our NGS approach.  
Analysis of the impact of sample preparation disclosed that the index-PCR had 
no significant effect on the mutation rates (Table 8, Figure 28, and Figure 29). In 
contrast, the presence of EdU in the template led to significantly increased error 
rates (Table 8, Figure 28, and Figure 29). As EdU is replaced by thymidine 
during index-PCR and therefore before the actual sequencing, the most likely 
reason for the increased mutation rates is a reduced PCR-fidelity due to the 
modification. This goes along with a publication by Oyola et al. that showed that 
the PCR-free preparation of AT-rich sequences leads to a significant reduction of 
mutations.247 Both AT-rich sequences and those containing EdU apparently 
increase mutation rates during PCR. 
The reduced PCR-fidelity has to be taken into account for click-SELEX in 
general, despite the incorporation of EdUTP instead of TTP in the PCRs during 
the selection process. On one hand, the resulting mutations during PCR might be 
helpful to generate better variants of target-binding sequences during the 
selection.248-250 On the other hand, the reduced fidelity might decrease the 
binding affinity of PCR-amplified clickmers due to the generation of non-binding 
mutants. Nevertheless, no such problems are described in literature. The only 
study comparing a solid-phase synthesised with a PCR-amplified clickmer 
describes no significant differences between the two.211 Regardless, the identified 
fidelity-reduction should be kept in mind when working with EdU-modified PCR-
templates. 
In addition to the strong impact of EdU, an increase in mutation frequency over 
the length of the analysed sequence was observed (Figure 28) and the 
nucleotides, into which mutations occurred, reflected the composition of the 
original C12-sequence (Figure 29B and C). The increase in mutation frequency 
over the length of the analysed sequence has been published before for samples 
analysed by SBS, even though the effects were less pronounced than observed 
in this thesis.166,168,173,251  
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The analysis of repetitive sequences revealed a significantly increased mutation 
frequency to the subsequent nucleotide (Figure 30C and D, Figure 31, and 
Table 10) that depended on the number of identical nucleotides in a row (Figure 
32). All these results could be explained by the occurrence of pre-phasing effects. 
These lead to an apparent shortening of the sequence, as one or more 
nucleotides are incorporated without readout and therefore skipped in the output 
sequence (Figure 7 and section 1.2.2). Analysis of the 25 most abundant 
sequences in all samples showed that singe-nucleotide deletions were the most 
frequent mutation type (Table A 3 to Table A 16). This contradicts literature that 
claims single-nucleotide substitutions as the most prevalent kind of mutation 
during SBS.165-167 We concluded that the majority of these deletions resulted from 
pre-phasing and decided to omit all deletion-containing, shortened sequences 
from further analyses.  
Exclusion of the shortened sequences reduced the error rate by an average of 
80%, although only about 5% of all sequences were omitted (Table 11). Single-
nucleotide deletions as generated by pre-phasing lead to the definition of all 
following nucleotides as mutated, which results in the observed, high error rates 
(Table 8 and Table 9). Software solutions for the reduction of phasing effects are 
available, but do not reach the same percentage of non-mutated sequences as 
omission of all shortened sequences (77% and 94% non-mutated sequences for 
All Your Base and omission of shortened sequences, respectively).171 
Nonetheless, this approach is only feasible for sequences of a known length like 
SELEX samples. For more complex samples, software solutions remain the best 
option available.  
After omission of the shortened sequences, the average error rate (without 
EdU_Pwo) of 0.24 ± 0.06% is in the lower range of error rates published for 
samples analysed with different Illumina sequencers (Table 20). All values are 
equal or well below those reported for Sanger sequencing (between 2 and 
10%).165,252  
Table 20: Error rates on Illumina sequencers 
publication instrument error rate [%] comments 
Fox et al. 165 HiSeq2000 0.1  
Fox et al. 165 MiSeq 0.1  
Dohm et al. 166 1G 0.3 at the start of sequence, 
increases due to phasing effects 
May et al. 167 MiSeq 0.21-2.6 depending on the reference 
sequence; substitutions only 
Kelley et al. 168 not 
disclosed 
0.5-2  
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The mutation rates from one nucleotide to another as displayed in Table 13 
confirm the hypothesis that the high mutation rates of EdU_Pwo result from the 
presence of EdU in the template as thymidine shows much higher mutation rates 
than any of the other nucleotides. In addition, thymidine is the nucleotide that 
mutates least when analysing the average of the other samples.  
The similarity of their fluorophores’ emission spectra leads to a relatively high 
probability of A and C as well as G and T being miscalled for each other on 
Illumina sequencers.173 This is only partly represented by our data: C to A has the 
highest mutation rate (0.13% in average) and G to T is amongst the highest rates 
(0.11% in average). In contrast, A to C and T to G are amongst the lowest 
mutation rates with 0.04 and 0.05%, respectively. Since the mutation rates 
between identical, re-sequenced samples (FT2_GATC and FT2_GATC_II as well 
as FT2_G4A4T4C4 and FT2_G4A4T4C4_II) vary by a factor of up to ten, the 
datasets obtained in this thesis are not sufficient for the comparison of single-
nucleotide conversions. 
We also evaluated the effect the omission of shortened sequences had on 
SELEX samples. As patterns instead of single sequences were analysed, the 
frequencies remained largely unchanged (Figure 34). This is because shortened 
sequences are excluded from every pattern. While the number of sequences a 
pattern consists of decreases, so does the overall number of analysed 
sequences. The resulting frequency is barely influenced. Together with the low 
error rate in comparison to Sanger sequencing, this means that NGS is perfectly 
useable for the analysis of (click-)SELEX samples. Omission of shortened 
sequences, which was not performed for the click-selections described in this 
thesis, is not required when analysing patterns instead of single sequences. 
 
4.5 Solubility determination of THC 
Knowledge about THC-solubility was necessary to perform affinity determination 
of the identified THC-sepharose binding sequences. The initial HPLC-
measurements showed that THC-solubility is below 10 µM in D-PBS, pH 5.4 with 
10% DMSO (Figure 35A). The addition of 0.1% Tween-20 led to values similar to 
those measured in 100% DMSO, which should keep THC well solubilised 
(section 3.2.5). While other detergents would most likely also ensure THC-
solubility in aqueous buffers, Tween was the obvious choice as it was part of the 
selection buffer. Because of its apparent ability to keep THC in solution (Figure 
35A), no additional detergents were tested.  
The initial analysis also showed that the area under the curve alone is not a good 
readout of THC-solubility as it varies depending on the solvent used. This is 
obvious from the differences between the values obtained for 100% DMSO and 
100% ACN (Figure 35B), both of which should be able to solubilise THC in 
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concentrations far above those used in the assay (section 3.2.5). Instead, 
linearity of the resulting curves was chosen as readout of THC-solubility for all 
assays.  
Although 10% DMSO with 0.1% Tween was promising according to Figure 35A, 
the lowest amount of organic solvent possible should be used to minimise the risk 
of influences on folding of the modified DNA-sequences.215 Tests with 5% organic 
solvent and 0.1% Tween demonstrated that DMSO was the worst option, while 
both ACN and EtOH led to usable linearities (Figure 35B). Due to its slightly 
lower boiling point and the thereby reduced chance of evaporation of the organic 
solvent, ACN was chosen.39,253,254 The evaluation of higher THC-concentrations 
identified 150 µM as the maximal solubility of THC in 5% ACN with 0.1% Tween. 
The measurement at 250 µM suffered from high error bars and its inclusion into 
the linearity determination severely reduced the obtained R2. This indicates that 
not all THC is stably solubilised at 250 µM (Figure 36).  
150 µM THC in 5% ACN with 0.1% Tween was used for all subsequent assays 
and the re-selection using affinity elution until the discovery of the solubility 
problems Tween evoked when combined with THC (section 4.7.2). The solubility 
assays concerning these problems (section 3.2.7) are discussed in section 4.7.2, 
the single assay performed for the toggle-SELEX in section 4.8. 
 
4.6 Re-selection with affinity elution 
All sequences identified from the initial click-selections either do not recognise 
THC in solution at all or with affinity constants far above the tested concentrations 
of 150 µM THC maximum (data not shown, Figure 36). It is not possible to 
differentiate between the two problems. Therefore, the re-selection was 
supposed to select clickmers with improved affinity constants and enforce the 
recognition of THC in solution. Towards the first end, more stringent selection 
conditions were chosen than in the initial selections: Incubation time was 
decreased over the course of the SELEX and the volume and duration of the 
wash steps increased. The incubation time limits the maximal kon, but is still quite 
long with 5 min and probably has no effect on the affinity. If a clickmer is 
successfully selected, the reduced incubation time might reduce the duration of a 
potential roadside test using this clickmer. In contrast, the duration of the wash 
steps enforces a higher koff as any sequence with a low value will dissociate and 
be removed. This should lead to the selection of high affinity binders.152 The 
second aim, the selection of clickmers that bind to THC in solution, was 
supposed to be reached using affinity elution to recover binding sequences 
instead of the unspecific heat elution used during the initial click-selections. For 
this, the DNA is denatured by heat and slowly cooled down in the presence of the 
target molecule both in solution and immobilised. Sequences with a higher affinity 
for the target in solution will remain in solution and be amplified. Those with a 
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higher affinity for the immobilised target and those that do not recognise the 
target molecule in solution at all will bind to the matrix and be removed from the 
selection pool. The elution buffer contained 5% ACN to solubilise THC. 
Therefore, the buffer used for washing was also supplemented with 5% ACN. 
Later on, it was discovered that the conditions used to solubilise THC most likely 
led to the formation of micelles that encapsulated THC. This effectively blocks 
THC from interacting with the DNA sequences (section 4.7.2). Therefore, 
sequences were not recovered for their ability to interact with THC in solution. 
Instead, sequences that did not bind to the THC-sepharose after denaturation by 
heat were recovered and amplified. Nonetheless, the selections were successful 
in identifying THC-sepharose-binding sequences (Figure 39). This is most likely 
because a small number of THC-binding sequences dissociated and was 
amplified. Sequences might also have misfolded while cooling down in the 
presence of Tween and therefore not bound to the sepharose even though they 
are capable of binding under normal circumstances.  
The DNA from selection cycle 8 and 10 of the selections with benzyl- and CF3-
modified DNA showed increased binding to THC-sepharose (Figure 38). While 
the enrichment of the selection with benzyl-modified DNA is similar to the initial 
selection with benzyl-modified DNA (Figure 22A), the CF3-modified DNA from 
selection cycles 8 and 10 discriminates better between THC- and unmodified 
sepharose than the corresponding DNA from the first selection (Figure 26A). 
This indicates that the change in selection conditions, most probably mainly the 
increase in the duration of the wash steps, improved the enrichment of THC-
binding sequences. A second indication is the fact that the non-binding B10 could 
not be detected by Sanger sequencing of the DNA of the final selection cycle 
(Table 15). B13 could also not be identified, which is explained by the fact that it 
does not bind THC-sepharose in the presence of the 5% ACN that were used 
during the new selection (Figure 37A). No explanation is obvious for the 
disappearance of B12. B11 has a higher frequency than in the first Sanger 
sequencing, but was the second most abundant sequence according to the NGS 
of the first selection and was probably just underrepresented in the sequences 
picked for the first Sanger sequencing (Table 16).  
All sequences identified in the final selection cycle from the benzyl-modified 
affinity-SELEX, even the unique sequence 27 (1 of 41 sequences = 2.4%), 
recognise THC-sepharose (Figure 39, Table 15, and Table A 17). All tested 
sequences from the selection with CF3-modified DNA bind THC-sepharose, but 
nine out of the 41 sequenced sequences (22.0%) were unique and not tested due 
to time constraints (Table A 18). As during the first selection (benzyl: 1 of 37 
sequences unique = 2.7%, 3.12% unique according to NGS, CF3: 13 of 32 
sequences unique = 40.6%, 12.83% unique according to NGS) (Table A 1, Table 
A 2, and Figure A 6), the selection with CF3-modified DNA was less enriched 
than the one using benzyl-modified DNA. This again indicates that benzyl might 
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be a better modification for the selection of THC-binding clickmers than CF3 as 
the selection conditions were as similar as possible during both setups. The 
sidechain of benzyl-azide is identical to the one of phenylalanine, which is 
supposed to interact with THC in the CB1 (Table 2 and Figure 3). CF3-azide was 
chosen due to the high hydrophobicity of the trifluoromethyl-group255 that we 
expected to increase the interaction with the hydrophobic THC. According to the 
data presented in this thesis, modifications as close as possible to the one known 
to interact with the target molecule in nature seem to be the best choice for click-
SELEX. To validate this, further click-selections with different targets and 
modifications chosen to imitate an interaction that occurs in nature are needed. 
 
4.7 Fluorescence polarisation assays 
4.7.1 Synthesis and characterisation of THC-FITC-conjugates 
Fluorescence polarisation assays allow the interaction analysis without 
immobilisation of either of the interaction partners. As the smaller interaction 
partner needs to be fluorescently labelled, THC was coupled to FITC. Two 
different strategies were employed: Direct coupling and the use of BDE as linker. 
The latter was performed to imitate the immobilisation of THC on the epoxy-
activated sepharose as closely as possible and thereby maximise the probability 
that the fluorescently labelled THC would be recognised by the THC-sepharose-
binding sequences.  
Both coupling reactions were successful and the products clean after purification 
by HPLC (Figure 42, Figure 56, and Figure 57). As expected, the absorption 
and fluorescence properties remained mostly unchanged from uncoupled FITC 
(absorption maximum: 485 nm, excitation maximum: 512 nm) (Figure 43 and 
Figure A 2).256 The only difference is an additional absorption peak at about 
450 nm that both coupling products exhibit if the measurement takes place in 
water (THC-FITC and TLF, Figure 43A and Figure A 2A) or D-PBS, pH 5.4 
(TLF, Figure A 2A) with 5% ACN each. Both are slightly acidic.257 The absorption 
spectrum of fluorescein is known to change depending on its protonation status. 
The protonation at low pH-values leads to a reduction of the absorption at 
490 nm and the appearance of a second peak around 450 nm.258 This 
phenomenon is what can be observed in the aforementioned figures. 
 
4.7.2 The effect of Tween on THC 
Initial fluorescence polarisation assays showed a dependency on the presence of 
Tween: Especially at pH 7.4, the polarisation of THC-FITC was much higher in 
the presence than in the absence of Tween. For FITC alone, no difference was 
apparent at neutral pH (Figure 44B).  
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According to the theory behind fluorescence polarisation (Figure 40), THC-FITC 
must rotate more quickly in the absence of Tween than in its presence. This can 
only be the case if THC-FITC is larger in the presence of Tween. As the 
percentage of Tween used in the assay is above its CMC, the only valid 
explanation is the hypothesis that THC-FITC is inside of Tween-micelles, thus 
rotating more slowly and leading to the measured, higher polarisation.  
To verify this hypothesis, HPLC-measurements of THC- and THC-FITC-solubility 
in the presence of different concentrations of Tween were performed. As 
presented in Figure 46, the solubility of 20 µM THC-FITC is reduced in the 
presence of Tween below (0.005%) and slightly above its CMC (0.01%). No 
Tween at all is better to keep THC-FITC in solution than those low concentrations 
of detergent. The same is true for THC: Concentrations of Tween below its CMC 
are worse for the THC-solubility than no Tween. However, any concentration of 
Tween above its CMC is able to keep THC in solution (Figure 46).  
Due to the distribution of detergents at different concentrations as presented in 
Figure 45, increasing amounts of the detergent are adsorbed at the surface of 
the liquid if concentrations approach the CMC. During the HPLC-measurements, 
1/3 of the prepared solution is injected from the bottom of the vial. Any THC or 
THC-FITC on the surface is therefore not injected.  
Taken together, the following hypothesis is the most likely explanation for the 
results depicted in Figure 44 and Figure 46: 
THC-FITC is soluble in 5% ACN without Tween as both Figure 46A and Figure 
47 show. At Tween concentrations below or slightly above its CMC, THC-FITC 
interacts with Tween at the surface and is therefore not injected. The effect is 
apparent at 20 µM, as lower concentrations are easier to solubilise. Above its 
CMC, Tween forms micelles, which enclose THC-FITC. It is therefore ‘in solution’ 
and can be injected and detected by HPLC (Figure 46A).  
Like THC-FITC, THC is also less soluble in the presence of Tween below its 
CMC than in its complete absence. Slight amounts of THC are therefore soluble 
even in 5% ACN, but as soon as the detergent is present, THC interacts with it 
and is adsorbed at the liquid surface. Since it is not injected, the measured 
solubility decreases. For THC, this effect is obvious at all three measured THC-
concentrations (Figure 46B). This is probably due to its higher hydrophobicity in 
comparison with THC-FITC. This means that THC interacts with the hydrophobic 
detergent as soon as any is present regardless of the THC-concentration. Both 
Tween-concentrations above the CMC lead to an immediate increase in THC-
solubility as THC is enclosed by the formed micelles and stays ‘in solution’. The 
fact that THC-solubility is good as soon as the CMC is reached, while THC-FITC-
solubility is still insufficient in the presence of 0.01% Tween, has to be attributed 
to the higher hydrophobicity of THC. It enters the micelles as soon as any are 
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present, since they present the most hydrophobic environment available. The 
slightly more hydrophilic THC-FITC is relatively well solubilised by the Tween at 
the surface and only enclosed by micelles when their concentration increases 
(Figure 46).  
All this indicates that while THC and THC-FITC can be found in solution and 
measured by HPLC in the presence of 0.1% Tween, both are not in solution as 
single, free molecules. This is necessary to enable the interaction between THC-
sepharose-binding sequences and THC or THC-FITC. All assays performed in 
the presence of Tween can therefore not be evaluated properly and were not 
mentioned in detail in this thesis. As already apparent from Figure 46A and 
confirmed in Figure 47, THC-FITC is soluble in 5% ACN without addition of any 
detergent up to a concentration of 25 µM. Since much lower concentrations are 
necessary for the fluorescence polarisation assays, these conditions were 
chosen to continue.  
 
4.7.3 Evaluation of the THC-sepharose-binding sequences under 
conditions differing from the original selection buffer 
Since the problems associated with the addition of Tween to solutions containing 
THC (section 4.7.2) necessitated the absence of Tween in any future binding 
assay, the THC-sepharose-binding sequences had to be tested for their 
interaction with THC-sepharose in the absence of Tween. For most sequences, 
the absence leads to a slight increase in binding to THC-sepharose. Tween most 
likely interacts unspecifically with the hydrophobic modifications of the DNA and 
thereby keeps them from the THC-sepharose. The effect is stronger for the CF3- 
than for the benzyl-modified sequences and most apparent for C15 and C47 
(Figure 49A). As CF3 is more hydrophobic than benzyl, it stands to reason that 
Tween has a stronger effect on the CF3-modified sequences. Individual 
differences between sequences are probably due to their folding and depend on 
their interaction with THC. Sequences, whose (hydrophobic) modifications are on 
the surface, have a higher probability to interact with Tween and be kept apart 
from the THC-sepharose. In addition, sequences with a high affinity for THC-
sepharose are less likely to dissociate and therefore have a lower probability of 
ending up in Tween-micelles. Therefore, the effect of Tween on C15 and C47 
might indicate that their affinity for THC-sepharose is worse than that of the other 
sequences. 
In addition to the effect of Tween, different buffer components were tested for 
their effect on the fluorescence polarisation. Figure 48 shows that BSA increases 
the fluorescence polarisation of THC-FITC. This is due to the fact that BSA 
interacts with THC.259 None of the other components (salmon sperm DNA, ACN) 
had an effect (Figure 48). To enable fluorescence polarisation assays, BSA had 
to be removed from the buffer. Therefore, the THC-sepharose-binding sequences 
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had to be investigated in the absence of BSA. In contrast to the effect of Tween, 
BSA slightly increases the interaction of all sequences with THC-sepharose. 
Again, the effect is most prominent for C15 and C47 (Figure 49B). As BSA 
interacts with THC, it should bind to THC-sepharose. BSA is mainly hydrophilic260 
and most probably unspecifically interacts with the DNA, leading to the observed 
increase in binding to THC-sepharose. The higher influence on the interaction of 
C15 and C47 can – again – be an indication of a weaker affinity or specificity of 
these sequences as they are more prone to unspecifically interact with the BSA 
on THC-sepharose than the other sequences.  
As the initial selections were the second click-selections after the GFP-selection 
published by Tolle et al.205, the selection conditions were kept as close to the 
original ones as possible to increase the chance of selection success. That also 
meant selecting at a pH of 5.4. The fluorescence of THC-FITC and TLF is higher 
(Figure 43B and Figure A 2B) and their polarisation lower at neutral than at 
acidic pH (Figure 44 and Figure 58). Therefore, the sequences were also tested 
for their interaction with THC-sepharose at neutral pH to enable fluorescence 
polarisation assays under these – improved – conditions. In comparison to the 
absence of either Tween or BSA, the change in pH has a drastic effect: Binding 
of a large number of sequences is completely abolished. Only two of the six 
benzyl- (B12 and 27) and five of the nine CF3-modified sequences (C15, C47, 49, 
53, and 77) interact with THC-sepharose at pH 7.4 and most (all but B12 and 
C15) to a reduced degree. The change in pH should have no effect on either 
THC, especially as it is coupled to the sepharose via the phenolic hydroxyl, nor 
on the nucleosides or click-modifications (pKA-values: THC 10.6
56, cytosine 4.2, 
guanosine 1.6 and 9.2, adenosine 3.5, uridine 9.2261, triazole 9.4262, benzyl 
(toluene) 40.9263. No value has been published for CF3, but it is probably similar 
to benzyl). The phosphate group of the nucleic acid backbone can be protonated 
at pH 5.4 and deprotonated at pH 7.4 (pKA 1.0 and 6-7
261). This indicates that the 
sequences that do not bind at pH 7.4 might depend on salt bridges with their 
phosphate backbone for folding and/or binding. An influence on folding seems 
more likely as THC does not present opportunities for salt bridges. It is also 
possible that the change in pH leads to a change somewhere on the surface of 
the sepharose, which somehow changes the way THC is presented. According to 
the manufacturer, the sepharose should be stable at pH-values as low as two.264 
No information on the surface chemistry apart from the functional group and 
linker is available to evaluate the effect a change in pH might have on it.  
 
4.7.4 Fluorescence polarisation measurements using THC-FITC and 
TLF 
After exclusion of effects that resulted from the micelle-formation of Tween 
(section 4.7.2) and the addition of BSA (section 4.7.3), both THC-FITC and TLF 
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lead to polarisation values that allow interaction assays. Nonetheless, the 
polarisation of the light emitted by THC-FITC is about twice as high as that of TLF 
at both tested pH-values (Figure 44 and Figure 58). According to the theory 
behind fluorescence polarisation assays as depicted in Figure 40, this indicates a 
slower rotation and larger size of THC-FITC. Most likely, this is due to the rigid 
connection between THC to FITC, which means that the molecule can only rotate 
as a whole. In comparison, the linker between THC and FITC in TLF allows more 
rotational freedom for FITC, resulting in lower polarisation values that are equal 
to those obtained with FITC alone (Figure 54, Figure 58, and Figure 59). 
To validate the fluorescence polarisation assay for Kd measurements, the affinity 
constant of the THC-antibody was determined. The divergence between the two 
measurements with THC-FITC is negligible (Figure 51, 27.8 ± 28.9 and 62.7 ± 
60.5 nM) and would probably be reduced along with the respective standard 
deviations if more concentrations in the range below 100 nM were measured. In 
comparison, the affinity for TLF is severely reduced by a factor of four to eight 
(Figure 59, 226.5 ± 175.8 nM). Since no structural knowledge about the 
interaction of the antibody and THC is available, further experiments are 
necessary to discover the reason for the affinity decrease. The evaluation of 
additional concentrations is needed to solidify the measured affinity discrepancy.  
Fluorescence polarisation assays were performed with both THC-FITC and TLF 
for all identified THC-sepharose-binding sequences (Figure 52 and Figure 60). 
In addition, the sequences that were determined to recognise THC-sepharose at 
pH 7.4 (section 4.7.3 and Figure 50) were also evaluated at this pH (Figure A 3 
and Figure A 4). None of the sequences led to any increase in polarisation at a 
DNA-concentration of 500 nM. Higher concentrations could not be measured due 
to the high cost of preparing the benzyl- and CF3-modified DNA by PCR. If single 
sequences had been deemed promising after this initial screening (Figure 52, 
Figure 60, Figure A 3, and Figure A 4), they could have been synthesised by 
solid-phase synthesis. For a screening of all sequences, the costs are too high.  
In an attempt to increase the sensitivity of the assay, the THC-sepharose-binding 
sequences were biotinylated and incubated with streptavidin during the 
fluorescence polarisation assay. As mentioned before (section 3.2.7.4), 
streptavidin was chosen as a simple way to increase the molecular weight of the 
sequences. This increases the polarisation if any interaction between sequence 
and THC-FITC or TLF occurred (section 3.2.7). Nonetheless, no effect on the 
polarisation could be observed with any tested sequence (Figure 53, Figure 61, 
and Figure A 5). 
Altogether, the fluorescence polarisation assay was shown to work well with the 
THC-antibody (Figure 51 and Figure 59). None of the controls ever led to 
unexpected results. Therefore, no doubts remain that the assay worked as it 
should have and that it would have shown an increase in polarisation if any of the 
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THC-sepharose-binding sequences interacted with THC-FITC or TLF. Two 
possible explanations for this are available: 
The affinity of the sequences is too low to enable the observation of interactions 
at the tested concentration of 500 nM. A number of aptamers for small molecules 
is known to have affinities in the low to high micromolar range.147,265 This 
explanation seems especially likely for the sequences identified during the initial 
selections (Table 6 and Table 7) as the selection conditions were not particularly 
stringent. During the re-selections with affinity elution (section 4.6), care was 
taken to increase the duration of the wash steps to deplete sequences with a low 
affinity for THC-sepharose.152 Nonetheless, no prior knowledge about selections 
for small molecule clickmers is available. SOMAmers, which contain a 
nucleobase-modification similar to clickmers, have only been published for 
protein targets. While they have affinities in the low nano- to picomolar range180, 
the increase in affinity in comparison to non-nucleobase-modified aptamers might 
not be transferrable to clickmers for small molecules. Further click-selections for 
small molecule targets are necessary to get an idea about the affinity distribution. 
If possible, the parallel and – apart from the click-modification – identical 
selection for one target with both unmodified and click-modified DNA would help 
to elucidate the effects of the modification on affinity. For now, it is entirely 
possible that the THC-sepharose-binding sequences are capable of recognising 
THC in solution with affinities in the high micro- or even millimolar range. They 
might then even be implementable into roadside testing devices for THC 
according to the original aim of this thesis, as some test designs allow significant 
increases in sensitivity in comparison to the original affinity of used 
aptamers.235,266 
The second explanation is that the sequences do not recognise THC-FITC and 
TLF. This might again have two different reasons: The sequences either do not 
bind their target molecule in solution at all or they would recognise THC itself, but 
do not bind THC-FITC or TLF. The latter seems rather unlikely as TLF was 
engineered to imitate THC-sepharose, which is recognised by all of the 
sequences. The most likely option might again be a lacking affinity, as the local 
concentration of THC on the sepharose is very high (section 4.8).  
If the sequences lack affinity for THC or if they are unable to recognise THC in 
solution cannot be answered on the basis of this thesis. While further 
experiments might be able to gain the required knowledge, even the best case 
scenario – the sequences recognise THC with a low affinity – necessitates the 
increase of sensitivity for any possible roadside testing device. Although the legal 
limit for THC in Germany of 1 ng/ml (3.18 nM) is only set in plasma82, any 
roadside testing device for oral fluid should operate with a similar sensitivity. The 
required effort would probably be tremendous. Therefore, any further evaluation 
of the THC-sepharose-binding sequences was foregone at this point in 
preference of new click-selections that utilise all so-far gained information.  
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4.8 Toggle-SELEX 
The toggle-SELEX was performed for two reasons: To circumvent the 
dependence on sepharose as a sole matrix and to utilise the gained knowledge 
on THC-solubility by performing affinity elution.  
THCA immobilised on tosylated magnetic beads was chosen as second matrix 
next to the well-established THC-sepharose. The different matrices in 
combination with the different immobilisation chemistries were supposed to 
maximise the chances of selecting clickmers that bind in solution. White et al., the 
inventors of toggle-SELEX, used both human and porcine thrombin as targets to 
circumvent the selection of species-specific aptamers.225 The aim of a decrease 
of specificity – in our case for THC immobilised on sepharose – is the same. To 
the best of our knowledge, this is the first time different matrices and 
immobilisation strategies instead of different target molecules were used in a 
toggle-SELEX. 
The selection buffer of the initial click-selections was chosen to be identical to the 
one used in the single successful, published click-SELEX (section 4.3).267 As all 
four click-selections for THC had successfully enriched THC-sepharose-binding 
sequences, we chose to change the buffer to one more appropriate to the final 
application: PBS, pH 7.0, with an increased potassium ion concentration to 
imitate oral fluid (section 3.3).226 In this buffer, THC-solubility was determined to 
be 200 µM (Figure 62). This is similar to the 150 µM determined in the selection 
buffer of the initial click-selections (Figure 36), as 200 µM were not tested for the 
initial buffer. The change in pH does not seem to affect THC-solubility at the 
tested concentrations. Alkaline conditions should deprotonate THC and therefore 
increase its solubility in aqueous buffers (section 3.1.2.1), but deviate from the pH 
in human oral fluid and were therefore not considered.  
A decrease of the concentration of the target molecule during the incubation 
period should enforce the selection of clickmers with high affinity.152 To decrease 
both the local as well as the global concentration of THC, sepharose with 
different amounts of THC on the surface was prepared and the amount of THC-
sepharose and THCA-beads reduced over the course of the SELEX (Table 19). 
No differences in the amount of THC on the surface could be determined 
between the 1:10- and 1:100-sepharose and the signal of the THC-antibody was 
only twice as strong for 1:1-sepharose as for the other two (Figure 63). 1:10-
sepharose can contain THC coupled to maximal 10% of the functional groups on 
the surface of the sepharose, 1:100-sepharose to maximal 1%. The affinity 
constant determined for the THC-antibody and TLF, which resembles THC-
sepharose more closely than THC-FITC, during the course of this thesis 
amounted to about 230 nM (Figure 59) and is therefore slightly lower than the 
250 nM used for the detection. Even though slight differences in coupling density 
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might not be detectable, the sensitivity should be high enough this close to the kD 
to discriminate between differences of a factor of 10.  
Assuming that the antibody signal obtained for 1:100-sepharose represents THC 
coupled to about 1% of the functional groups (the maximum possible), 1:10-
sepharose would also contain THC coupled to about 1% of the functional group 
as no difference in the signal intensity was observed (Figure 63). 1:1-sepharose 
would then carry THC on about 2% of the functional groups on the surface of the 
sepharose. This is far from the yield obtained for the coupling in solution, where 
99.4% THC was coupled to the linker (Figure 18). This difference must result 
from surface-specific effects that decreased the coupling efficiency. After all, the 
same coupling chemistry did not work at all on magnetic epoxy-beads, indicating 
a major effect of the solid support (data not shown).  
Due to the low coupling efficiency, the values given for THC in Table 19 are too 
high. The amount was reduced from maximal 9.5-20 nmol in selection cycle 1 to 
190 to 400 pmol THC from selection cycle 9 onwards. These values are still 
approximated from the signals of the antibody on the sepharose and no 
corresponding values are available for the THCA-beads. Therefore, the values in 
the table were not adjusted and left as the maximal possible amounts of THC(A).  
As for the affinity-selections, the incubation time was reduced and the duration of 
the wash steps increased over the course of the toggle-SELEX to enforce the 
selection of high affinity clickmers (section 4.6). Affinity elution was not performed 
on the THC-sepharose, as the matrix cannot be heated above 80°C without 
starting to melt and it could not be guaranteed that all DNA would be denatured 
at 80°C. 
After ten selection cycles, interaction assays with both THC-sepharose and 
THCA-beads showed no enrichment for either of the selections (Figure 64). The 
values obtained for THC-sepharose are similar to those of the SL for the first 
click-selections (Figure 22A and Figure 26A). DNA-binding to the THCA- and 
methylamine-blocked tosylated beads is surprisingly high: While about 3.5% of 
the benzyl-modified DNA from the first selection cycle of the initial SELEX 
interacted with the THCA-beads and exhibited a clear preference for the modified 
beads (Figure 25), 50-60% of the DNA of the SL remain on both types of beads 
(Figure 64C, D). This observation is the most likely explanation for the fact that 
less PCR-cycles were necessary for amplification during the selection cycles 
performed on THCA-beads (Table 19).  
DNA-libraries are not amplified before use, resulting in a variation of the 
sequence composition between single aliquots. Nonetheless, it seems unlikely 
that the new aliquot should contain so many sequences that bind to tosylated 
beads. It is also improbable that the single selection cycle performed with the 
DNA presented in Figure 25 reduced sequences that bind to tosylated beads so 
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thoroughly. The remaining difference between the two assays is the selection 
buffer: The increase from pH 5.4 to 7.0 as well as the removal of Tween and 
addition of ACN are the most likely explanation for the increase in unspecific 
binding.  
The high unspecific interaction with both forms of tosylated beads also explains 
the failure of the toggle-SELEX. Every selection cycle performed on THCA-beads 
enriched sequences non-specifically binding to the magnetic beads and not to 
THCA. The parallel selection on THC-sepharose managed to slowly (CF3-
modified DNA) or rapidly (between the start and cycle four, benzyl-modified DNA) 
reduce the unspecific interaction with the magnetic beads. The difference 
between the two selections has to be due to the modification. Further knowledge 
about what kind of interaction leads to the high binding to the tosylated beads 
and how the sequence compositions change between the different selection 
cycles is necessary to elucidate how exactly the modifications have such a strong 
impact. 
In a last attempt to enrich THC-binding sequences, four selection cycles were 
added. Most of these were performed on THC-sepharose and included a pre-
selection step to deplete matrix-binding sequences (Table 19). Regardless of 
these efforts, the DNA from the final selection cycle did not show increased 
binding to THC-sepharose (Figure 65).  
Altogether, both toggle-selections were unsuccessful. While other changes (e.g., 
the buffer with its neutral instead of acidic pH) from the successful click-
selections before cannot be excluded as causes, the most probable reason is the 
high unspecific binding of the modified DNA to the tosylated magnetic beads.  
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5 Outlook 
While this thesis was successful in enabling the selection of THC-sepharose-
binding sequences through the use of click-SELEX and the structure-guided 
choice of DNA-modifications, none of the selected sequences could be shown to 
recognise THC in solution. For the desired application, the incorporation of a 
clickmer into a roadside oral fluid test, in-solution binding is required. 
Immobilisation of THC via its hydroxyl group during the roadside test is not 
possible, as the reaction takes days (Figure 18).  
Therefore, the development of a roadside test first has to focus on the selection 
of a clickmer that is able to recognise THC in solution.  
Two different approaches appear to be the most promising towards this aim: 
another toggle-SELEX or a capture-SELEX. 
 
5.1 Toggle-SELEX 
To reach selection-success with another toggle-SELEX, a second matrix without 
any problems due to unspecific interactions of the DNA with the matrix itself is 
necessary. The THCA-functionalised amine beads used in the initial selections 
with non-nucleobase-modified nucleic acids (section 3.1.1) are already well 
established. Nonetheless, they are accompanied by their own problem regarding 
unspecific interactions with DNA and 2’F-RNA due to their hydrophilic coating. 
High salt concentrations and competitors as used in SELEX 1 to 5 can reduce the 
unspecific interactions sufficiently to enable selection (Table 3). In addition, the 
hydrophobic modifications of the benzyl- and CF3-modified DNA might lessen the 
problem. In any case, thorough investigations of the unspecific interactions are 
recommended before starting any selection.  
The immobilisation of THC on epoxy-functionalised magnetic beads presents 
another alternative. The chemistry is well established and should be transferable 
from THC-sepharose, but has already failed with three different kinds of magnetic 
beads (data not shown). Since information on the composition and surface of the 
magnetic beads apart from the functional group itself is rare, it cannot be 
excluded that a fourth or fifth epoxy-functionalised magnetic bead would be 
modifiable as desired.  
Establishing a new immobilisation technique is the final option. A possibility that 
bypasses magnetic beads completely is adipic acid dihydrazide–agarose.268 The 
linker, adipic acid dihydrazide, is commercially available and could be used to 
determine the optimal conditions for the coupling reaction, analogue to what has 
been presented for THC-sepharose in this thesis (section 3.1.2.1). Adipic acid 
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dihydrazide reacts with carboxyl groups under formation of an amide bond and 
could be used in combination with THCA or THC-COOH.  
If two similar matrices with different surface chemistries are used to ‘toggle’ (e.g., 
epoxy-activated sepharose and adipic acid dihydrazide-agarose), a pre-selection 
is recommended to deplete matrix-binding sequences. While the problem did not 
arise during the click-selections in this thesis (Figure 22A and Figure 26A), two 
different presentations of the target molecule might lead to a stronger enrichment 
to the non-changing matrix.  
A number of selections in this thesis were performed using affinity elution to 
specifically recover sequences that recognise THC in solution. However, none of 
them was successful. In all cases, some DNA or 2’F-RNA was unspecifically 
recovered and amplified. Accordingly, the effectiveness of a specific elution is not 
apparent during the selection itself. Such an unplanned, unspecific elution 
enriches sequences that do not bind to the immobilised target again after 
denaturation and is therefore worse than a completely unspecific heat elution. To 
exclude this risk, two selections can be performed in parallel with either heat or 
affinity elution as exemplified by SELEX 1 and 2 (Table 3). 
 
5.2 Capture-SELEX 
For capture-SELEX, the DNA-library contains a docking sequence that is 
complementary to a capture oligo. The latter is immobilised onto magnetic beads. 
The library is annealed with the capture oligo and remains on the magnetic 
beads. Only if a sequence interacts with the target molecule in such a way that 
the parallel basepairing with the capture oligo is no longer possible is the 
sequence removed from the solid support and amplified for the subsequent 
selection cycles.151,269 Since the target molecule is not immobilised during the 
selection process, this technique guarantees the selection of aptamers that 
recognise the target molecule in solution.  
Most publications utilise a target concentration of 1 mM or higher.151,270-273 This 
will not be achievable with THC in an aqueous solution. However, there are some 
examples, in which lower target concentrations were used to successfully select 
specific aptamers. For instance, Nutiu et al. used 100 µM of each of the 
nucleoside triphosphates (NTPs), Spiga et al. 200 µM tobramycin for selection 
cycle one to four and 20 µM for the remaining ones.269,274 These concentration 
ranges are realistic according to the data in this thesis (Figure 36 and Figure 
62), indicating that capture-SELEX might be a valid approach to select a clickmer 
for THC.  
Capture-SELEX has been used for the selection of both DNA-151,269-272,274 and 
RNA-aptamers275, but not in combination with nucleobase-modified nucleic acids. 
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To combine capture- and click-SELEX, special care has to be taken concerning 
library design. The base pairing of the docking sequence and the capture oligo 
has to be stable enough to prevent dissociation of the library during incubation 
with the target molecule, while still enabling the dissociation if it results from the 
interaction between sequence and target molecule.151 Since the effect of the 
click-modifications on base pair stability is unknown, melting point studies should 
precede library design.  
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6 Material & Methods 
6.1 Material 
6.1.1 Equipment 
Equipment Manufacturer 
Agarose gel camera, UV-transilluminator Bio-Rad Laboratories 
Agarose running chamber In house construction, peqlab 
Amicon ultra centrifugal filter units, MWCO 10k Merck 
Analytical balances Sartorius 
Analytical HPLC system, 1100 Agilent 
Analytical HPLC system, 1260 Infinity Agilent 
Autoclave Systec 
Bacterial incubator shaker, 4430 Innova 
BAS cassettes  Fuji 
Centrifuges Eppendorf, Sigma 
Cling film Roth 
Counter Berthold 
Electrophoresis power supply, E865 Consort 
Empty micro Bio-Spin columns Bio-Rad 
EnSpire multimode reader PerkinElmer 
Eppi racks Roth 
Glass frit RobuGlas 
Glass pipette tips Hirschmann 
Glass plates for PAGE Baack 
Glass wool Sigma-Aldrich 
Heating cabinet WTB binder 
HiSeq 1500 Illumina 
HPLC vials N11 with snap ring caps Macherey-Nagel 
HPLC-column EC/50/4.6 Nucleodur 100-5 18 
ec 
Macherey-Nagel 
HPLC-column Zorbax_50x2.1_5µm Agilent 
HTC Esquire Bruker 
Image eraser Raytest 
Liquid Scintillation counter, WinSpectral 1414 PerkinElmer 
Lyophiliser (Alpha 2-4 LD plus) Christ 
Magnetic rack, Dynamag 2 Life Technologies 
Microspin G25 columns GE healthcare 
Microwave Bosch 
NanoDrop  Peqlab 
NanoQuant infinite M200 Tecan 
NanoQuant Plate Tecan 
Odyssey blot imager LI-COR 
PAGE running chamber In house construction 
Parafilm Faust 
Pasteur pipette with rubber bulb Sigma-Aldrich 
125 
 
  
PCR 8er Deckelkette flach Sarstedt 
PCR multiply strip 0.2 ml Kette Sarstedt 
PCR Thermocycler Biometra, Eppendorf 
Petri dishes (94 x 16 mm) Labomedic 
pH meter Inolab 
Phosphoimager screens Fujifilm 
Phosphoimager, FLA-3000 Fujifilm 
Pierce streptavidin coated high binding 
capacity black 96-well plate 
Thermo Fisher Scientific 
Pipette tips Sarstedt 
Pipetteboy Accu-jet Pro Brand 
Pipettes Eppendorf 
Proxi Plate 384 F Plus PerkinElmer 
Radioactive protection shield Nalgene 
Reaction tubes 0.2 ml, 0.5 ml, 1.5 ml, 2 ml Eppendorf 
Refrigerators and Freezer 4°C, -20°C, -80°C AEG, New Brunswick, Liebherr 
Scalpel blades Labormedic 
Speedvac (Concentrator 5301) eppendorf 
Syringe, 5 ml Braun 
Tecan ultra Tecan 
Thermomixer 1.5 ml, 2 ml Eppendorf, HLC 
Thermomixer HLC 2 ml  Ditabis  
Tube rotator, REAX 2 Heidolph 
Vacuum distillation rotator Heidolph 
Vials for liquid scintillation counter, Maxi-
Vial,18 ml 
PerkinElmer 
Vortex Neolab 
Water bath GFL, Julabo 
 
6.1.2 Chemicals 
Reagents Manufacturer 
1,4-dithiothreitol (DTT) Roth 
2’fluoro cytidine triphosphate (2’F-CTP) Metkinen 
2’fluoro uridine triphosphate (2’F-UTP) Metkinen 
7 N ammonia (NH3) in MeOH Sigma-Aldrich 
ACN, HPLC grade Sigma-Aldrich 
ACN, LC-MS grade Sigma-Aldrich 
Adenosine triphosphate (ATP) Jena Bioscience 
Agar, bacteriology grade AppliChem 
Agarose Bio-Budget technologies 
Ammonium peroxodisulfate (APS)  Roth 
Ampicillin Roth 
BDE Sigma-Aldrich 
Benzyl-azide Sigma-Aldrich 
Boric acid AppliChem 
Bovine serum albumin Calbiochem 
Bromphenol blue Merck 
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Calf intestine alkaline phosphatase (CIAP) with 10x 
buffer 
Promega 
CF3-azide In house production, AK 
Mayer; Malte Rosenthal 
Chloroform Fisher Scientific 
Copper(II) sulfate Sigma-Aldrich 
Cremophor EL Sigma-Aldrich 
DCC Sigma-Aldrich 
Deoxyadenosine triphosphate (dATP) Jena Bioscience 
Deoxycytidine triphosphate (dCTP) Jena Bioscience 
Deoxyguanosine triphosphate (dGTP) Jena Bioscience 
Deoxynucleoside triphosphate (dNTP)-mix Jena Bioscience 
DMF Fisher Scientific 
DMSO Sigma-Aldrich 
DNA Polymerase I, Large (Klenow) Fragment NEB 
D-PBS, 10x (cat. no. RNBF8385) Sigma-Aldrich 
Dynabeads M-270 Amine Thermo Fisher Scientific 
EDTA AppliChem 
EdUTP BaseClick 
Epoxy-activated sepharose 6B GE Healthcare 
Ethanol VWR 
Ethidium bromide Roth 
Formamide Sigma-Aldrich 
Formic acid, HPLC and LC-MS grade Merck 
Glycogen  Roche 
Goat anti-mouse IgG (L+H) Dylight 800 conjugated Thermo Fisher Scientific 
GoTaq DNA Polymerase with 10x buffer Promega 
GoTaq Flexi DNA Polymerase with 10x buffer Promega 
Guanosine triphosphate (GTP) Jena Bioscience 
Heparin  Sigma-Aldrich 
Hydrochlorid acid (HCl) Roth 
Hydroxylamine Sigma-Aldrich 
Inorganic pyrophosphatase (iPP) Roche 
Lennox broth (LB) Roth 
Magnesium chloride (MgCl2) Roth 
MeOH Fisher Scientific 
N,N,N,N-Tetramethylethylendiamide (TEMED) Roth 
Phenol (Roti-Phenol) Roth 
Potassium chloride (KCl) Roth 
Potassium phohsphate monobasic (KH2PO4)  Fluka 
Pwo DNA Polymerase with 10x buffer Genaxxon 
RNAsin Promega 
Rotiphorese sequencing gel concentrate Roth 
Salmon sperm DNA Invitrogen 
Sodium acetate (NaOAc) VWR 
Sodium chloride (NaCl) Roth 
Sodium dodecylsulfate (SDS) Roth 
Sodium L-ascorbate Sigma-Adrich 
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Sodium phosphate dibasic (Na2HPO4) Roth 
Super optimal growth (SOC) medium NEB 
SuperScript II reverse transcriptase with 5x first 
strand buffer 
Thermo Fisher Scientific 
T4 Polynucleotide kinase (PNK) with 10x buffer NEB 
T7 Y639F RNA polymerase In house production, AK 
Famulok; Nicole Krämer 
Taq polymerase with 10x buffer In house production, AK 
Famulok; Nicole Krämer 
TEA Acros Organics 
THC (dronabinol) THC Ohara 
THCA Lipomed 
THC-antibody, sequence M4020412 (cat. no. 10-
T43F) 
Fitzgerald 
Tris Roth 
Tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) BaseClick 
Tween-20 Roth 
Urea Roth 
Xylenecyanole Merck 
λ-exonuclease with 10x buffer Thermo Fisher Scientific 
 
6.1.3 Buffers 
All buffers were solubilised in ddH2O and the pH (negative logarithm of the H
+-
concentration) adjusted using HCl and NaOH.  
Buffer composition 
0.1 M phosphate buffer 61.5 mM K2HPO4 
38.5 mM KH2PO4, pH 7.0 
10x TBE buffer 890 mM Tris/HCl 
890 mM boric acid 
20 mM Na2EDTA, pH 8.0 
2x RNA loading dye 95% (v/v) formamide 
0.5 mM EDTA 
0.025% (w/v) SDS 
0.025% (w/v) Xylencyanol 
4x PAGE loading dye 9 M urea 
50 mM EDTA, pH 8.0 
6x DNA loading dye 60% (v/v) glycerol 
10 mM Tris/HCl 
0.03% (w/v) Xylencyanol 
60 mM Na2EDTA, pH 8.0 
PBS, pH 7.4 137 mM NaCl 
3.93 mM Na2HPO4 * 2 H2O 
1.47 mM KH2PO4, pH 7.4 
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6.1.4 Kits  
Product Manufacturer 
Gel and PCR clean-up kit Macherey-Nagel 
NTC buffer for Gel and PCR clean-up kit Macherey-Nagel 
NucleoSpin Plasmid Macherey-Nagel 
TOPO TA cloning kit with One Shot TOP10 
chemically competent Escherichia coli 
Life Technologies 
TruSeq DNA PCR-Free Sample Preparation 
Kit LT 
Illumina 
 
6.1.5 Standards, radioactive nucleotides 
Type Length  Manufacturer  
Ultra low range DNA 
ladder 
10 – 300 base pairs (bp) Thermo Fisher Scientific 
γ 32P-ATP purchased from Perkin Elmer. 
6.1.6 Synthetic oligos 
Name Sequence (5´ - 3´) 
Click-competitor N42 – A 
D3-F GCT GTG TGA CTC CTG CAA 
D3-library GCT GTG TGA CTC CTG CAA - N43 –
GCA GCT GTA TCT TGT CTC C 
D3-R-P Phosphate – GGA GAC AAG ATA CAG 
CTG C 
FT2-F CAC GAC GCA AGG GAC CAC AGG 
FT2-F-bio Biotin – CAC GAC GCA AGG GAC CAC 
AGG 
FT2-F-Cy5 Cy5 – CAC GAC GCA AGG GAC CAC 
AGG 
FT2-library CAC GAC GCA AGG GAC CAC AGG – N42 – 
CAG CAC GAC ACC GCA GAG GCA 
FT2-R TGC CTC TGC GGT GTC GTG CTG 
FT2-R-P Phosphate – TGC CTC TGC GGT GTC 
GTG CTG 
GDNA-F GGG AGA GGA GGG AAG TCT ACA 
TCT T 
GDNA-library GGG AGA GGA GGG AAG TCT ACA 
TCT T NNN GGG NNN GGG NNN GGG 
NNN GGG NNN AAG ATG TCT GGA 
GTT GAC GAA GCT T 
GDNA-R-P Phosphate – AAG CTT CGT CAA CTC 
CAG ACA TCT T 
GRNA-F ATA GCT AAT ACG ACT CAC TAT AGG 
GAG AGG AGG GAA GTC TAC ATC TT 
GRNA-library ATA GCT AAT ACG ACT CAC TAT AGG 
GAG AGG AGG GAA GTC TAC ATC TT 
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NNN GGG NNN GGG NNN GGG NNN 
GGG NNN AAG ATG TCT GGA GTT 
GAC GAA GCT T 
GRNA-R AAG CTT CGT CAA CTC CAG ACA 
TCT T 
M111-F GCG CCA GTC TAG GGC ACC 
M111-library GCG CCA GTC TAG GGC ACC - N75 – 
CAT TGA CTC GGT GGA TCC 
M111-R-P Phosphate – GGA GGA TCC ACC GAG 
TCA ATG 
SulI-F GGG GGA ATT CTA ATA CGA CTC 
ACT ATA GGG AGG ACG ATG CGG 
SulI-library GGG GGA ATT CTA ATA CGA CTC 
ACT ATA GGG AGG ACG ATG CGG - 
N40 – CAG ACG ACT CGC TGA GGA 
TCC GAG A 
SulI-R TCT CGG ATC CTC AGC GAG TCG TC 
T_w/o CTT GTA CAC GAC GCA AGG GAC 
CAC AGG GTT GGA AGC GAC GGG 
ACG GTA AGG CTT GGG CCC CAA 
GGA GTG CAG CAC GAC ACC GCA 
GAG GCA TAC AAG 
C12_EdU CAC GAC GCA AGG GAC CAC AGG 
GXX GGA AGC GAC GGG ACG GXA 
AGG CXX GGG CCC CAA GGA GXG 
CAG CAC GAC ACC GCA GAG GCA 
C12_T CAC GAC GCA AGG GAC CAC AGG 
GTT GGA AGC GAC GGG ACG GTA 
AGG CTT GGG CCC CAA GGA GTG 
CAG CAC GAC ACC GCA GAG GCA 
FT2_GATC_sense CTT GTA CAC GAC GCA AGG GAC 
CAC AGG GAT CGA TCG ATC GAT 
CGA TCG ATC GAT CGA TCC AGC 
ACG ACA CCG CAG AGG CAT ACA AG 
FT2_G4A4T4C4_sense GGC TAC CAC GAC GCA AGG GAC 
CAC AGG GGG GAA AAT TTT CCC 
CGG GGA AAA TTT TCC CCC AGC 
ACG ACA CCG CAG AGG CAG TAG 
CC 
FT2_G2A2T2C2_sense GCC AAT CAC GAC GCA AGG GAC 
CAC AGG GGA ATT CCG GAA TTC 
CGG AAT TCC GGA ATT CCC AGC 
ACG ACA CCG CAG AGG CAA TTG GC 
FT2_G3A3T3C3_sense ACA GTG CAC GAC GCA AGG GAC 
CAC AGG GGG AAA TTT CCC GGG 
AAA TTT CCC GGG AAA TTC AGC 
ACG ACA CCG CAG AGG CAC ACT GT 
FT2-TGCA_sense ACT TGA CAC GAC GCA AGG GAC 
CAC AGG TGC ATG CAT GCA TGC 
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ATG CAT GCA TGC ATG CAC AGC 
ACG ACA CCG CAG AGG CAT CAA GT 
D3-TGCA_sense TAG CTT GCT GTG TGA CTC CTG 
CAA TGC ATG CAT GCA TGC ATG 
CAT GCA TGC ATG CAG CAG CTG 
TAT CTT GTC TCC AAG CTA 
FT2-T4G4C4A4_sense CAG ATC CAC GAC GCA AGG GAC 
CAC AGG TTT TGG GGC CCC AAA 
ATT TTG GGG CCC CAA AAC AGC 
ACG ACA CCG CAG AGG CAG ATC TG 
D3-T4G4C4A4_sense GAT CAG GCT GTG TGA CTC CTG 
CAA TTT TGG GGC CCC AAA ATT TTG 
GGG CCC CAA AAG CAG CTG TAT 
CTT GTC TCC CTG ATC 
FT2_GATC_antisense CTT GTA TGC CTC TGC GGT GTC 
GTG CTG GAT CGA TCG ATC GAT 
CGA TCG ATC GAT CGA TCC CTG 
TGG TCC CTT GCG TCG TGT ACA AG 
FT2_G4A4T4C4_antisense GGC TAC TGC CTC TGC GGT GTC 
GTG CTG GGG GAA AAT TTT CCC 
CGG GGA AAA TTT TCC CCC CTG 
TGG TCC CTT GCG TCG TGG TAG CC 
FT2_G2A2T2C2_antisense GCC AAT TGC CTC TGC GGT GTC 
GTG CTG GGA ATT CCG GAA TTC 
CGG AAT TCC GGA ATT CCC CTG 
TGG TCC CTT GCG TCG TGA TTG GC 
FT2_G3A3T3C3_antisense ACA GTG TGC CTC TGC GGT GTC 
GTG CTG AAT TTC CCG GGA AAT 
TTC CCG GGA AAT TTC CCC CTG 
TGG TCC CTT GCG TCG TGC ACT GT 
FT2-TGCA_antisense ACT TGA TGC CTC TGC GGT GTC 
GTG CTG TGC ATG CAT GCA TGC 
ATG CAT GCA TGC ATG CAC CTG 
TGG TCC CTT GCG TCG TGT CAA GT 
D3-TGCA_antisense TAG CTT GGA GAC AAG ATA CAG 
CTG CTG CAT GCA TGC ATG CAT 
GCA TGC ATG CAT GCA TTG CAG 
GAG TCA CAC AGC AAG CTA 
FT2-T4G4C4A4_antisense CAG ATC TGC CTC TGC GGT GTC 
GTG CTG TTT TGG GGC CCC AAA 
ATT TTG GGG CCC CAA AAC CTG 
TGG TCC CTT GCG TCG TGG ATC TG 
D3-T4G4C4A4_antisense GAT CAG GGA GAC AAG ATA CAG 
CTG CTT TTG GGG CCC CAA AAT TTT 
GGG GCC CCA AAA TTG CAG GAG 
TCA CAC AGC CTG ATC 
All oligos were purchased from Ella Biotech GmbH. For RNA-libraries, the start of 
the transcribed RNA-sequence is underlined. X = EdU. 
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6.1.7 Software  
Software  Manufacture 
Adobe Illustrator  Adobe Systems 
AIDA Biopackage  Raytest 
ChemDraw PerkinElmer 
COMPAS AptaIT 
Compass DataAnalyser Bruker 
GraphPad Prism GraphPad Software 
Magellan data analysis software Tecan 
Microsoft office package Microsoft 
Odyssey 2.1 LI-COR 
QuantityOne Bio-Rad 
 
 
6.2 Methods 
6.2.1 General procedures 
6.2.1.1 Agarose gel electrophoresis 
4% (w/v) agarose gels were prepared by dissolving the respective amount of 
agarose in water and solubilisation in a microwave. The resulting liquid was 
supplemented with 0.1% (v/v) ethidium bromide and left to solidify in gel casting 
chambers. Samples for agarose gel electrophoresis were prepared as follows: 
5 µl DNA were mixed with 1 µl 6x DNA loading dye or 5 µl RNA were mixed with 
5 µl 2x RNA loading dye. 4 µl ultra-low range DNA ladder were used as standard 
for both RNA- and DNA-gels. The gels were run for 13 min at 150 V and the 
DNA/RNA visualised by UV-transillumination. 
 
6.2.1.2 Phenol-chloroform extraction 
One volume phenol was added to the sample, vortexed vigorously, and 
centrifuged at 14000 rpm for 5 min. The upper phase was transferred to a new 
vial. Two volumes chloroform were added, vortexed vigorously, and centrifuged 
at 14000 rpm for 3 min. The upper phase was transferred to a new vial and 
ethanol precipitated (section 6.2.1.3). 
 
6.2.1.3 Ethanol precipitation 
1/10 volume 3 M NaOAc, pH 5.4, 0.5 µl glycogen, and three volumes EtOH were 
added to the sample. The precipitation was incubated for 10 min at -80°C and 
centrifuged for 20 min at 4°C and 14000 rpm. The supernatant was discarded, 
the pellet was washed with 1 volume 70% (v/v) EtOH, and centrifuged for 3 min 
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at RT, 14000 rpm. The supernatant was discarded and the pellet dried on air 
before resuspension in ddH2O. 
 
6.2.1.4 5’-Dephosphorylation of 2’F-RNA 
The dephosphorylation mix was setup as described in Table 21 and added up to 
50 µl with ddH2O. The mix was incubated at 37°C for 15 min. 0.425 µl 20 u/µl 
CIAP were added and incubated at 55°C for 15 min. 0.5 µl 0.5 M EDTA, pH 8.0 
were added and incubated at 75°C for 10 min. Finally, 150 µl ddH2O were added 
and the RNA purified by phenol-chloroform extraction and ethanol precipitation. 
The pellet was resuspended in 5 µl, 3 of which were used for radioactive 
phosphorylation (section 6.2.1.5).  
Table 21: Setup of 5'-dephosphorylation 
Reagent Stock 
concentration 
Volume for 1 
reaction  
Final concentration 
in 50 µl 
CIAP buffer 10x 5 µl 1x 
BSA 10 mg/ml 5 µl 1 mg/ml 
RNA   75 pmol 
RNAsin 40 u/µl 0.5 µl 20 u 
CIAP 20 u/µl 0.85 µl 17 u 
 
 
6.2.1.5 Radioactive phosphorylation of single-stranded nucleic acids 
The dephosphorylated 2’F-RNA or DNA (either solid-phase synthesised or 
amplified by PCR, both of which are already 5’-dephosphorylated) was mixed for 
the radioactive phosphorylation according to Table 22 and filled up to 50 µl with 
ddH2O. The reaction was incubated at 37°C for 1 h and purified using MicroSpin 
G-25 columns according to the manufacturer’s instructions. 
Table 22: Setup of 5' radioactive phosphorylation 
Reagent Stock 
concentration 
Volume for 1 
reaction  
Final concentration 
in 50 µl 
2’F-RNA or 
DNA 
 3 µl  
15 pmol 
T4 PNK buffer 10x 5 µl 1x 
T4 PNK 10 u/µl 2 µl 0.4 u/µl 
γ-32P-ATP 10 µCi/µl 1 µl 10 µCi 
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6.2.1.6 Radioactive polyacrylamide gel electrophoresis 
10% Polyacrylamide gel electrophoresis (PAGE) gels were prepared according to 
Table 23 and polymerised. The gel was inserted into a gel running chamber and 
pre-run at 375 V, 15 W for 30 min. The samples were prepared by mixing 0.5 µl 
radioactively labelled 2’F-RNA or DNA with 14.5 µl ddH2O and 5 µl 4x PAGE 
loading buffer. The samples were heated at 95°C for 1 min and loaded onto the 
gel. The gel was run at 350 V, 15 W for 45 min to 1.5 h. It was carefully removed 
from the glass plates, wrapped in cling film and placed into a BAS cassette with a 
Fujifilm phosphoimager screen on top. The screen was exposed overnight 
at -80°C and read out using a Phosphoimager FLA-3000. 
Table 23: Composition of 10% PAGE-gels 
Reagent Volume for 1 gel
  
8.3 M Urea in 10x TBE 4 ml 
Rotiphorese Sequenziergel Konzentrat 16 ml 
8.3 M Urea 20 ml 
10% (w/v) APS 320 µl 
TEMED 16 µl 
 
 
6.2.1.7 Concentration determination of nucleic acids 
The concentration of the nucleic acids was determined with a NanoQuant Infinite 
M200 and 2 µl sample on a NanoQuant Plate using the absorption at 260 nm. 
The molar concentration was calculated using the concentration in ng/µl obtained 
by the NanoQuant and the molar mass of the respective nucleic acid. 
 
6.2.1.8 Single-strand displacement 
6 µl 10 u/µl λ-exonuclease and 1/10 volume 10x λ-exonuclease buffer were 
added to the PCR-product and incubated for 1 h at 37°C, 650 rpm for single-
strand displacement. The displacement was monitored by agarose gel 
electrophoresis according to section 6.2.1.1. The ssDNA was purified with a Gel 
and PCR clean-up kit according to the manufacturer’s instructions using one 
column and four volumes NTC buffer. The purified ssDNA was eluted in two 
times 25 µl ddH2O. 
For the selections with non-nucleobase-modified DNA-libraries, 5 µl instead of 
6 µl λ-exonuclease were used and the incubation performed until no more dsDNA 
was detectable on the agarose gel (45 min and 2 h). 
For the amplification of DNA from selection cycles and sequences, 2.7 µl 10 u/µl 
λ-exonuclease were used for 100 pmol dsDNA.  
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6.2.2 Immobilisation of THC(A) 
6.2.2.1 Immobilisation of THCA on amine-functionalised magnetic 
dynabeads 
THCA was coupled to Dynabeads® M270 Amine as depicted in Figure 13. To 
prepare sufficient beads for a selection, 400 µl 30 mg/ml magnetic beads were 
washed three times with 1.5 ml DMSO each and resuspended in 1370 µl DMSO. 
After addition of 190 µl 5 mg/ml THCA and 24 µl 10 mg/ml DCC (both in DMSO), 
the coupling reaction was rotated overnight at RT. Then, 175 µl 100 mM 
hydroxylamine (in DMSO) was added according to the manufacturer’s 
instructions and the sample rotated for 15 min at RT. The coupled beads were 
washed three times with 1.5 ml DMSO and three times with 1.5 ml PBS before 
resuspension in 1.2 ml PBS, pH 7.4, for a final concentration of 10 mg/ml.  
Unmodified beads as negative control were prepared accordingly, but without 
addition of THCA and DCC and without overnight incubation. 
 
6.2.2.2 Coupling of THC to 1,4-butanedioldiglycidyl ether 
THC was coupled to BDE as depicted in Figure 16. 12.5 µmol THC (39.3 µl 
100 mg/ml in EtOH) were dried in a speedvac and resuspended in 93.1 µl 90% 
DMSO with 10% (v/v) TEA. 6.9 µl BDE were added and rotated for one to seven 
days at 50°C. After 1, 3, and 6 days, a sample containing 0.53 µl of the coupling 
solution was taken and stored at -20°C after addition of 99.5 µl ddH2O for LC-MS-
analysis. Two additional samples were taken on coupling day 7: One contained 
0.53 µl of the coupling solution and 99.5 µl 80% ACN with 20% ddH2O with 0.1% 
(v/v) formic acid. The more concentrated sample contained 5.3 µl of the coupling 
solution and 94.7 µl 80% ACN with 20% ddH2O with 0.1% (v/v) formic acid.  
 
6.2.2.3 Coupling of THC to epoxy-activated sepharose 
For the preparation of 1:1-THC-sepharose, 2.3 g epoxy-activated sepharose 6B 
were swelled in 50 ml ddH2O. Once the sepharose had taken up the water, it was 
washed with 550 ml ddH2O on a glass frit and with three times 20 ml 90% DMSO 
with 10% (v/v) TEA. The sepharose was transferred to a 50 ml falcon in overall 
4 ml 90% DMSO with 10% (v/v) TEA.  
800 µmol THC (2515 µl 100 mg/ml in EtOH) were dried in a speedvac and 
resuspended in the sepharose solution. The sample was rotated at 50°C for 
seven days.  
The THC-sepharose was transferred to a glass frit and washed three times with 
30 ml 90% DMSO with 10% (v/v) TEA. Afterwards, it was washed three times 
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with 50 ml ddH2O. The THC-sepharose was washed three times alternatingly with 
45 ml each 0.1 M NaOAc, pH 4.0 with 500 mM NaCl and 0.1 M Tris-HCl, pH 8.0 
with 500 mM NaCl. Finally, the THC-sepharose was washed three more times 
with 50 ml ddH2O and resuspended in ca. 6 ml ddH2O for a final concentration of 
50% (v/v) resin (sepharose). The THC-sepharose was stored at 4°C.  
For the same amount of 1:10- and 1:100-THC-sepharose, 11.99 and 1.2 µmol 
THC were used, respectively. 
Unmodified sepharose was prepared by letting it swell in ddH2O and washing it 
on a glass frit with an amount of water equal to what was used for THC-
sepharose at the start. The sepharose was resuspended to a final concentration 
of 50% (v/v) resin in ddH2O 
 
6.2.2.4 Detection of THC(A) on the solid support 
50 µl sepharose were washed in an empty micro BioSpin column with 2 ml PBS, 
pH 7.4. The sepharose was resuspended in 150 µl PBS with 0.1% (v/v) Tween-
20 and 1 mg/ml BSA and rotated for 30 min at RT. The sepharose was 
transferred to a column and washed with 3 ml PBS with 0.1% (v/v) Tween. It was 
resuspended in 148.5 µl PBS and 1.5 µl 3.75 mg/ml THC-antibody (final 1:100-
dilution). The sample was rotated for 1 h at RT. The sepharose was transferred to 
a column and washed with 3 ml PBS with 0.1% (v/v) Tween. It was resuspended 
in 149 µl PBS and 1 µl 1:100-diluted goat anti-mouse IgG, Dylight 800 conjugated 
(stock 1 mg/ml) secondary antibody. The sample was protected from light from 
here on and rotated for 30 min at RT. The sepharose was transferred once more 
to a column and washed with 3 ml PBS with 0.1% (v/v) Tween, before 
resuspension in 150 µl PBS. 50 µl were spotted onto the glass plate of an 
Odyssey reader for evaluation. AIDA was used for quantification.  
For the magnetic beads, the assay was performed using 18.75 µl 10 mg/ml 
magnetic beads and without the transferral to the empty BioSpin columns for the 
wash steps. 
 
6.2.3 Selections with non-nucleobase-modified nucleic acids 
6.2.3.1 General procedure for 2’F-RNA-selections 
All selections with 2’F-RNA were performed as described here. 50 µl 10 mg/ml 
non-modified amine dynabeads (section 6.2.2.1) were washed twice with 100 µl 
selection buffer. The beads were resuspended in 1 nmol 2’F-RNA-library in 
overall 200 µl selection buffer and incubated for 30 min at 20°C. To keep the 
beads in suspension, they were pipetted up and down every 5 min. The 
supernatant, which contains all sequences not binding to the matrix itself, was 
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transferred onto 50 µl 10 mg/ml THCA-functionalised dynabeads that had also 
been washed twice with 100 µl selection buffer beforehand. The remaining library 
was incubated with the target-modified beads for 30 min at 20°C. As before, the 
beads were pipetted up and down every 5 min to keep them in suspension. The 
beads were then washed with 100 µl selection buffer for 30 sec, followed by a 
second wash step that lasted 3 min. Depending on the selection cycle, this wash 
procedure was repeated as detailed in Table 24. 
Table 24: Repeats of the wash procedure during SELEX 1 to 5 
Selection cycle Repeats wash procedure 
1 and 2 1 
3 and 4 2 
5 and 6 3 
7 and 8 4 
9 to 15 5 
Only selection cycle 1 to 10 were performed for SELEX 3 to 5. 
The binding sequences were then recovered as detailed in the respective 
SELEX-section. 50 µl eluate was added to 49 µl of the respective RT-PCR-
mastermix (Table 29 and Table 30) and incubated for 5 min at 65°C. The PCR 
was cooled down to 4°C and 0.5 µl SuperScript II Reverse Transcriptase 
(200 U/µl) and 0.5 µl GoTaq DNA Polymerase (5 U/µl) were added. The PCR 
was continued according to Table 25.  
Table 25: PCR-method for 2'F-RNA-selections 
Step Temperature [°C] Duration 
1 54 10 min 
2 95 30 sec 
3 SELEX 1 + 2: 60 
SELEX 3: 71 
30 sec 
30 sec 
4 72 30 
5 72 2 min 
Steps 2 to 4 were repeated according to Table 26. 
The PCR was monitored by agarose gel electrophoresis as detailed in section 
6.2.1.1. 
10 µl of the PCR-product was mixed with the transcription mastermix (Table 27), 
2.5 µl 50 u/µl T7 Y639F RNA polymerase, and 1 µl 40 u/µl RNAsin. The 
remaining PCR-product was stored at -20°C. The transcription was incubated for 
20 min at 37°C and its success verified by agarose gel electrophoresis (section 
6.2.1.1). 
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Table 26: Number of RT-PCR-cycles needed for amplification during SELEX 1, 2, and 3 
Selection 
cycle 
RT-PCR-cycles 
SELEX 1 
RT-PCR-cycles 
SELEX 2 
RT-PCR-cycles 
SELEX 3 
1 13 5 11 
2 19 9 24 
3 19 11 21 
4 19 11 16 
5 19 11 16 
6 16 10 18 
7 18 10 20 
8 18 10 20 
9 17 9 22 
10 14 7 21 
11 16 8 - 
12 16 7 - 
13 18 7 - 
14 16 8 - 
15 16 8 - 
 
Table 27: Composition of the transcription-master mix for SELEX 1, 2, and 3 
Reagent Stock 
concentration 
Volume for 
1 reaction 
Final concentration 
in 100 µl 
Tris, pH 7.9 200 mM 20 µl 40 mM 
DTT 100 mM 5 µl 5 mM 
ATP, GTP (each) 100 mM 1 µl 1 mM 
2’F-CTP, 2’F-UTP (each) 100 mM 3 µl 3 mM 
MgCl2 100 mM 15 µl 15 mM 
ddH2O  38.5 µl  
 
For all subsequent selection cycles, 20 µl transcription product was added to 
50 µl washed, non-modified beads in overall 100 µl selection buffer. 
 
6.2.3.2 Preparation of radioactive 2’F-RNA for interaction assays 
2’F-RNA of the selection cycles was prepared by transcription according to Table 
28. The transcription was incubated at 37°C for 4 h. The resulting 2’F-RNA was 
purified using the Gel and PCR clean-up kit according to the manufacturer’s 
instructions.  
The purified 2’F-RNA was dephosphorylated as detailed in section 6.2.1.4 and 
3 µl of the resulting dephosphorylated 2’F-RNA radioactively phosphorylated 
according to section 6.2.1.5. The phosphorylation was then verified by PAGE as 
described in section 0. 
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Table 28: Setup of transcription 
Reagent Stock 
concentration 
Volume for 
1 reaction 
Final concentration 
in 100 µl 
Tris, pH 7.9 200 mM 20 µl 40 mM 
DTT 100 mM 5 µl 5 mM 
ATP, GTP (each) 100 mM 1 µl 1 mM 
2’F-CTP, 2’F-UTP (each) 100 mM 3 µl 3 mM 
MgCl2 100 mM 25 µl 25 mM 
RNAsin 40 u/µl 1 µl 0.4 u/µl 
iPP 200 u/µl 0.2 µl 2 u/µl 
T7 Y639F RNA 
polymerase 
50 u/µl 2.5 µl 1.25 u/µl 
RT-PCR-product  10 µl  
ddH2O  28.3 µl  
 
 
6.2.3.3 SELEX 1 
The selection buffer for SELEX 1 contained 3 mM MgCl2, 500 mM NaCl (overall, 
including the NaCl in PBS), 0.1 mg/ml salmon sperm DNA in PBS, pH 7.4. SulI 
was used as selection library. 
To recover the bound sequences, the beads were resuspended in 55 µl ddH2O 
and incubated at 80°C for 3 min. The supernatant was quickly removed and used 
as eluate as described above. 
The composition of the RT-PCR-mastermix is given in Table 29. 
Table 29: Composition of the RT-PCR-mastermix for SELEX 1 and 2 
Reagent Stock 
concentration 
Volume for 
1 reaction 
Final concentration 
in 100 µl 
Colorless GoTaq buffer 5x 20 µl 1x 
First strand buffer 5x 4 µl 0.2x 
DTT 100 mM 2 µl 2 mM 
SulI-F 100 µM 1 µl 1 µM 
SulI-R 100 µM 1 µl 1 µM 
MgCl2 100 mM 1.5 µl 1.5 mM 
dNTPs 25 mM (each) 1.2 µl 0.3 mM (each) 
ddH2O  17.3  
 
 
6.2.3.4 SELEX 2 
The selection buffer for SELEX 2 contained 3 mM MgCl2, 500 mM NaCl (overall, 
including the NaCl in PBS), 0.1 mg/ml salmon sperm DNA in PBS, pH 7.4. SulI 
was used as selection library. 
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To recover the bound sequences, the beads were resuspended in 100 µl affinity 
elution buffer (3 mM MgCl2, 500 mM NaCl (overall, including the NaCl in PBS), 
0.1 mg/ml salmon sperm DNA, 3% (v/v) ethanol, 7% (v/v) Cremophor EL, 5 mM 
THC in PBS, pH 7.4) and incubated for 30 min at 20°C. The beads were carefully 
pipetted up and down every 5 min to keep them in suspension and to prevent the 
formation of bubbles.  
The supernatant was transferred to a new vial and precipitated by ethanol 
precipitation according to section 6.2.1.3. The pellet was resuspended in 55 µl 
ddH2O, which were used as eluate as described above.  
The composition of the RT-PCR-mastermix is given in Table 29. 
 
6.2.3.5 SELEX 3 
The selection was performed by Patrick Günther. 
The selection buffer for SELEX 3 contained 50 mM KCl, 3 mM MgCl2, and 
1 mg/ml heparin in 50 mM HEPES, pH 8.0. GRNA was used as selection library. 
After incubation and the washes, the beads were resuspended in 50 µl ddH2O 
and used as eluate (including the beads) as described above. 
The composition of the RT-PCR-mastermix is given in Table 30. 
Table 30: Composition of the RT-PCR-mastermix for SELEX 3 
Reagent Stock 
concentration 
Volume for 
1 reaction 
Final concentration 
in 100 µl 
Colorless GoTaq buffer 5x 20 µl 1x 
First strand buffer 5x 4 µl 0.2x 
DTT 100 mM 2 µl 2 mM 
GRNA-F 100 µM 1 µl 1 µM 
GRNA-R 100 µM 1 µl 1 µM 
MgCl2 100 mM 1.5 µl 1.5 mM 
dNTPs 25 mM (each) 1.2 µl 0.3 mM (each) 
ddH2O  17.3  
 
 
6.2.3.6 DNA-selections on amine-functionalised magnetic beads 
The selection buffer for both SELEX 4 and 5 contained 50 mM KCl, 1 mg/ml 
heparin, and 3 mM MgCl2 in 50 mM Hepes, pH 8.0. SELEX 4 used the D3-library, 
SELEX 5 was performed with the M111-library.  
50 µl 10 mg/ml THCA-functionalised amine dynabeads (section 6.2.2.1) were 
washed twice with 100 µl selection buffer. The beads were resuspended in 
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1 nmol DNA-library in overall 200 µl selection buffer and incubated for 30 min at 
20°C. To keep the beads in suspension, they were pipetted up and down every 5 
min. The beads were then washed with 100 µl selection buffer for 30 sec, 
followed by a second wash step that lasted 3 min. Depending on the selection 
cycle, this wash procedure was repeated as detailed in Table 24.  
The beads were resuspended in 50 µl ddH2O and added to 945 µl of the PCR-
mastermix (Table 31) along with 5 µl 5 u/µl GoTaq Flexi DNA polymerase. 
SELEX 4 used D3-F and D3-R-P, SELEX 5 M111-F and M111-R-P as primers. 
The sample was aliquoted in 10 samples à 100 µl and the PCR continued 
according to Table 32.  
Table 31: Composition of the PCR-mastermix for SELEX 4 and 5 
Reagent Stock 
concentration 
Volume for 
10 reactions 
Final concentration 
in 1000 µl 
GoTaq Flexi buffer 5x 200 µl 1x 
DTT 100 mM 20 µl 2 mM 
5’ primer 100 µM 10 µl 1 µM 
3’ primer  100 µM 10 µl 1 µM 
MgCl2 100 mM 15 µl 1.5 mM 
dNTPs 25 mM (each) 12 µl 0.3 mM (each) 
ddH2O  678 µl  
 
Table 32: PCR-method for SELEX 4 to 7 
Step Temperature [°C] Duration 
1 95 3 min 
2 95 30 sec 
3 SELEX 4 and 6: 64 
SELEX 5: 50 
SELEX 7: 55 
30 sec 
30 sec 
30 sec 
4 SELEX 4 and 7: 72 
SELEX 5: 72 
SELEX 6: 72 
30 sec 
1 min 
45 sec 
5 72 2 min 
Steps 2 to 4 were repeated according to Table 33. 
The PCR was monitored by agarose gel electrophoresis as detailed in section 
6.2.1.1. The beads were removed and the PCR-product cleaned up with a Gel 
and PCR clean-up kit according to the manufacturer’s instructions. 200 µl PCR-
product were loaded onto one column and eluted with two times 25 µl ddH2O for 
overall 250 µl purified PCR-product. 25 µl were stored as backup at -20°C. 
The single-strand displacement was performed according section 6.2.1.8 and the 
concentration of the eluate determined as detailed in section 6.2.1.7. 150 pmol 
DNA were used for selection cycle 2 to 5, 100 pmol for selection cycle 6 to 10. 
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Table 33: Number of PCR-cycles needed for amplification during SELEX 4 to 7 
Selection 
cycle 
PCR-cycles 
SELEX 4 
PCR-cycles 
SELEX 5 
PCR-cycles 
SELEX 6 
PCR-cycles 
SELEX 7 
1 21 14 28 19 
2 21 13 22 18 
3 20 14 17 16 
4 20 15 18 18 
5 16 16 17 15 
6 16 17 15 15 
7 16 12 14 13 
8 16 13 15 15 
9 16 15 14 15 
10 17 14 14 15 
 
For all subsequent selection cycles, a pre-selection step was performed. For this, 
50 µl 10 mg/ml non-modified dynabeads were washed twice with 100 µl selection 
buffer. The ssDNA was added in final 100 µl selection buffer and incubated at 
20°C for 30 min. To keep the beads in suspension, they were pipetted up and 
down every 5 min. The supernatant, which contained all sequences not binding to 
the matrix itself, was transferred onto 50 µl 10 mg/ml THCA-functionalised 
dynabeads that had also been washed twice with selection buffer beforehand. It 
was proceeded as detailed above. 
 
6.2.3.7 DNA-selections on sepharose 
The selection buffer for both SELEX 6 and 7 contained 137 mM NaCl, 3.93 mM 
Na2HPO4 * 2 H2O, 1.47 mM KH2PO4, 18.53 mM KCl, and 3 mM MgCl2 at a pH of 
7.0. SELEX 6 was performed with the D3-library, SELEX 7 with the GDNA-library. 
100 µl THC-sepharose (1:1-coupled, 50 µl pure resin, prepared according to 
section 6.2.2.3) was washed with 2 ml selection buffer. The THC-sepharose was 
resuspended in 1 nmol DNA-library in overall 200 µl selection buffer and 
incubated at 20°C for 15 min. To keep the THC-sepharose in suspension, it was 
pipetted up and down every 5 min. It was placed into an empty micro Bio-Spin 
column and the supernatant forced through by applying pressure with a Pasteur 
pipette rubber bulb. The THC-sepharose was washed with the volume of 
selection buffer indicated in Table 34. During washing, no external pressure was 
applied to increase the flow rate.  
The THC-sepharose was resuspended in 200 µl 4.25 M Urea with 12.5 mM 
EDTA, pH 8.0, transferred to a new vial, and incubated at 65°C for 10 min. To 
keep the THC-sepharose in suspension, it was pipetted up and down after 5 min. 
The sample was then placed into an empty micro Bio-Spin column and the eluate 
collected quickly by applying pressure with a Pasteur pipette rubber bulb. The 
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eluate was precipitated by ethanol precipitation according to section 6.2.1.3 and 
resuspended in 50 µl ddH2O. 
Table 34: Volume of selection buffer used to wash the sepharose during SELEX 6 and 7 
Selection cycle Volume selection buffer [ml] 
1  1 
2 2 
3 3 
4 4 
5 5 
6 6 
7 7 
8 8 
9 9 
10 10 
 
The eluate was added to 945 µl of the PCR-mastermix (Table 31) along with 5 µl 
5 u/µl GoTaq Flexi DNA polymerase. SELEX 6 used D3-F and D3-R-P, SELEX 7 
GDNA-F and GDNA-R-P as primers. The sample was aliquoted in 10 samples à 
100 µl and the PCR continued according to Table 32.  
The PCR was monitored by agarose gel electrophoresis as detailed in section 
6.2.1.1 and the PCR-product cleaned up with a Gel and PCR clean-up kit 
according to the manufacturer’s instructions. 200 µl PCR-product were loaded 
onto one column and eluted with two times 25 µl ddH2O for overall 250 µl purified 
PCR-product. 25 µl were stored as backup at -20°C. 
The remaining sample was single-strand displaced according to section 6.2.1.8 
and the concentration of the eluate determined as detailed in section 6.2.1.7. 
150 pmol DNA were used for selection cycle 2 to 6, 100 pmol for selection cycles 
7 and 8, and 65 pmol for selection cycles 9 and 10. 
 
6.2.3.8 Preparation of radioactive DNA for interaction assays 
DNA was prepared by PCR and single-strand displacement as detailed in 
sections 6.2.3.6, 6.2.3.7, and 6.2.1.8. 15 pmol ssDNA was radioactively 
phosphorylated (section 6.2.1.5) and the phosphorylation verified with a 10% 
PAGE-gel (section 0). 
For SELEX 4 and 5, all radioactively labelled and purified DNA was loaded onto a 
preparative 10% PAGE-gel and proceeded as explained in section 0. Instead of 
overnight, the screen was only exposed for 30 min and a printout of the gel image 
used to localise and cut out the radioactive DNA bands. The resulting gel pieces 
were smashed with a pipette tip and soaked in 0.3 M NaOAc, pH 5.4 at 65°C and 
1200 rpm for 1.5 h. The liquid was filtered through a syringe filled with glass wool 
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and the remaining gel pieces washed several times with 0.3 M NaOAc, pH 5.4. 
The sample was precipitated by ethanol precipitation (section 6.2.1.3) and the 
purified DNA resuspended in 50 µl ddH2O and used for interaction analysis. 
 
6.2.4 Click-selections 
6.2.4.1 Cupper-catalysed alkyne-azide cycloaddition 
A catalyst solution was prepared by addition of 4 µl 100 mM THPTA, 1 µl 100 mM 
CuSO4, and 25 µl freshly prepared 100 mM sodium ascorbate to 70 µl ddH2O. To 
enable reduction of CuII to CuI, the catalyst was incubated for 10 to 15 min  at RT 
before use. The EdU-modified DNA (maximal 500 pmol) was mixed with 10 µl 
10 mM azide and 10 µl 0.1 M phosphate buffer, pH 7 before addition of 10 µl 
freshly prepared catalyst solution. The sample was incubated for 1 h at 37°C and 
650 rpm. For purification, Amicon Ultra centrifugal filter unit with MWCO 10 kDa 
were used according to the manufacturer’s instructions.  
 
6.2.4.2 PCR 
PCRs with click-modified DNA were prepared according to Table 35. The eluate 
served as template during the selections. For amplification of the DNA of 
selection cycles, 2 µl of a 1:100-dilution of the backup of the DNA of the 
respective selection cycle were used as template for 100 µl PCR. For 
amplification of the DNA of single sequences, 1 µl of a 1:100-dilution of PCR-
product I (section 6.2.6.5) were used as template for 100 µl PCR.  
The PCR was aliquoted in 10 samples à 100 µl and the PCR continued according 
to Table 36 using a PCR-block that had been preheated to 95°C. Steps 2 to 4 
were repeated according to Table 5 during the initial click-selections, according 
to Table 14 during the affinity re-selections, and according to Table 19 during the 
toggle-SELEX. Twenty PCR-cycles were performed for the amplification of DNA 
of single sequences and of selection cycles. 
Table 35: Composition of the PCR-mastermix for the click-selections  
Reagent Stock 
concentration 
Volume for 
10 reactions 
Final concentration 
in 1000 µl 
Pwo PCR buffer 10x 100 µl 1x 
FT2-F-Cy5 50 µM 10 µl 0.5 µM 
FT2-R-P 50 µM 10 µl 0.5 µM 
Pwo DNA polymerase 2.5 u/µl 10 µl 0.025 u/µl 
dN*TPs 25 mM (each) 10 µl 0.25 mM (each) 
ddH2O   add up to 
1000 µl 
 
dN*TPs = 1:1:1:1-mix of dATP, dGTP, dCTP, and EdUTP 
144 
 
  
Table 36: PCR-method for the click-selections 
Step Temperature [°C] Duration 
1 95 2 min 
2 95 30 sec 
3 62 30 sec 
4 72 30 sec 
5 72 2 min 
Steps 2 to 4 were repeated according to the text. 
The PCR was monitored by agarose gel electrophoresis as detailed in section 
6.2.1.1 and the PCR-product cleaned up with a Gel and PCR clean-up kit 
according to the manufacturer’s instructions. 200 µl PCR-product were loaded 
onto one column and eluted with two times 25 µl ddH2O for overall 250 µl purified 
PCR-product.  
 
6.2.4.3 General procedure for click-selections on sepharose 
All click-selections were performed using the FT2-library. For each selection 
approach, one selection was performed using benzyl- and one CF3-azide.  
500 pmol of the library and the click-competitor were click-modified according to 
section 6.2.4.1 using D-PBS for the purification on the Amicon filters. Library and 
competitor were heated separately to 95°C for 3 min and cooled down for 5 min 
at RT. Library and competitor were mixed and 15 µl 10x selection buffer added 
for a final volume of ~150 µl.  
100 µl THC-sepharose (1:1-coupled, 50 µl pure resin, prepared according to 
section 6.2.2.3) was washed with 2 ml selection buffer. The sepharose was 
resuspended in the 150 µl library and competitor in selection buffer and incubated 
at 20°C for 15 min. To keep the sepharose in suspension, it was pipetted up and 
down every 5 min. The sepharose was placed into an empty micro Bio-Spin 
column and the supernatant forced through by applying pressure with a Pasteur 
pipette rubber bulb. The sepharose was washed with the volume of selection 
buffer indicated in Table 5, Table 14, or Table 19 depending on the selection. 
During washing, no external pressure was applied to increase the flow rate.  
The recovery of the binding sequences is explained in sections 6.2.4.6 to 6.2.4.8. 
PCR was performed according to section 6.2.4.2 using the eluate as template. 
25 µl of the purified PCR-product were stored as backup at -20°C. The remaining 
PCR-product was single-strand displaced as detailed in section 6.2.1.8. 
All purified ssDNA as well as 500 pmol click-competitor were click-modified for 
the subsequent selection cycle according to the start of this section. 
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6.2.4.4 Preparation of radioactive click-modified nucleic acids for 
interaction assays 
DNA was prepared by PCR and single-strand displacement according to sections 
6.2.4.2 and 6.2.1.8. After single-strand displacement, the DNA was eluted two 
times with 15 µl ddH2O and all purified ssDNA was loaded onto an agarose gel 
(section 6.2.1.1). The gel was run for 30 min at 100 V and the bands were 
excised and purified using a Gel and PCR clean-up kit according to the 
manufacturer’s instructions using four volumes NTC buffer. Fifteen pmol ssDNA 
was radioactively phosphorylated (section 6.2.1.5). The radioactively labelled 
DNA was click-modified according to section 6.2.4.1, but purified using the Gel 
and PCR clean-up kit with four volumes NTC buffer instead of Amicon filters. The 
ssDNA was eluted in four times 25 µl ddH2O. The phosphorylation was verified 
with a 10% PAGE-gel (section 0). 
 
6.2.4.5 Preparation of click-modified nucleic acids for fluorescence 
polarisation assays 
DNA was prepared by PCR and single-strand displacement according to sections 
6.2.4.2 and 6.2.1.8. The concentration was determined according to section 
6.2.1.7. 
 
6.2.4.6 Initial click-selections 
The selection buffer for the two initial click-selections was composed of 1 mg/ml 
BSA, 0.1 % (v/v) Tween-20, and 0.1 mg/ml salmon sperm DNA in 1x D-PBS, 
pH 5.4. 10x selection buffer contained 10 mg/ml BSA, 1% (v/v) Tween-20, and 
1 mg/ml salmon sperm DNA in 1x D-PBS, pH 5.4.  
For recovery of the binding sequences, the THC-sepharose was resuspended in 
200 µl ddH2O, transferred to a new vial, and incubated at 80°C for 3.5 min. The 
sample was then placed into an empty micro Bio-Spin column and the eluate 
collected quickly by applying pressure with a Pasteur pipette rubber bulb. The 
eluate was used as PCR-template as described in section 6.2.4.3. 
 
6.2.4.7 Re-selections using affinity elution 
The re-selections were performed using the same selection buffer as the initial 
click-selections (section 6.2.4.6).  
The backup DNA from selection cycle 4 of the initial click-selections was re-
amplified in 1 ml total PCR-volume per selection and single-strand displaced 
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according to sections 6.2.4.2 and 6.2.1.8. The resultant ssDNA was used for 
selection cycle 5.  
The selection was performed as explained in section 6.2.4.3 with incubation 
times according to Table 14.  
For recovery of the binding sequences, the THC-sepharose was resuspended in 
150 µl D-PBS with 5% (v/v) ACN, 0.1% (v/v) Tween, and the concentration of 
THC indicated in Table 14. The sample was heated to 80°C for 3 min and cooled 
down for 5 min at 20°C. It was then incubated at 20°C for a time equal to the 
incubation time during that selection cycle (Table 14). The THC-sepharose was 
transferred to a new empty micro BioSpin column and the flow-through collected 
by applying pressure with a Pasteur pipette rubber bulb. The flow-through was 
used as eluate for the PCR as described in section 6.2.4.3. 
 
6.2.4.8 Toggle-SELEX 
The selection buffer for the toggle-SELEX consisted of 137 mM NaCl, 3.93 mM 
Na2HPO4 * 2 H2O, 1.47 mM KH2PO4, 18.53 mM KCl, 3 mM MgCl2, and 0.1 mg/ml 
salmon sperm DNA at a pH of 7.0.  
500 pmol of the library and the click-competitor were click-modified according to 
section 6.2.4.1 using the selection buffer without salmon sperm DNA for the 
purification on the Amicon filters. Library and competitor were heated separately 
to 95°C for 3 min and cooled down for 5 min at RT. Library and competitor were 
mixed, filled up to 148.5 µl and 1.5 µl 10 mg/ml salmon sperm DNA added for a 
final volume of ~150 µl.  
The volume of solid support (sepharose: 50% (v/v) resin, 50% ddH2O, prepared 
according to section 6.2.2.3) indicated in Table 19 was washed with A ml 
selection buffer without salmon sperm DNA (Table 37). The matrix was 
resuspended in the 150 µl library and competitor in selection buffer and incubated 
at 20°C for the amount of time indicated in Table 19. To keep the solid support in 
suspension, it was pipetted up and down every 5 min.  
The wash steps were performed as described in section 6.2.4.3. Magnetic beads 
were placed onto a magnet.  
The solid support was washed with selection buffer with 5% (v/v) ACN and 
without salmon sperm DNA as detailed in B (Table 37).  
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Table 37: Volume of wash steps in selection cycles performed with sepharose and 
magnetic beads. 
Step THC-sepharose THCA-beads 
A 1 ml 0.2 ml 
B Time and volume according to 
Table 19 
Time according to Table 19, 200 µl 
for each step 
 
For heat elution, the solid support was resuspended in 200 µl ddH2O and heated 
for 3 min at 80°C. The eluate was collected quickly. 
For affinity elution, the magnetic beads were resuspended in 200 µl selection 
buffer with 5% (v/v) ACN and the THC-concentration indicated in Table 19, but 
without salmon sperm DNA. They were incubated at 80°C for 3 min and cooled at 
RT for 5 min. The beads were incubated for an amount of time equal to the 
incubation time of the respective selection cycle at 20°C (Table 19). The 
supernatant was used as eluate.  
PCR was performed according to section 6.2.4.2 using the eluate as template. 
25 µl of the purified PCR-product were stored as backup at -20°C. The remaining 
PCR-product was single-strand displaced as detailed in section 6.2.1.8. 
All purified ssDNA as well as 500 pmol click-competitor were click-modified for 
the subsequent selection cycle.  
If selection cycles contained a pre-selection step on the unmodified solid support 
(selection cycle 12 to 15), the ~150 µl library and click-competitor were added to 
the unmodified solid support as indicated in Table 19, which had been washed 
with A ml selection buffer without salmon sperm DNA beforehand. The sample 
was incubated at 20°C for the amount of time indicated in Table 19. To keep the 
solid support in suspension, it was pipetted up and down every 5 min. The 
supernatant was collected and added again to unmodified solid support, which 
had been washed with A ml selection buffer without salmon sperm DNA 
beforehand. The sample was incubated at 20°C for the amount of time indicated 
in Table 19. To keep the solid support in suspension, it was pipetted up and 
down every 5 min. The supernatant was collected and added to the modified 
solid support. The selection proceeded as described above. 
 
6.2.5 Cherenkov for interaction analysis of radioactively labelled 
nucleic acids 
1/10 volume 10x selection buffer (10x D-PBS for all click-selections but the 
toggle-SELEX) was added to the radioactively labelled DNA and to the click-
modified click-competitor with the same modification (prepared according to 
section 6.2.4.1) for a final concentration of 1x D-PBS or 1x selection buffer. 5 µl 
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radioactively labelled DNA and the click-competitor were separately heated to 
95°C for 3 min and cooled at RT for 5 min.  
100 µl THC- or unmodified sepharose (50 µl pure resin) was placed in an empty 
micro BioSpin column and washed with 1 ml selection buffer. The sepharose was 
resuspended in 5 µl 2’F-RNA or DNA and 1 µl 10 µM clicked competitor (only for 
click-selections) in final 150 µl selection buffer. The sample was incubated for 
15 min at 20°C. To keep the sepharose in suspension, the sample was pipetted 
up and down every 5 min. The sepharose was transferred into an empty column 
and the flow-through collected by applying pressure with a Pasteur pipette rubber 
bulb. Two washes with 1 ml selection buffer each were left to run through without 
application of pressure and collected separately. The sepharose was transferred 
into a new vial using two times 200 µl ddH2O.  
All samples were added up to 1 ml with ddH2O and the vials place in liquid 
scintillation vials. The 32P-signal was measured using a liquid scintillation counter. 
Counts per minute were measured for 3 min per sample.  
The Cherenkov for samples containing ACN, no Tween, no BSA, and those 
measured at pH 7.4 was performed identically with the modifications only 
applying to the selection buffer.  
For assays using non-nucleobase-modified nucleic acids (2’F-RNA and DNA), 
the initial addition of 10x selection buffer and the folding step (95°C 3 min, RT 5 
min) were not performed and the click-competitor not added. 
Assays using magnetic beads were performed using 25 µl 10 mg/ml magnetic 
beads and two washes with 100 µl instead of 1 ml selection buffer each. Instead 
of the columns, the vials containing the beads were placed on a magnet to 
remove the supernatant.  
All assays were performed at least twice. 
 
6.2.6 Cloning and sequencing 
6.2.6.1 Cloning 
The DNA of the selection cycle was amplified in a 100 µl PCR as detailed in 
Table 38. 0.3 µl of a 1:100-dilution of the backup DNA of the respective selection 
cycle were used as template. The PCR was performed in overall 18 cycles 
according to Table 36. The final elongation step at 72°C was set to last 20 
instead of 2 min.  
The success of the PCR was verified by agarose gel electrophoresis (section 
6.2.1.1). 
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Table 38: Composition of the PCR-mastermix for cloning 
Reagent Stock 
concentration 
Volume for 1 
reactions 
Final concentration 
in 100 µl 
Taq buffer 10x 10 µl 1x 
FT2-F 50 µM 1 µl 0.5 µM 
FT2-R 50 µM 1 µl 0.5 µM 
Taq DNA polymerase 2.5 u/µl 1 µl 0.025 u/µl 
dNTPs 25 mM (each) 1 µl 0.25 mM (each) 
MgCl2 25 mM 6 µl 1.5 mM 
ddH2O  79.7 µl  
 
1 µl PCR-product was mixed with 1 µl salt solution (1.2 M NaCl, 0.06 M MgCl2, 
part of the kit), 3 µl ddH2O, and 1 µl TOPO TA vector. The sample was incubated 
at 23°C and 300 rpm for 30 min and placed on ice afterwards. 
One aliquot TOP10 bacteria was thawed slowly on ice. 2 µl of the cloning 
reaction were added to 1/3 aliquot bacteria without pipetting up and down and 
incubated on ice for 10 min. The bacteria were heat shocked for 30 sec at 42°C 
and placed on ice for 5 min immediately afterwards. 250 µl room-tempered SOC 
medium was added to the sample and incubated for 1 h at 37°C, 300 rpm. The 
bacteria were spread onto a 100 µg/ml ampicillin plate and grown over night at 
37°C.  
 
6.2.6.2 Colony-PCR 
Colonies were numbered and placed with a pipette tip into 5 µl ddH2O. After heat 
treatment for 10 min at 95°C, the bacteria were spun down for 5 min at 
14,000 rpm. 3 µl of the supernatant was used for a 20 µl PCR according to Table 
38 with 17 PCR-cycles as described in Table 36. The success of the PCR was 
verified by agarose gel electrophoresis (section 6.2.1.1) and the colonies with a 
PCR-product of the expected length, which contain the desired insert, identified. 
 
6.2.6.3 Overnight culture and plasmid preparation 
The insert-containing colonies were picked again and transferred into a falcon 
containing 5 ml LB medium with 100 µg/ml ampicillin. They were grown overnight 
at 37°C and 115 rpm.  
The overnight culture was spun down for 15 min at 3250 rpm and purified with a 
Plasmid kit according to the manufacturer’s instructions. The plasmid was eluted 
in two times 25 µl ddH2O. 
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6.2.6.4 Sanger sequencing 
Sanger sequencing was performed by GATC Biotech, Konstanz, Germany. The 
random region was identified using the known primer binding sites of the library. 
The obtained random region sequences were analysed for sequence similarity by 
multiple sequence alignment (Clustal Omega276,277) and motif recognition 
software (MEME278). 
 
6.2.6.5 Preparation of DNA for interaction assays from plasmids  
1 µl 1:10-diluted purified plasmid was used as a template for a 50 µl PCR 
according to Table 38 with 18 PCR-cycles as described in Table 36. The 
resultant PCR-product I was diluted 1:100 and 1 µl used for 100 µl PCR.  
 
6.2.6.6 Preparation of next-generation sequencing samples 
Samples for NGS were prepared and sequenced in different runs: 1) THC-click-
SELEX samples, 2) EdU_Pwo, 3) T_Pwo, T_Taq, and T_w/o, 4) FT2_GATC and 
FT2_G4A4T4C4, 5) FT2_GATC_II, FT2_G4A4T4C4_II, FT2_G3A3T3C3, 
FT2_G2A2T2C2, FT2_TGCA, D3_TGCA, FT2_T4G4C4A4, and D3_T4G4C4A4, 
and 5) GFP-click-SELEX samples for Figure 34. 
All samples were prepared as published.279 Briefly, the DNA from the respective 
selection cycles was amplified by PCR with primers containing 5’-indices (index-
PCR). Table 39 describes which index was used for which selection cycle of the 
THC-click-SELEX. Table 40 describes the indices used for the mutational 
analysis study. The purified PCR-products with different indices were pooled and 
adaptors, which enable hybridisation to the sequencing flow cell, annealed to the 
5’-ends. After gel purification, the sample-concentration was measured by qPCR. 
Index-PCR was performed using Pwo DNA polymerase for all samples but 
T_Taq, T_w/o, and all repetitive sequences. C12_EdU was used as template for 
EdU_Pwo. C12_T was used as template for T_Taq and T_Pwo. For T_Taq, Taq 
DNA polymerase was used for amplification and large Klenow fragment was 
utilised according to the manufacturer’s instructions for blunt end generation. 
T_w/o and all repetitive sequences were obtained as sense and antisense strand 
including the indices and annealed. For annealing, 100 pmol of each strand were 
mixed in 40 mM Tris, pH 7.9 and heated to 95°C for 5 min. Afterwards, the 
strands were cooled down to 4°C in 30 min (0.05°C/s). Annealing was confirmed 
by agarose gel electrophoresis (section 6.2.1.1). 
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Table 39: Indices used for NGS-analysis of the initial click-selections 
Selection cycle Lane Index number Index sequence279 
4 (benzyl) 2 9 GATCAG 
6 (benzyl) 2 10 TAGCTT 
8 (benzyl) 2 11 GGCTAC 
10 (benzyl) 2 12 CTTGTA 
4 (CF3) 1 6 GCCAAT 
6 (CF3) 1 7 CAGATC 
8 (CF3) 2 6 GCCAAT 
10 (CF3) 2 7 CAGATC 
 
Table 40: Indices used for NGS-analysis of the mutational analysis study 
sample name index279 index 
seq.  
primer 
sites 
from 
library 
random region 
EdU_Pwo 6 GCCAAT FT2205 see C12 in section 6.1.6 
T_Pwo 10 TAGCTT FT2 see C12 in section 6.1.6 
T_Taq 11 GGCTAC FT2 see C12 in section 6.1.6 
T_w/o 12 CTTGTA FT2 see C12 in section 6.1.6 
FT2_GATC 12 CTTGTA FT2 (GATC)8 
FT2_GATC_II 12 CTTGTA FT2 (GATC)8 
FT2_G4A4T4C4 11 GGCTAC FT2 (GGGGAAAATTTTCCCC)2 
FT2_G4A4T4C4_II 11 GGCTAC FT2 (GGGGAAAATTTTCCCC)2 
FT2_G2A2T2C2 6 GCCAAT FT2 (GGGAAATTTCCC)2GGGAAATT 
FT2_G3A3T3C3 5 ACAGTG FT2 (GGAATTCC)4 
FT2-TGCA 8 ACTTGA FT2 (TGCA)8 
D3-TGCA 10 TAGCTT D3280 (TGCA)8 
FT2-T4G4C4A4 7 CAGATC FT2 (TTTTGGGGCCCCAAAA)2 
D3-T4G4C4A4 9 GATCAG D3 (TTTTGGGGCCCCAAAA)2 
 
 
6.2.6.7 Next-generation sequencing 
Next-generation sequencing was performed by Joachim L. Schultze, Kristian 
Händler, and Marc Beyer (University of Bonn, Germany) on a HiSeq1500 as 
described in Pfeiffer et al.281 76 base pairs and 7 index bases were sequenced. 
 
6.2.6.8 Analysis of next-generation sequencing 
Analysis of NGS-data was performed by Carsten Gröber and Michael Blank 
(AptaIT GmbH, Planegg, Germany) using the software COMPAS.154,282 The 
analysis is detailed in Pfeiffer et al.281 For the analysis of samples after exclusion 
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of shortened sequences, only sequences of the correct length and longer were 
analysed. 
The frequency of unique sequences was calculated by dividing the number of 
unique sequences by the total number of sequences analysed in the respective 
selection cycle and multiplying with 100.  
The frequency of mutated sequences was calculated by calculating the 
percentage of non-mutated sequences and subtracting it from 100%.  
The error rate was calculated by subtracting the frequency of the correct 
nucleotide at the specified position from 1. The mutation frequency of a specific 
nucleotide was defined as ‘mutated nt’. The average and SD of the mutation 
frequency of all nucleotides in a sequence is the ‘error rate’.  
The ‘mutated into nt’ was calculated by averaging the frequency of that 
nucleotide at all positions where it was not the original nucleotide. The conversion 
from one nucleotide into another nucleotide was calculated alike, but by 
restricting the positions to those of the original nucleotide.  
The mutation frequency into the subsequent nucleotide was calculated by 
calculating 100/(1-frequency correct nucleotide)*frequency subsequent nt for 
each position and then calculating the average. 
All data is given as average ± SD. 
Statistical analysis was performed by testing normality using the Shapiro-Wilk 
normality test. Normally distributed datasets were analysed by one-way ANOVA 
followed by two-tailed t-tests. Not normally distributed datasets were analysed 
using the Kruskal-Wallis test followed by two-tailed Mann-Whitney tests. Alpha 
was set to 0.05 for all tests. 
 
6.2.7 HPLC-(MS)-analysis 
6.2.7.1 HPLC-measurements for solubility determination 
Apart from the measurements leading to Figure 35A, two samples of 30 µl each 
were prepared with the respective buffer/organic solvent, Tween-20- and THC(-
FITC)-concentration. For all samples but those for Figure 62, D-PBS, pH 5.4 was 
used as buffer. For Figure 62, the buffer consisted of 137 mM NaCl, 3.93 mM 
Na2HPO4 * 2 H2O, 1.47 mM KH2PO4, and 18.53 mM KCl at a pH of 7.0. The 
samples were prepared in HPLC-vials. Each sample was injected twice, leading 
to overall four measurements per concentration. The samples for Figure 35A 
were pipetted once and injected once. 
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For the measurement, 10 µl of the sample were injected on an analytical HPLC 
system (1260 Infinity) with an EC/50/4.6 Nucleodur 100-5 C18ec column. Buffer 
A consisted of ddH2O with 0.1% (v/v) formic acid, buffer B of ACN. The gradient 
was described for both the first and second method in Table 41 and the total 
runtime of the first method was 56 min and of the second method 30 min with a 
flowrate of 0.8 ml/min each.  
The samples leading to Figure 35 and Figure 36 were measured according to 
the first method, all others according to the second method. 
Table 41: Timetable of the HPLC-measurements 
Time [min] – 1st  Time [min] – 2nd  Buffer A [%] Buffer B [%] 
0 0 60 40 
10 5 30 70 
40 20 0 100 
45 23 0 100 
46 24 60 40 
 
 
6.2.7.2 LC-MS-analysis 
For THC-L, the samples from the different days (section 6.2.2.2) were centrifuged 
at 14000 rpm for 5 min and the supernatant discarded. The pellet was 
resuspended in 80% ACN with 20% ddH2O with 0.1% (v/v) formic acid. The 
samples from day 7 were left untreated.  
For THC-FITC, 0.3 µl sample were mixed with 100 µl 80% ACN with 20% ddH2O 
with 0.1% (v/v) formic acid for analysis before clean-up. After clean-up, 2 µl of the 
purified sample were mixed with 48 µl 80% ACN with 20% ddH2O with 0.1% (v/v) 
formic acid. 
For TLF, the sample before clean-up was taken according to section 6.2.8.3, the 
one after clean-up according to section 6.2.8.4.  
10 µl of each sample were injected for analysis on an analytical 1100 series 
HPLC system with a Zorbax_50x2.1_5 µm column. Buffer A consisted of ddH2O 
with 0.1% (v/v) formic acid, buffer B of ACN. The gradient was described in Table 
42 and the total runtime of the method 60 min with a flowrate of 0.2 ml/min. Mass 
spectrometry was performed from min 5 to min 30 with an HTC Esquire using 
ultra mode (alternating). The settings were as follows: nebulizer: 40 psi, dry gas: 
9 l/min , dry temperature 365°C, target mass 400 m/z, ICC negative: 70000, ICC 
positive: 200000, analysed mass 90-1000 m/z.  
For TLF, target mass was set to 900 m/z with analysed mass 300-1700 m/z. 
Everything else was as described in the preceding paragraph. 
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The UV-peaks were integrating using Compass DataAnalyser. 
Table 42: Timetable of the LC-MS-analysis 
Time [min] Buffer A [%] Buffer B [%] 
0 40 60 
30 0 100 
48 0 100 
50 40 60 
 
 
6.2.8 Synthesis of fluorescently labelled THC-compounds 
6.2.8.1 THC-FITC 
The coupling of THC to FITC was based on the publications by Taldone et al. and 
Llauger-Bufi et al. and is depicted in Figure 41.283,284 9.54 µmol THC were dried 
in a speedvac at 45°C and solubilized in 30 µl DMF. 47.7 µmol FITC (5 times 
molar excess) were solubilised in 50 µl DMF. THC and FITC were mixed, 20 µl 
TEA added, and the reaction rotated at 65°C for 2 days.  
0.5 µl sample were mixed with 100 µl 80% ACN with 20% ddH2O with 0.1% (v/v) 
formic acid, spun down for 5 min at 18000 rpm and 30 µl of the supernatant used 
for LC-MS-analysis (section 6.2.7.2).  
 
6.2.8.2 HPLC-purification of THC-FITC 
1137.5 µl 50% ddH2O with 50% (v/v) ACN were added to the remaining coupling 
reaction.  
99 µl of the sample were injected per run on an analytical HPLC system (1260 
Infinity) with an EC/50/4.6 Nucleodur 100-5 C18ec column. Buffer A consisted of 
ddH2O with 0.1% (v/v) formic acid, buffer B of ACN. The gradient was described 
in Table 43 and the total runtime of the method 70 min with a flowrate of 
0.8 ml/min. The peak at minute 36.5 to 37.5 was collected. 
Table 43: Timetable of the HPLC-purification of THC-FITC 
Time [min] Buffer A [%] Buffer B [%] 
0 60 40 
10 40 60 
50 0 100 
55 0 100 
56 60 40 
 
All fractions were dried in a speedvac at 45°C and resuspended in overall 100 µl 
ACN. 2 µl were mixed with 48 µl 80% ACN with 20% ddH2O with 0.1% (v/v) 
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formic acid for LC-MS-analysis (section 6.2.7.2). The remaining sample was 
stored at 4°C. 
 
6.2.8.3 TLF 
The synthesis of TLF is depicted in Figure 55. 12.5 µmol THC-L (non-purified, 
prepared according to section 6.2.2.2) were lyophilised overnight and 
resuspended in 50 µl 7 N NH3 in MeOH. The reaction was incubated for 4 h at 
70°C in a PCR-cycler with the lid heated to 110°C to prevent evaporation. 
Afterwards, the sample was cooled down to 4°C and dried in a speedvac 
overnight at 4°C to remove the unreacted NH3. 
100 µmol FITC (38.94 mg) were solubilised in 1.56 ml MeOH. The reaction 
product (THC-L-NH2) was solubilised in 2.34 ml DMF and FITC (in MeOH) and 
reaction product mixed. The reaction was rotated for 3 h at RT (25.5°C) and dried 
in a speedvac.  
The reaction product was resuspended in 100 µl ACN, centrifuged for 5 min at 
18000 rpm and 2.2 µl of the supernatant mixed with 47.8 µl 80% ACN with 20% 
ddH2O with 0.1% (v/v) formic acid for LC-MS-analysis (section 6.2.7.2). 
 
6.2.8.4 HPLC-purification of TLF 
33 ml 80% ACN with 20% ddH2O with 0.1% (v/v) formic acid were added to the 
coupling reaction (supernatant and pellet combined). The sample was incubated 
for 30 min at 65°C, cooled down and centrifuged for 10 min at 5000 g. The 
supernatant was used for purification and the small pellet discarded. 
99 µl of the sample were injected per run on an analytical HPLC system (1260 
Infinity) with an EC/50/4.6 Nucleodur 100-5 C18ec column. Buffer A consisted of 
ddH2O with 0.1% (v/v) formic acid, buffer B of ACN. The gradient was described 
in Table 44 and the total runtime of the method 30 min with a flowrate of 
1 ml/min. The peak at minute 11 to 12 was collected. 
Table 44: Timetable of the HPLC-purification of TLF 
Time [min] Buffer A [%] Buffer B [%] 
0 60 40 
5 30 70 
20 0 100 
23 0 100 
24 60 40 
 
All collected samples were pooled and dried, first in a vacuum distillation rotator 
to reduce the volume, then in a speedvac overnight at RT.  
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TLF was resuspended in 500 µl ACN, centrifuged for 3 min at 14000 rpm and 
2.2 µl of the supernatant mixed with 47.8 µl 80% ACN with 20% ddH2O with 0.1% 
(v/v) formic acid used for LC-MS-analysis (section 6.2.7.2). 
500 µl ddH2O were added to the TLF (pellet and supernatant), incubated at 65°C 
for 30 min, and centrifuged for 10 min at 14000 rpm. The supernatant was used 
for all assays and stored at 4°C. The pellet was discarded. 
 
6.2.9 Absorption and emission scans of fluorescently labelled THC-
compounds 
6.2.9.1 Absorption scans 
THC-FITC (prepared according to sections 6.2.8.1 and 6.2.8.2) was diluted 1:20 
in ddH2O (final 5% (v/v) ACN). The blank consisted of 5% (v/v) ACN in ddH2O.  
TLF (prepared according to sections 6.2.8.3 and 6.2.8.4, 50% ddH2O, 50% (v/v) 
ACN) was diluted 1:10 in either ddH2O, D-PBS, pH 5.4, or PBS, pH 7.4. The 
blanks consisted of equally prepared dilutions of 50% ddH2O with 50% (v/v) ACN. 
For both compounds, 2 µl in duplicates were spotted onto a NanoQuant Plate 
and the absorption measured between 400 and 600 nm with a NanoQuant infinite 
M200.  
The concentration was determined using the absorption at 492 nm (in ddH2O for 
TLF) and the molar extinction coefficient of FITC (ε = 75000 L/(mol*cm)).285 The 
blank (in ddH2O for TLF) was subtracted from the absorption before calculation. 
 
6.2.9.2 Emission scans 
The fluorescence intensity was measured with an EnSpire using a 384 well 
Perkin Elmer Proxi Plate 384 F Plus. 15 µl of a 1:20-dilution (THC-FITC) or a 
1:10-dilution (TLF) in either ddH2O, D-PBS, pH 5.4, or PBS, pH 7.4, were loaded 
per well and all samples measured in duplicates. The samples were excited at 
492 nm and the emission measured from 510 to 600 nm. 
 
6.2.10 Fluorescence polarisation assays 
For all assays, a final volume of 15 µl in one well of a black 384 well Perkin Elmer 
Proxi Plate 384 F Plus was measured in a Tecan Ultra. Excitation was set to 
485 nm, emission to 535 nm. The number of flashes was 20, lag time 0 µs, 
integration time 40 µs, z-position 12300 µm, and G-factor 1.06. The gain varied 
depending on the experiment and is indicated in the respective subsection. 
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Fluorescence polarisation was calculated as follows: The parallel and 
perpendicular fluorescence intensity of the blank (without fluorophore, but 
identical buffer to the rest of the samples) was subtracted from the parallel and 
perpendicular intensities of the samples. Then, polarisation in mP was calculated 
according to Equation 1. FII is the parallel intensity, F the perpendicular 
intensity. 
Equation 1: Calculation of fluorescence polarisation 
𝐹∥ + 𝐹⊥
𝐹∥ − 𝐹⊥
 ×  1000 = 𝐹𝑃 
Measurements were performed at least as n = 2 with duplicates each. Each plate 
was measured twice. 
 
6.2.10.1 Fluorophore concentration ranges 
The desired concentration of fluorophore was measured in D-PBS, pH 5.4 with 
5% (v/v) ACN and with or without 0.1% (v/v) Tween-20. For measurements at pH 
7.4, PBS, pH 7.4 with or without 0.1% (v/v) Tween-20 was used. The gain was 
set to 55. 
 
6.2.10.2 Test of different buffer components 
All experiments were performed in D-PBS, pH 5.4 with the indicated additives. 
The gain was set to 45. 
 
6.2.10.3 Kd-determination of the THC-antibody 
PBS, pH 7.4 was used as buffer. Antibody-dilutions of 1.5 times the desired 
concentration and fluorophore-dilutions of 3 times the desired concentration were 
prepared. 10 µl antibody-dilution was mixed with 5 µl fluorophore-dilution in the 
384-well plate and incubated for 30 min at RT. The gain was set to 45 for the 
measurement using THC-FITC and to 52 for TLF. 
 
6.2.10.4 Interaction analysis of the THC-sepharose-binding 
sequences 
For measurements at pH 5.4, 7.5 pmol DNA (in ddH2O) was diluted to a final 
volume of 10 µl with ddH2O in a well of a 384-well plate. For the control, 1.5 µl 
10 mg/ml BSA was mixed with 8.5 µl ddH2O. 
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A fluorophore-mastermix was prepared according to Table 45. 5 µl fluorophore-
mastermix were added per well for final 15 µl sample per well and the sample 
was incubated for 15 min at RT before measurement. 
Table 45: Composition of the fluorophore-mastermix at pH 5.4 
Reagent Stock 
concentration 
Volume for 10 
reactions 
Final concentration 
in 1 well 
THC-FITC (in ACN) 
TLF (in ACN) 
6.625 µM 
41.13 µM 
1.2 µl 
0.29 µl 
53 nM 
80 nM 
D-PBS, pH 5.4 10x 14.25 µl 0.95x 
Salmon sperm 
DNA 
10 mg/ml 1.5 µl 0.1 mg/ml 
ACN 100% Add volume 
THC-FITC/TLF 
up to 7.5 µl 
5% (v/v) (incl. ACN 
from THC-FITC/TLF) 
ddH2O  Add up to 50 µl  
 
For measurements at pH 7.4, the DNA was dried in a speedvac and 7.5 pmol 
DNA resuspended in 10 µl D-PBS, pH 7.4. The antibody was diluted 1:10 in D-
PBS, pH 7.4. 0.48 µl dilution were mixed with 9.52 µl D-PBS, pH 7.4 per well. 
1.5 µl 10 mg/ml BSA were mixed with 8.5 µl D-PBS, pH 7.4 for the control. The 
fluorophore-mastermix was prepared as described in Table 46 and 5 µl added 
per sample. The plate was incubated for 15 min at RT before measurement. 
Assays including the THC-antibody as positive control were incubated for 30 
instead of 15 min at RT. 
Table 46: Composition of the fluorophore-mastermix at pH 7.4 
Reagent Stock 
concentration 
Volume for 10 
reactions 
Final concentration 
in 1 well 
THC-FITC (in ACN) 
TLF (in ACN) 
6.625 µM 
41.13 µM 
1.2 µl 
0.29 µl 
53 nM 
80 nM 
Salmon sperm DNA 10 mg/ml 1.5 µl 0.1 mg/ml 
ACN 100% Add volume 
THC-FITC/TLF 
up to 7.5 µl  
5% (v/v) (incl. ACN 
from THC-FITC/TLF) 
D-PBS, pH 7.4 1x 41 µl  
 
Measurements using THC-FITC at either pH were performed using a gain of 45. 
Measurements using TLF were performed using a gain of 69 at pH 5.4 and 56 at 
pH 7.4. 
For assays containing streptavidin, 0.67 µl 16.7 µM (1.5x molar excess) 
streptavidin were added to the sample before addition of the fluorophore-
mastermix. The amount of ddH2O or D-PBS, pH 7.4 was decreased accordingly 
for a final volume of 10 µl per well. The plate was incubated for 40 min at RT. 
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Then, 5 µl of the fluorophore-mastermix was added and the plate incubated for 
15 min at RT before measurement.  
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7 Appendix 
 
Figure A 1: Frequency of the tested sequences according to the NGS-analysis 
Frequency in the analysed selection cycles 4, 6, 8, and 10. (A) Frequency of all tested sequences 
from the initial selection with benzyl-modified DNA. The non-binding B10 is depicted in red, the 
binding sequences in shades of blue. (B) Frequency of all tested sequences from the initial 
selection with CF3-modified DNA. The binding sequences are depicted in shades of green. C15 
and C30 could not be detected in selection cycle 4.  
 
 
Figure A 2: Absorption and emission spectra of THC-L-FITC 
(A) Absorption spectrum of THC-L-FITC (shades of red) (d = 0.05 cm) in different solvents 
(shades of grey and black). (B) Emission spectrum of THC-L-FITC (excitation at 492 nm, depicted 
in shades of red) in different solvents (shades of grey and black). All samples contained 5% ACN 
to solubilize THC-L-FITC. Samples were measured in the following solvents: ddH2O (dark red 
and black), D-PBS, pH 5.4 (medium red and light grey), and PBS, pH 7.4 (light red and dark 
grey). 
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Figure A 3: Fluorescence polarisation of THC-FITC at pH 7.4 in the presence of different 
sequences 
The fluorescence polarisation of THC-FITC (53 nM) was measured in the presence of 500 nM of 
the different sequences that bind at pH 7.4, 1 mg/ml BSA, or without any sequence (w/o). BSA 
was used as a positive control. No sequence (w/o) was used as negative control and the dotted 
line represents the corresponding polarisation. Benzyl-modified DNA is depicted in blue, CF3-
modified DNA in green.  
 
 
Figure A 4: Fluorescence polarisation of THC-L-FITC at pH 7.4 in the presence of different 
sequences 
The fluorescence polarisation of THC-L-FITC (80 nM) was measured in the presence of 500 nM 
of the different sequences that bind at pH 7.4, 1 mg/ml BSA, 80 nM THC-antibody, or without any 
sequence (w/o). BSA and the THC-antibody were used as positive controls. No sequence (w/o) 
was used as negative control and the dotted line represents the corresponding polarisation. 
Benzyl-modified DNA is depicted in blue, CF3-modified DNA in green. C pool indicates FT2-pool 
that has been CF3-modified. 
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Figure A 5: Fluorescence polarisation of THC-L-FITC at pH 7.4 in the presence of different 
biotinylated sequences and streptavidin 
The fluorescence polarisation of THC-L-FITC (80 nM) was measured in the presence of 500 nM 
of the different, biotinylated sequences, 1 mg/ml BSA, 80 nM THC-antibody, or without any 
sequence (w/o). All assays but those represented by grey bars contained 750 nM streptavidin. 
BSA and the THC-antibody were used as positive controls. No sequence (w/o) was used as a 
negative control and the dotted line represents the corresponding polarisation. Benzyl-modified 
DNA is depicted in blue, CF3-modified DNA in green.  
 
 
Figure A 6: Frequency of unique sequences in the selection cycles according to NGS 
Frequency of unique sequences in the analysed selection cycles of the initial selection with 
benzyl- (A) and CF3-modified DNA (B).  
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Table A 1: Multiple sequence alignment of all sequences identified by Sanger sequencing 
in the initial click-SELEX with benzyl-modified DNA 
Seq. Sequence of the random region 
B27 
B37 
B20 
B18 
B26 
B22 
B34 
B29 
B40 
B9 
B38 
B42 
B17 
-CTACAATC---GTGCG---------ATC--CCCTATCTCC-AGACCTACGGGAACAC 
-CTACAATC---GTGCG---------ATC--CCCTATCTCC-AGACCTACGGGAACAC 
-CTACAATC---GTGCG---------ATC--CCCTATCTCC-AGACCTACGGGAACAC 
-CTACAATC---GTGCG---------ATC--CCCTATCTCC-AGACCTACGGGAACAC 
-CTACAATC---GTGCA---------ATC--CCCTATCTCC-AGACCTACGGGAACAC 
-CCACAATT---GTGCG---------ATC--CCCTATCTCC-GGACCTACGGAAACAC 
-CCACAATT---GTGCG---------ATC--CCCTATCTCC-GGACCTACGGAAACAC 
-CCACAATT---GTGCG---------ATC--CCCTATCTCC-GAACCTACGGAAACAC 
-CCACAATC---GTGCG---------ATC--CCCTATCTCC-AGACCTACGGNAACAC 
-NTNCAATC---GTGCG---------ATC--CCCTATNTCC-AGACNTACGGAAACAC 
-CTACAATC---GTGCG---------ATC--CCCTATCTCC-GGACCTACGGTAACAC 
-CTACAATC---GTGCG---------ATC--CCCTATCTCC-GGACCTACGGGAACAC 
-CTATGATC---GTGCG---------ATC--CCCTATCTCC-GAACCTACGGGAACAC 
B12 
B25 
B46 
B41 
B36 
-CAGCGGTCCTAGCGCGGTACTACGCATC--CCCTATCTCC---CCCT---------- 
-CAGCGGTCCTAGCGCGGTACTACGCATC--CCCTATCTCC---CCCT---------- 
-CAGCGGTCCTAGCGCAGTACTACGCATC--CCCTATCTCC---CCCT---------- 
-CAGCGGTCCTAGCGCGGNNTTACNCANC--CCCTATCTCC---CCCT---------- 
-CAGCGGTCCTAGTACGGTACTATGTATC--CCCTATCTCC---CCCT---------- 
B13 
B15 
B3 
---GTGG----GGCGCA-------TCAGCGACCGTATCCCCCAGACAGACTCAGGC-- 
---GTGG----GGCACA-------TCAGCGACCGTATCCCCCAGACAGACTCAGGC-- 
---GTGG----GGTACA-------TCAGCGACCGTATCCCCCAGACAGACTCAGGC—- 
B10 
B35 
-ATACTG-----GACCG-------CTACACCCCGCACCACCTC--GCCAATTGGTGA- 
-ATACTG-----GACCG-------TTACACCCCGCACCACCTC--GCCAGTTGGTGA- 
B32 -ACACTG-----GATAG-------ATGCGGGGGGCAACGCCTTCAGGCA-TCAGT--- 
B14 
B33 
B6 
B44 
B28 
B7 
B23 
B24 
B16 
AACCCTGACTGGGAGTG-------ATGCCTACCGTAACACCTCCCG-CAC-------- 
AACCCTGACTGGGAGTG-------ATGCCTACCGTAACACCTCCCG-CAC-------- 
AACCCTGACTGGGAGTG-------ATGCCTACCGTAACACCTCCCG-CAC-------- 
AACCCTGACTGGNAGTG-------ATGCCTACCGTAACACCTCCCG-CAC-------- 
AACCCTGACTGGGAGTG-------ATGCCGACCGTAACACCTCCCG-CAC-------- 
AACCCTGACTGGGAGTG-------ATGCCAACCGTAACACCTCCCA-CAC-------- 
AGCCCTGACTGGGAGTA-------CTGCCGACCGTAACACCTCCCA-CAC-------- 
AGCCCTGACTGGGAGTA-------CTGCCGACCGTAACACCTCCCA-CAC-------- 
AGCCCTGACTGGGAGTN-------CTGCCAACCGTAACACCTCCCG-CAC-------- 
B11 
B39 
B5 
B19 
GATGCCG---GACGTTG-------GAACGGGC-GTGTCATCATAGG-TACAGG----- 
GATGCCG---GACGTTG-------GAACGGGC-GTGTCATCATAGG-TACAGG----- 
GATGCCG---GACGTTG-------GAACGGGT-GTGTCATCATAGG-TACAGG----- 
GATTCCG---GACATTG-------GAACGGGC-GTGTCATCATAGG-TACAGA----- 
Seq. = sequence. T = EdU in the tested sequences. N = unidentified nucleotide. Tested 
sequences are indicated in bold letters. The sequences were analysed using Clusta Omega.
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Table A 2: Multiple sequence alignment of all sequences identified by Sanger sequencing 
in the initial click-SELEX with CF3-modified DNA 
Seq. Sequence of the random region 
C47 
C9 
C27 
C31 
C12 
C42 
C44 
----CGATAATACACGTTCGGCCCCTAAAGCCGGTCGG---CCCT----TGCA------ 
----CGATAATACACGTTCGGCCCCTAAAGCCGGTCGG---CCCT----TGCA------ 
----CGATAATACACGTTCGGCCCCTAAAGCCGGTCGG---CCCT----TGCA------ 
----CGATAATACACGTTCGGTCCCTAAAGCCGGTCGG---CCCT----TGCA------ 
----CGATAATACACGTTCGGCCCCTAAAGCCGGCCGG---CCCT----TGCA------ 
----CGATAATACACGTTCGGCCCCTAAAGCCGGCCGG---CCCT----TGCA------ 
----CGATAATACACGTTCGGCCCCTAAAGCCGGCCGG---CCCT----TGCA------ 
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C40 
C45 
C4 
C41 
C29 
C16 
C8 
----CGATAATACACGTTCGGCCCCTAAAACCGGCCGG---CCCT----TGCA------ 
----CAATAATACACGTTCGGCCCCTAAAACCGGCCGG---CCCT----TGCA------ 
----CGATAATACACGTTCGGCCCCTAAAACCTGCCGG---CCCT----TGCA------ 
----CGATAATACACGTTCGGCCCCTAAANCCGGCCGG---CCCT----TGCA------ 
----CGATAATACACGTTCGGCCCCTAAAGCCGATCGG---CCCT----TACA------ 
----CGATAATACACGTTCGGCCCCTAAAGCCGACCGG---CCCT----TGCA------ 
----CGATAATACACGTTCGGTCCCTAAAGCCGACCTA---CCCT----TGCA------ 
C30 
C7 
C28 
--CCAGC---CGCGCGGAAGACAA---TACACGTTGGG---CCACTAA--GGAAG---- 
--CCGGC---CGCGCGTAAGACAA---TACACGTTGGG---CCACTAA--GGAAG---- 
--CNNNT---CNNNNGGAAGACAA---TACACGTTGGG---CCACTAA--GGAAG---- 
C15 
C25 
---------TGGCGCGTCCAGAGGCT-TATAGGGGGGGAGCCTACG--TTGAAT----- 
---------TGGCGCGTCCAGAGGCT-TATAGGGGGGGAGCCTACG--TTGAAT----- 
C17 --------TACACACAAGCGGCCGA-GTAGACACCCCTTCCCCCCT---TTAAC----- 
C10 ----AACATAG--GGAGT-G---GGTGTGACCAT-TAACCGCCACTAGTTAC------- 
C46 -----GTCTGG--GATGT-GTAGGGTATTCCCAAATAAC--CCAGCGGCCAA------- 
C11 ----GACCAGG-AAAGGCCGTCGGGTCTCACCCG--TCCTCCGAG-CTTC--------- 
C6 -------CAAG-CGAAGC-GTGGGGGTAAACCCA--AATTGAAAGACATCAAC------ 
C35 GCCACGCCAAGTCGGGGGCGTGAGGCTTACCCCA--ACTTACGC--------------- 
C21 ---GCGCGAACACACCTTTACCCCCTTC-CCCGGCGCA---CGGC----CGGG------ 
C19 ---------ATACACGTTGGGTCACTA--CCCTGGGGA---CCATG---TACAATACCC 
C38 -----GT---AGCACGGAATACACGTTTGAACACTAGA---CCAAAGA--GAATA---- 
C34 ---CGGTACACACACATTGGGCAA---TATACGTTGGG---TCGAT-A--GGAT----- 
C32 --TGAAC-----TAGGTAGGA------TACACGTTGGGGCCCTAGTCACCGAAC----- 
C36 -CTAGATGCATGCTCGAGCGGCCGCC-AGTGTGATGGA---TATNT--GCAGAATTC-- 
C5 ----GTTGCA--CCCGG--GACAACC-TGCCTGGTAAA---TCTC-----GTACCTCAG 
Seq. = sequence. T = EdU in the tested sequences. N = unidentified nucleotide. Tested 
sequences are indicated in bold letters. The sequences were analysed using Clusta Omega.
276,277
 
 
Table A 3: Original sequence and 25 most frequent mutations of T_Pwo 
Sequence Sequence count 
GTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 982317 
GGTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 4753 
TTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 4240 
GTTGGAAGCGACGGGACGGTAGGGCTTGGGCCCCAAGGAGTG 3792 
GTTGGAAGCGACGGGACGGTAAGGCTTGGCCCCAAGGAGTG 3722 
GTTGGAAGCGACGGACGGTAAGGCTTGGGCCCCAAGGAGTG 3515 
GTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCAAGGAGTG 2732 
GTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 2226 
GTTGGAAGCGACGGGACGTAAGGCTTGGGCCCCAAGGAGTG 1970 
GTTGGAAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 1943 
GTTGGAAGCGACGGGACGGTAGGCTTGGGCCCCAAGGAGTG 1886 
GTTGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 1727 
GTTGGAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 1711 
GTTGGAAGCGACGGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 1688 
GTTGGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 1641 
GTTGGAAGCGACGGGACGGTAAGGCTGGGCCCCAAGGAGTG 1590 
GTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCCAAGGAGTG 1412 
GTTGGAAGCGACGGGCGGTAAGGCTTGGGCCCCAAGGAGTG 1319 
GTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAAGGAGTG 1301 
GTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGAGTG 1291 
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GTTGGAAGCGACGGGACGGTAAGCTTGGGCCCCAAGGAGTG 1239 
GTTGGAAGCGACGGGACGGTAAGGCTGGGGCCCCAAGGAGTG 1193 
GTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGAAGTG 1137 
GTTGGAAGCGACGGGACGGTGAGGCTTGGGCCCCAAGGAGTG 1123 
GTTGGAAGCGACGGGAGGTAAGGCTTGGGCCCCAAGGAGTG 1085 
GTTGGAAGCGACGGGACGGTAAGGTTGGGCCCCAAGGAGTG 1059 
Yellow indicates substitutions, green insertions, and turquoise deletions. The original sequence is 
indicated in bold. 
 
Table A 4: Original sequence and 25 most frequent mutations of T_Taq 
Sequence Sequence count 
GTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 2990041 
GGTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 13977 
GTTGGAAGCGACGGGACGGTAGGGCTTGGGCCCCAAGGAGTG 12302 
TTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 11493 
GTTGGAAGCGACGGGACGGTAAGGCTTGGCCCCAAGGAGTG 11343 
GTTGGAAGCGACGGACGGTAAGGCTTGGGCCCCAAGGAGTG 10431 
GTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCAAGGAGTG 7847 
GTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 6353 
GTTGGAAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 6098 
GTTGGAAGCGACGGGACGTAAGGCTTGGGCCCCAAGGAGTG 5541 
GTTGGAAGCGACGGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 5406 
GTTGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 5179 
GTTGGAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 5091 
GTTGGAAGCGACGGGACGGTAGGCTTGGGCCCCAAGGAGTG 5059 
GTTGGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 4909 
GTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCCAAGGAGTG 4721 
GTTGGAAGCGACGGGACGGTAAGGCTGGGCCCCAAGGAGTG 4541 
GTTGGAAGCGACGGGACGGTGAGGCTTGGGCCCCAAGGAGTG 4053 
GCTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 3972 
GTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAAGGAGTG 3948 
GTTGGAAGCGACGGGACGGTAAGGCTGGGGCCCCAAGGAGTG 3914 
GTTGGAGGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 3772 
GTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGAGTG 3694 
GTTGGAAGCGACGGGCGGTAAGGCTTGGGCCCCAAGGAGTG 3635 
GTTGGAAGCGACGGGACGGTAAGCTTGGGCCCCAAGGAGTG 3560 
GTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGAAGTG 3536 
Yellow indicates substitutions, green insertions, and turquoise deletions. The original sequence is 
indicated in bold. 
 
Table A 5: Original sequence and 25 most frequent mutations of T_w/o 
Sequence Sequence count 
GTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 1640067 
GTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCAAGGAGTG 7565 
GTTGGAAGCGACGGGACGGTAAGGCTTGGCCCCAAGGAGTG 5878 
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GGTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 5444 
TTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 4726 
GTTGGAAGCGACGGACGGTAAGGCTTGGGCCCCAAGGAGTG 4683 
GTTGGAAGCGACGGGACGGTAGGCTTGGGCCCCAAGGAGTG 4033 
GTTGGAAGCGACGGGACGGTAAGCTTGGGCCCCAAGGAGTG 3930 
GTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTGC 3777 
GTTGGAAGCGACGGGACGGTAAGGCTGGGCCCCAAGGAGTG 3700 
GTTGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 3346 
GTTGGAAGCGACGGGACGGAAGGCTTGGGCCCCAAGGAGTG 3342 
GTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAGGAGTG 3119 
GTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGT 2986 
GTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGATG 2715 
GTTGGAAGCGACGGGACGGTAAGGCTTGGGCCACAAGGAGTG 2713 
GTTGGAAGCGACGGGACGTAAGGCTTGGGCCCCAAGGAGTG 2659 
GTTGGAAGCGACGGGACGGTAAGGTTGGGCCCCAAGGAGTG 2635 
GTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGAGTG 2609 
GTTGGAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 2500 
TTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 2437 
GTTGGAAGCGACGGGCGGTAAGGCTTGGGCCCCAAGGAGTG 1991 
GTTGGAAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 1989 
GTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 1842 
GTTGGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 1839 
GCTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 1740 
Yellow indicates substitutions, green insertions, and turquoise deletions. The original sequence is 
indicated in bold. 
 
Table A 6: Original sequence and 25 most frequent mutations of EdU _Pwo 
Sequence Sequence count 
GTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 3122777 
GTTGGAAGCGACGGGACGGTAAGGCCTGGGCCCCAAGGAGTG 51393 
GTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGATG 42097 
GTTGGAAGCGACGGGACGTAAGGCTTGGGCCCCAAGGAGTG 35342 
TTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 29569 
GTCGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 27323 
GCTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 25350 
GTTGGAAGCGACGGGACGGTAAGGCATGGGCCCCAAGGAGTG 24557 
GTAGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 24291 
GTTGGAAGCGACGGACGGTAAGGCTTGGGCCCCAAGGAGTG 23940 
GGTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 21405 
GTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGG 20464 
GTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCAAGGAGTG 18605 
GATGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 18243 
GTTGGAAGCGCCGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 18183 
GTTGGAAGCGACGGGCCGGTAAGGCTTGGGCCCCAAGGAGTG 17191 
GTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGAGTG 16764 
GTTGGAAGCGACGGGACGGTAAGGCGTGGGCCCCAAGGAGTG 15361 
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GTTGGAAGCGACGGGACGGTAAGGCTAGGGCCCCAAGGAGTG 15273 
GTTGGAAGCGACGGGACGGTAGGCTTGGGCCCCAAGGAGTG 15044 
GTTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGAG 14747 
GTTGGAAGCGACGGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 14639 
GTGGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 14417 
GTTGGAAGCGACGGGACGGTAAGGCTTGGCCCCAAGGAGTG 13760 
GTTGAAGCGACGGGACGGTAAGGCTTGGGCCCCAAGGAGTG 13186 
GTTGGAAGCGACGGGACGGTAAGGCTTTGGCCCCAAGGAGTG 13117 
Yellow indicates substitutions, green insertions, and turquoise deletions. The original sequence is 
indicated in bold. 
 
Table A 7: Original sequence and 25 most frequent mutations of FT2_GATC 
Sequence Sequence count 
GATCGATCGATCGATCGATCGATCGATCGATC 9210580 
GATCGATCGATCGTTCGATCGATCGATCGATC 40756 
GATCGATCGATCGATCGATCGATCGATC 16625 
ATCGATCGATCGATCGATCGATCGATCGATC 15189 
GATCGATCGATCGATCGATCGATCGATCGAT 12245 
GATCGATCGATCGATTGATCGATCGATCGATC 11192 
GATCGATCGATCGATCGATCGATAGATCGATC 10571 
GATCGATCGATCGATCGTTCGATCGATCGATC 10186 
GATCGATTGATCGATCGATCGATCGATCGATC 10022 
GATCGATCGATCGCTCGATCGATCGATCGATC 9607 
GATCGATCGATCTATCGATCGATCGATCGATC 9462 
GATCGATCGATCGATCGATCGATCAATCGATC 9387 
GATCGATCGATCGATCGTCGATCGATCGATC 8657 
GATCGATCGATCGATCGATCGATCGATCGTTC 8628 
GATTGATCGATCGATCGATCGATCGATCGATC 8511 
GATCGATCGATCGATCGACGATCGATCGATC 8406 
GATCGATCGATCGATCGATCGAACGATCGATC 8334 
GATCGATCGATCGATCGATTGATCGATCGATC 8294 
GATCGATCGATCGATCGATCGACGATCGATC 8159 
GTTCGATCGATCGATCGATCGATCGATCGATC 8081 
GATCGATCGATCGATCTATCGATCGATCGATC 7884 
GATCGATCGATCGATCAATCGATCGATCGATC 7740 
GATCGATCTATCGATCGATCGATCGATCGATC 7715 
GATCGATCGATCGATCGATAGATCGATCGATC 7604 
GATCGATCGATCGATCGAACGATCGATCGATC 7408 
GATCGATCGATTGATCGATCGATCGATCGATC 7398 
Yellow indicates substitutions, green insertions, and turquoise deletions. The original sequence is 
indicated in bold. 
 
Table A 8: Original sequence and 25 most frequent mutations of FT2_GATC_II 
Sequence Sequence count 
GATCGATCGATCGATCGATCGATCGATCGATC 2178012 
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GATCGATCGATCGTTCGATCGATCGATCGATC 6052 
GATCGATCGATCGATCGATCGATCGATC 4924 
ATCGATCGATCGATCGATCGATCGATCGATC 3450 
GATCGATCGATCGATCGATCGATCGATCGAT 2870 
GATCGATCGATCGATCTATCGATCGATCGATC 2324 
GATCGATCGATCGATCGTTCGATCGATCGATC 2019 
GATCGATCGATCGATCGTCGATCGATCGATC 2003 
GATCTATCGATCGATCGATCGATCGATCGATC 1992 
GATCGATCGATCGATTGATCGATCGATCGATC 1972 
GATCGATCGATCGATCGACGATCGATCGATC 1948 
GATCGATCGATCTATCGATCGATCGATCGATC 1942 
GATCGATTGATCGATCGATCGATCGATCGATC 1921 
GATCGATCGATCGATCGATCGATCGATCGTTC 1905 
GATCGATCGATCGATCGATCGATAGATCGATC 1851 
GATCGATCGATCGATCGATCGATCAATCGATC 1740 
GATCGATCGATCGATCGATCGACGATCGATC 1721 
GTTCGATCGATCGATCGATCGATCGATCGATC 1715 
TATCGATCGATCGATCGATCGATCGATCGATC 1676 
GATCGATCGATCGATCGATTGATCGATCGATC 1640 
GATCGATCGATCGATCGATCGTCGATCGATC 1596 
GATCGATCGATCGATGATCGATCGATCGATC 1594 
GATCGATCGATCATCGATCGATCGATCGATC 1588 
GATCGATCGATCGTCGATCGATCGATCGATC 1583 
GATCGATCGATCGACGATCGATCGATCGATC 1577 
GATTGATCGATCGATCGATCGATCGATCGATC 1565 
Yellow indicates substitutions, green insertions, and turquoise deletions. The original sequence is 
indicated in bold. 
 
Table A 9: Original sequence and 25 most frequent mutations of FT2_G4A4T4C4 
Sequence Sequence count 
GGGGAAAATTTTCCCCGGGGAAAATTTTCCCC 7340975 
GGGGAAAATTTTCCCCGGGGAAAGTTTTCCCC 62115 
GGGGAAAATTTTCCCCGGGGAAATTTTTCCCC 29603 
GGGGAAAATTTTCCCCGGGGAAACTTTTCCCC 28885 
GGGAAAATTTTCCCCGGGGAAAATTTTCCCC 27528 
GGGGAAAATTTTCCCCGGGGAAAATTTTCCC 26734 
GGGGAAAATTTTCCCGGGGAAAATTTTCCCC 25567 
GGGGAAAATTTTCCCCGGGGAATATTTTCCCC 25363 
GGGGAAAATTTTCCCCGGGAAAATTTTCCCC 22129 
GGGGAAAATTTTCCCCGGGGAAGATTTTCCCC 20528 
GGGGAAAATTTCCCCGGGGAAAATTTTCCCC 18488 
GGGGAAAATTTTCCCCGGGGAAATTTTCCCC 14789 
GGGGAAATTTTCCCCGGGGAAAATTTTCCCC 13789 
GGGGAAAATTTTCCCCGGGGAAAATTTCCCC 13618 
GGGGAAAATTTTCCCGGGGGAAAATTTTCCCC 12188 
GGGGAAAATTTTCCACGGGGAAAATTTTCCCC 11202 
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GGGGAAAATTTTCCTCGGGGAAAATTTTCCCC 10651 
GGGGAAAATTTTCCCCGGGGAACATTTTCCCC 9828 
GGGGAAAATTTTCCCCGGGGTAAATTTTCCCC 9817 
GGGGAAAATTTTCACCGGGGAAAATTTTCCCC 9097 
GGGGAAAATTTTCTCCGGGGAAAATTTTCCCC 8683 
GGGGAAAATTTTCCCCGAGGAAAATTTTCCCC 8659 
GGGGATAATTTTCCCCGGGGAAAATTTTCCCC 8512 
TGGGAAAATTTTCCCCGGGGAAAATTTTCCCC 8250 
GGGGAAAATTTTCCCCGTGGAAAATTTTCCCC 8185 
GGGGAAAATTTTCCCCGGGGATAATTTTCCCC 8177 
Yellow indicates substitutions, green insertions, and turquoise deletions. The original sequence is 
indicated in bold. 
 
Table A 10: Original sequence and 25 most frequent mutations of FT2_G4A4T4C4_II 
Sequence Sequence count 
GGGGAAAATTTTCCCCGGGGAAAATTTTCCCC 6549166 
GGGGAAAATTTTCCCCGGGGAAAGTTTTCCCC 45606 
GGGGAAAATTTTCCCCGGGGAAAATTTTCCC 25874 
GGGAAAATTTTCCCCGGGGAAAATTTTCCCC 25002 
GGGGAAAATTTTCCCCGGGGAAATTTTTCCCC 24447 
GGGGAAAATTTTCCCGGGGAAAATTTTCCCC 23700 
GGGGAAAATTTTCCCCGGGAAAATTTTCCCC 20951 
GGGGAAAATTTTCCCCGGGGAAACTTTTCCCC 20084 
GGGTAAAATTTTCCCCGGGGAAAATTTTCCCC 19289 
GGGGAAAATTTTCCCCGGGGAATATTTTCCCC 18918 
GGGGAAAATTTCCCCGGGGAAAATTTTCCCC 16348 
GGGGAAAATTTTCCCCGGGGAAAATTTTACCC 15108 
GGGGAAAATTTTCCCCGGGGAAGATTTTCCCC 14713 
GGGGAAAATTTTCCCCGGGGAAATTTTCCCC 13451 
GGGGAAAATTTTCCCCGGGGAAAATTTCCCC 13426 
GGGGAAATTTTCCCCGGGGAAAATTTTCCCC 12803 
GGGGAAAATTTTCCCGGGGGAAAATTTTCCCC 11949 
GGGGAAAATTTTACCCGGGGAAAATTTTCCCC 11730 
TGGGAAAATTTTCCCCGGGGAAAATTTTCCCC 8438 
GGTGAAAATTTTCCCCGGGGAAAATTTTCCCC 8037 
GGGGAAAATTTTCCCCGGGTAAAATTTTCCCC 7069 
GGGGATAATTTTCCCCGGGGAAAATTTTCCCC 6921 
GGGGAAAATTTTCACCGGGGAAAATTTTCCCC 6831 
GGGGAAAATTTTCCCCGGGGAAAATTTTCACC 6576 
GGGGAATATTTTCCCCGGGGAAAATTTTCCCC 6558 
GGGGAAAATTTTCCCCGGGGAAAATTTTCCAC 6555 
Yellow indicates substitutions, green insertions, and turquoise deletions. The original sequence is 
indicated in bold. 
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Table A 11: Original sequence and 25 most frequent mutations of FT2_G2A2T2C2 
Sequence Sequence count 
GGAATTCCGGAATTCCGGAATTCCGGAATTCC 2040896 
GAATTCCGGAATTCCGGAATTCCGGAATTCC 6073 
GGAATTCCGGAATTCCGTAATTCCGGAATTCC 5990 
GGAATTCCGGAATTACGGAATTCCGGAATTCC 5539 
GGAATTCCGGAATTCCGGAATTCCGGAATTC 5123 
GGAATTCCGGAATTCCGGAATTCCGTAATTCC 5085 
GGAATTTCGGAATTCCGGAATTCCGGAATTCC 5080 
GGAATTCCGGAATTCCGGAATTCCGGAATTAC 4697 
GGAATTCCGTAATTCCGGAATTCCGGAATTCC 4674 
GGAATTCCGGAATTCCGGAATTACGGAATTCC 4548 
GGAATTACGGAATTCCGGAATTCCGGAATTCC 4547 
GTAATTCCGGAATTCCGGAATTCCGGAATTCC 4165 
GGAATTCCGGAATTCGGAATTCCGGAATTCC 4057 
GGAATTCCGGAATTCCGAATTCCGGAATTCC 3949 
GGAATTCCGGAATTCAGGAATTCCGGAATTCC 3664 
GGAATTCCGGAATTCCGGAATTCAGGAATTCC 3571 
GGAATTCCGGAATTCCGGAATTCCGGAATTCA 3541 
TGAATTCCGGAATTCCGGAATTCCGGAATTCC 3522 
GGAATTCCGGAATTCCTGAATTCCGGAATTCC 3473 
GGAATTCCTGAATTCCGGAATTCCGGAATTCC 3450 
GGAATTCCGAATTCCGGAATTCCGGAATTCC 3374 
GGAATTCCGGAATCCGGAATTCCGGAATTCC 3215 
GGAATTCTGGAATTCCGGAATTCCGGAATTCC 3196 
GGAATTCCGGAATTCCGGAATCCGGAATTCC 3180 
GGAATTCCGGAATTCTGGAATTCCGGAATTCC 3161 
GGAATTCCGGAATTCCGGATTCCGGAATTCC 3152 
Yellow indicates substitutions, green insertions, and turquoise deletions. The original sequence is 
indicated in bold. 
 
Table A 12: Original sequence and 25 most frequent mutations of FT2_G3A3T3C3 
Sequence Sequence count 
GGGAAATTTCCCGGGAAATTTCCCGGGAAATT 5535182 
GGAAATTTCCCGGGAAATTTCCCGGGAAATT 21093 
GGGAAATTTCCCGGGAAATTCCCGGGAAATT 19864 
GGGAAATTTCCGGGAAATTTCCCGGGAAATT 19079 
GGGAAATTTCCCGGGAATTTCCCGGGAAATT 18549 
GGGAAATTTCCCGGGAAATTTACCGGGAAATT 17688 
GGGAAATTTCCCGGAAATTTCCCGGGAAATT 16754 
GGGAAATTTCCAGGGAAATTTCCCGGGAAATT 16257 
GGGAAATTTCCCGGGAAATTTCCAGGGAAATT 16206 
GGGAAATTTCCCTGGAAATTTCCCGGGAAATT 15353 
GGGAAATTTCCCGGGAAATTTCCGGGAAATT 14511 
GGTAAATTTCCCGGGAAATTTCCCGGGAAATT 13353 
GGGAAATTTCCCGGGAAATTTCCCGGAAATT 12584 
TGGAAATTTCCCGGGAAATTTCCCGGGAAATT 12115 
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GGGAAATTTCCCGGTAAATTTCCCGGGAAATT 12041 
GGGAAATTTCCCGGGAAATTTCCCTGGAAATT 11707 
GGGAAATTCCCGGGAAATTTCCCGGGAAATT 11475 
GGGAAATTTCCCGTGAAATTTCCCGGGAAATT 11190 
GGGAAATTTCCCGGGAAATTTCCCGGGAATT 10863 
GGGAAATTTCACGGGAAATTTCCCGGGAAATT 10839 
GGGAAATTTCCCGGGAAATTTCACGGGAAATT 10796 
GGGAAATTTCCCGGGAAATTTCCCGTGAAATT 10637 
GGGAATTTCCCGGGAAATTTCCCGGGAAATT 10332 
GTGAAATTTCCCGGGAAATTTCCCGGGAAATT 10015 
GGGAAATTTACCGGGAAATTTCCCGGGAAATT 9290 
GGGAAATTTCCCGGGAAATTTCCCGGTAAATT 8848 
Yellow indicates substitutions, green insertions, and turquoise deletions. The original sequence is 
indicated in bold. 
 
Table A 13: Original sequence and 25 most frequent mutations of FT2_TGCA 
Sequence Sequence count 
TGCATGCATGCATGCATGCATGCATGCATGCA 6627344 
TGCATGCATGCATGCATGCTTGCATGCATGCA 45693 
TGCATGCATGCTTGCATGCATGCATGCATGCA 36139 
TGCAAGCATGCATGCATGCATGCATGCATGCA 26613 
TGCATGCATGCATGCATGCATGCATGCA 24728 
TGCATGCATGCATGCATGCATGCATGCATGAA 19114 
TGCATGCATGAATGCATGCATGCATGCATGCA 18958 
TGTATGCATGCATGCATGCATGCATGCATGCA 12451 
TGCATGCATTCATGCATGCATGCATGCATGCA 11260 
TGCATGTATGCATGCATGCATGCATGCATGCA 10812 
TGCATGCATGCATGTATGCATGCATGCATGCA 10365 
TGCATGCATGTATGCATGCATGCATGCATGCA 10306 
TGCATGCATGCATGAATGCATGCATGCATGCA 9163 
TGCATGCATGCATGCATGTATGCATGCATGCA 8532 
TGCATGCATGCATGCATGCATGCATGTATGCA 7920 
TGCATGCATGCATGCATGCATGTATGCATGCA 7487 
TGCATGCATGCTGCATGCATGCATGCATGCA 7444 
TGCATGCATGCATGCATGCATGCATGCATACA 7208 
TGCATGCATCATGCATGCATGCATGCATGCA 7143 
TGCATGCATGCATGCATGAATGCATGCATGCA 7044 
TGCATGCATGCATGCATGCATGCATGAATGCA 6912 
TGCATGAATGCATGCATGCATGCATGCATGCA 6769 
TGAATGCATGCATGCATGCATGCATGCATGCA 6711 
TGCATGCATGCATGCATGCATGATGCATGCA 6706 
TGCATGCATGCATCATGCATGCATGCATGCA 6549 
TGCATGCATGCATGCATGCATGCATACATGCA 6531 
Yellow indicates substitutions, green insertions, and turquoise deletions. The original sequence is 
indicated in bold. 
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Table A 14: Original sequence and 25 most frequent mutations of D3_TGCA 
Sequence Sequence count 
TGCATGCATGCATGCATGCATGCATGCATGCA 398611 
TGCATGCATGCATGCATGCTTGCATGCATGCA 1654 
TGCATGCATGCATGCTTGCATGCATGCATGCA 1560 
TGCATGTATGCATGCATGCATGCATGCATGCA 1190 
TGCATGCATGCATGCATGCATGCATGCA 1026 
TGCATGCATGCATGCATGCATGTATGCATGCA 588 
TGCATGCTTGCATGCATGCATGCATGCATGCA 555 
TGCATGCATGCATGCATGTATGCATGCATGCA 545 
TGCATGCATGCATGCATGCATGCATGCATACA 530 
TGTATGCATGCATGCATGCATGCATGCATGCA 518 
TGCATGCATGCATGCATGCATGCATACATGCA 498 
TGCATGCATGTATGCATGCATGCATGCATGCA 459 
TGCATGCATTCATGCATGCATGCATGCATGCA 455 
TGAATGCATGCATGCATGCATGCATGCATGCA 418 
TGCATGCATGCATGCATACATGCATGCATGCA 395 
TGCATGCATGCATACATGCATGCATGCATGCA 393 
TGCATGCATGCATGTATGCATGCATGCATGCA 392 
TGCATGCATGCATGCATGCATACATGCATGCA 390 
TGCATGAATGCATGCATGCATGCATGCATGCA 379 
TGCATGCTGCATGCATGCATGCATGCATGCA 368 
TGCATGCATGCATGAATGCATGCATGCATGCA 364 
TGCATGCATGCATGCATTCATGCATGCATGCA 345 
TGCATGCATGCATGCATGCATGCATGCATGAA 344 
TGCATACATGCATGCATGCATGCATGCATGCA 335 
TGCATGCATGCATGCATGAATGCATGCATGCA 332 
TGCATGCATGCATGCATGCATGCATGAATGCA 306 
Yellow indicates substitutions, green insertions, and turquoise deletions. The original sequence is 
indicated in bold. 
 
Table A 15: Original sequence and 25 most frequent mutations of FT2_T4G4C4A4 
Sequence Sequence count 
TTTTGGGGCCCCAAAATTTTGGGGCCCCAAAA 1745068 
TTTTGGGGCCCAAAAATTTTGGGGCCCCAAAA 9556 
TTTTGGGGCCCCAAAATTTGGGGCCCCAAAA 7973 
TTTTGGGGCCCCAAATTTTGGGGCCCCAAAA 7625 
TTTTGGGGCCCCAAAATTTTGGGCCCCAAAA 7388 
TTTTGGGGCCCAAAATTTTGGGGCCCCAAAA 6884 
TTTTGGGCCCCAAAATTTTGGGGCCCCAAAA 4855 
TTTTGGGGCCCCAAAATTTTGGGGCCCAAAA 4841 
TTTTGGGGCTCCAAAATTTTGGGGCCCCAAAA 4576 
TTTTGGGGCCTCAAAATTTTGGGGCCCCAAAA 4488 
TTTTGGGGCCCCAAAATTTTGGGGCCCCAAA 4334 
TTTGGGGCCCCAAAATTTTGGGGCCCCAAAA 4234 
TTTTGGGGCCCCAAAATTTTTGGGCCCCAAAA 4229 
TTTTGGGGCCCTAAAATTTTGGGGCCCCAAAA 4204 
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TTTTGGGGCCCCAAAATTTTGGGGCTCCAAAA 3987 
TTTTGGGGTCCCAAAATTTTGGGGCCCCAAAA 3946 
TTTTGGGGCCCCAAAATTTTAGGGCCCCAAAA 3878 
TTTTGGGGCCCCAAAATTTTGGAGCCCCAAAA 3860 
TTTTGGGGCCCCAAAATTTTGAGGCCCCAAAA 3606 
TTTTGGGGCCCCAAAATTTTGGGACCCCAAAA 3308 
TTTTGGGGCCCCAAAATTTTGTGGCCCCAAAA 2968 
TTTTGGGGCCACAAAATTTTGGGGCCCCAAAA 2940 
TTTTGTGGCCCCAAAATTTTGGGGCCCCAAAA 2649 
TTTTGGGGCCCCAAATTTTTGGGGCCCCAAAA 2524 
TTTTGGGGCCCCAAAAATTTTGGGGCCCCAAAA 2469 
TTTTGGGGCCCCAAAATTTTGGGGCCACAAAA 2430 
Yellow indicates substitutions, green insertions, and turquoise deletions. The original sequence is 
indicated in bold. 
 
Table A 16: Original sequence and 25 most frequent mutations of D3_T4G4C4A4 
Sequence Sequence count 
TTTTGGGGCCCCAAAATTTTGGGGCCCCAAAA 5284258 
TTTTGGGGCCCCAAAAATTTGGGGCCCCAAAA 56226 
TTTTGGGGCCCCAAATTTTGGGGCCCCAAAA 33501 
TTTTGGGGCCCCAAAATTTGGGGCCCCAAAA 31991 
TTTTGGGGCCCAAAAATTTTGGGGCCCCAAAA 19746 
TTTTGGGGCCCCAAAATTTTGGGCCCCAAAA 18308 
TTTTGGGGCCCCAAAATTTTGGGGCCCAAAA 18108 
TTTTGGGGCCCAAAATTTTGGGGCCCCAAAA 16172 
TTTTGGGGCCCCAAAATTTTTGGGCCCCAAAA 16010 
TTTTGGGCCCCAAAATTTTGGGGCCCCAAAA 15538 
TTTTGGGGCCCTAAAATTTTGGGGCCCCAAAA 14219 
TTTTGGGGCTCCAAAATTTTGGGGCCCCAAAA 14016 
TTTTGGGGCCTCAAAATTTTGGGGCCCCAAAA 13073 
TTTTGGGGCCCCAAAATTTTGGGGCCCCAAA 12625 
TTTTGGGGTCCCAAAATTTTGGGGCCCCAAAA 10980 
TTTGGGGCCCCAAAATTTTGGGGCCCCAAAA 10697 
TTTTGGGGCCACAAAATTTTGGGGCCCCAAAA 9072 
TTTTGGGGCCCCAAAATTTTGTGGCCCCAAAA 8441 
TTTTGTGGCCCCAAAATTTTGGGGCCCCAAAA 8378 
TTTTGGGGCCCCAAAATTTTAGGGCCCCAAAA 7925 
TTTTGGGGCCCCAAAATTTTGGGGCCACAAAA 7891 
TTTTTGGGCCCCAAAATTTTGGGGCCCCAAAA 7708 
TTTTGGGGCCCCAAAATTTTGGGACCCCAAAA 7669 
TTTTGGTGCCCCAAAATTTTGGGGCCCCAAAA 7171 
TTTTGGGGCCCCAAAATTTAGGGGCCCCAAAA 7018 
TTTTGGGGCCCCAAAATTTTGAGGCCCCAAAA 6677 
Yellow indicates substitutions, green insertions, and turquoise deletions. The original sequence is 
indicated in bold. 
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Table A 17: Multiple sequence alignment of all sequences identified by Sanger sequencing 
in the re-selection with benzyl-modified DNA 
Seq. Sequence of the random region 
27 ----ACGTCCTCATCACCTCCCATGTCTCCGGAGTCCACGGACAGG- 
B27 
 
43 
35 
29 
33 
22 
36 
17 
32 
14 
9 
18 
26 
39 
4 
6 
10 
23 
45 
31 
7 
----CTACAATCGTGCGATCCCCTATCTCCAGACCTACGGGAACAC- 
 
----CTACAGTCGTGCGATCCCCTATCTCCAGACCTACGGGAACAC- 
----CTACAATCGTGCGATCCCCTATCTCCGAACCTACGGGAACAC- 
----CTACAATCGCGCGATCCCCTATCTCCAGACCTACGGGAACAC- 
----CTACAATCGCGCGATCCCCTATCTCCAGACCTACGGGAACAC- 
----CTACAATCGTGCAATCCCCTATCTCCAGACCTACGGGAACAC- 
----CTACAATCGTGCAATCCCCTATCTCCAGACCTACGGGAACAC- 
----CTACAATCGTGCGATCCCCTATCTCCAAACCTACGGGAACAC- 
----CTACAATCGTGCGATCCCCTATCTCCAAACCTACGGGAACAC- 
----CTACAATCGTGCGATCCCCTATCTCCAGACCTACGGAAACAC- 
----CTACAATCGTGCGATCCCCTATCTCCAGACCTACGGAAACAC- 
----CTACAATCGTGCGATCCCCTATCTCCAGACCTACGGGAACAC- 
----CTACAATCGTGCGATCCCCTATCTCCAGACCTACGGGAACAC- 
----CTACAATCGTGCGATCCCCTATCTCCAGACCTACGGGAACAC- 
----CTACAATCGTGCGATCCCCTATCTCCAGACCTACGGGAACAC- 
----CTACAATCGTGCGATCCCCTATCTCCAGACCTACGGGAACAC- 
----CCACAATCGTGCGATCCCCTATCTCCAGACTTACGGAAACAC- 
----CCACAATCGTGCGATCCCCTATCTCCAGACCTACGGAAACAC- 
----CCACAATCGTGCGATCCCCTATCTCCAGACCTACGGAAACAC- 
----CCACAATTGTGCGATCCCCTATCTCCAAACCTACGGAAACAC- 
----CCACAATCGTGCGATCCCCTATCTCCAAACCTACGGAAACAC- 
B11 
 
37 
42 
12 
24 
44 
21 
15 
40 
41 
8 
16 
2 
----GATGCCGGACG--TTGGAACGGGCGTGTCATCATAGGTACAGG 
 
----GATACCAAACG--TTGGAACGGGTGTGTCAACATAGGTACAGG 
----GATGCCGGACG--TTGGAACGGGTGTGTCATCATAGGTACAGG 
----GATGCCGGACG--TTGGAACGGGTGTGTCAACATAGGTACAGG 
----GATGCCGGACG--TTGGAACGGGCGTGTCAACATAGGTACAGG 
----GATGCCGAACG--TTGGAACGGGTGTGTCATCATAGGTACAGG 
----GATGCCGGACG--TTGGAACGGGCGTGTCATCATAGGTATAGG 
----GATGCCGGACG--TTGGAACGGGCGTGTCATCATAGGTACAGG 
----GATGCCGGACG--TTGGAACGGGCGTGTCATCATAGGTACAGG 
----GATGCCGGACG--TTGGAACGGGCGTGTCATCATAGGTACAGG 
----GATGCCGGACG--TTGGAACGGGCGTGTCATCATAGGTACAGG 
----GATGCCGGACG--TTGGAACGGGCGTGTCATCATAGGTACAGA 
----GATGCCGAACG—-TTGGAACGGGCGTGTCATCATAGGTACAGG 
B32 
 
3 
5 
30 
-ACACTGGATAGA-----TGCGGGGGGCAACGCCTTCAGGCATCAGT 
 
-ACACTGGATAGA-----TGCGGGGGGCAACGCCTTCAGGCATCAGT 
-ACACTGGATAGA-----TGCGGGGGGCAACGCCTTCAGGCATCAGT 
-ACACTGGATAGA-----TGCGGGAGGCAACGCCTTCAGGCATCAGT 
B14 
 
28 
47 
38 
19 
46 
AACCCTGACTGGGAGTGATGCCTACCGTAACACCTCCCGCAC----- 
 
AACCCTGACTGGAAGTGATGCCAACCGTAACACCTCCCACAC----- 
AACCCTGACTGGGAGTGATGCCAACCGTAACACCTCCCGCAC----- 
AATCCTGACTGGGAGTGATGCCTACCGTAACACCTCCCGCAC----- 
AACCCTGACTGGGAGTGATGTCTACCGTAACACCTCCCGCAC----- 
AACCCTGACTGGGAGTGATGCCTACCGTAACACCTCCCGCAC----- 
Seq. = sequence. T = EdU in the tested sequences. N = unidentified nucleotide. Tested 
sequences are indicated in bold letters. Identical sequences from the initial click-selection are 
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given for comparison and separated by an empty line. The sequences were analysed using 
Clusta Omega.
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Table A 18: Multiple sequence alignment of all sequences identified by Sanger sequencing 
in the re-selection with CF3-modified DNA 
Seq. Sequence of the random region 
73 
69 
74 
75 
---------GCACGGGACAACCGCAAACGTACTAGCATC-----------CCGCGGCAAACA- 
---------GCACGGGACAACCGCGAACGTACTAGCATC-----------CCGCGGCGAATA- 
---------GCACGGAACAACCGCGAACGTACTAGCATC-----------CCGCGGCGAACA- 
---------GCACGGGACAACCGTGAACGTACTAGCATC-----------CCGCGGCGAACA- 
61 -------------------GTTGCACCCGGGACAACCTGCC—TGGTAAATCCCGTACCTCAG 
80 
67 
------------------AACTGCAGAAAGGGGAAGGCGAG--GAATAGTCCCCGGTTGGCA- 
------------------AACTGCAGAAAGGGGAAGGC--GAGGAATAGTCCCCGGTTGGCA- 
77 
48 
60 
-------------GGTAATGGTGGAGGGTAAGGAGGACCCC--GAATTGTCCCCGTG------ 
-------------GGTAACGGTGGAGGGTAATGAGGGCCCC--GAATTGTCCCCGTG------ 
-------------AGTCACGGTGGAGGGTAAGGAGGGCCCC--GAATTGTCCCCGTG------ 
87 -AATGCATACGGAGGGCTGGCTACCCAGGCTGAGTCCCC----ATCA---------------- 
88 CGGTGATTAGGATGGGCT--GGAAATT----------TG----AGTCCCACCAGCGAG----- 
83 --------------GAAC--CGACAGTGGACACATAACC----CTAACTTCCAGTGTAGGCA- 
53 
54 
57 
58 
64 
86 
------TTCGGACGGAGA--GAGCAGGGGGTGAGTAAAG----AGTAGGTCCAG--------- 
------TTCGGACGGAGA--GAGCAGGGGGTGAGTAAAG----AGTAGGTCCAG--------- 
------TTCGGACGGAGA--GAGCAGGGGGTGAGTAAAG----AGTAGGTCCAG--------- 
------TTCGGACGGAGA--GAGCAGGGGGTGAGTAAAG----AGTAGGTCCAG--------- 
------TTCGGACGGAGA--GAGCAGGGGGTGAGTAAAG----AGTAGGTCCAG--------- 
------TTCGGACGGAGA--GAGCAGGGGGTGAGTAAAG----AGTAGGTCCAG--------- 
55 ---GACTTTCGGAGGAGG--GGACCGGGGAT-----AAC----AGTAGATCCGCAGA------ 
63 
76 
85 
---------GCTCACGCCACACAAGGCAGATCCTGAGCTCCGGGGGTC---CAC--------- 
---------GCTCACGCCGCACAAGGCAGATCCTGAGTTCCGGGGGTC---CGC--------- 
---------GCTCACGCCGCACAAGGCAGATCCTGAGCTCCGGGGGTC---TGC--------- 
52 ----GACCAATACGTGCTGAGTTCCAGACACAAAT----------------GGGCTGATGA— 
49 
59 
68 
92 
------TGCGCGAGGGATGATTAAGAGAAGCTCAACCGCGCGGAGGCC--------------- 
------TGCGCGAGGGATGATTAAGAGAAGCTCAACCGCGCGGAGGCC--------------- 
------TGCGCGAGGGATGATTAAGAGAAGCTCAACCGCGCGGAGGCC--------------- 
------TGCGCGAGGGATGATTAAGAGAAGTTCAACCGCGCGGAGACC--------------- 
62 ----------CGCGGGCCAAGTACCGGGACCGTCTGCTAACTGAGGTCCAAC----------- 
89 -------CATAANGGGCTGGTCAGACTACACGNNAGGACACTAGGAAAA-------------- 
81 --------------GATCACACACGATACACGTTCGGACACTAGGTCACTACACCA------- 
C30 
 
66 
79 
-------CCAGCCGCGCGGAAGACAATACACGTTGGGCCACTAAGGAAG-------------- 
 
-------CCGGCCGTGCGGAAGACAATACACGTTGGGTCACTAAGGAAG-------------- 
-------CCGGCCGCGCGGAAGACAATACACGTTGGGCCACTAAGGAAG-------------- 
C47 
 
78 
71 
94 
56 
91 
50 
90 
81 
--------------------CGATAATACACGTTCGGCCCCTAAAGCCGGTCGGCCCTTGCA- 
 
--------------------CGATAATACACGTTCGGCCACTAAAGCCGTCCATCCCTTGCA- 
--------------------CAATAATACACGTTCGGTCACTAAAGCCGGCCGGCCCTTGCA- 
--------------------CGATAATACACGTTCGGCCACTAAAGCCGTCCGGCCCTTACA- 
--------------------CGATAATACACGTTCGGCCATTAAAGCCGGCCGGCCCTNGCA- 
--------------------CGATAATACACGTTCGGCCACTAAAGCCGGCCGACCCTTGCA- 
--------------------CGATAATACACGTTCGGCCACTAAAGCCGGCCGGCCCTTGCA- 
--------------------CGATAATACACGTTCGGCCACTAAAGCCGGCCGGCCCTTGCA- 
--------------------CGATAATACACGTTCGGCCACTAAAGCCGACCGGCCCTTGCA- 
Seq. = sequence. T = EdU in the tested sequences. N = unidentified nucleotide. Tested 
sequences are indicated in bold letters. Identical sequences from the initial click-selection are 
given for comparison and separated by an empty line. The sequences were analysed using 
Clusta Omega.
276,277
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